



***In Vitro And In Vivo Models Investigating***  
**Pharmacological Modulators Of The**  
**Metabolic Syndrome**

Neera Agarwal

MBBCh, MRCP (UK)

Centre for Endocrine and Diabetes Sciences  
School of Medicine, Cardiff University

A dissertation submitted to Cardiff University in candidature for the degree of  
Doctor of Philosophy (Ph.D.)

2010

UMI Number: U584494

All rights reserved

INFORMATION TO ALL USERS

The quality of this reproduction is dependent upon the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



UMI U584494

Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.  
Microform Edition © ProQuest LLC.

All rights reserved. This work is protected against  
unauthorized copying under Title 17, United States Code.



ProQuest LLC  
789 East Eisenhower Parkway  
P.O. Box 1346  
Ann Arbor, MI 48106-1346

ॐ

मेरे लोधी और आशी के लिये।

# CONTENTS

	<b>Page No</b>
<b>Summary</b>	<b>17</b>
<b>Acknowledgements</b>	<b>18</b>
<b>Publications and Presentations</b>	<b>19</b>
<b>Abbreviations</b>	<b>21</b>
<b>List of Figures</b>	<b>29</b>
<b>List of Tables</b>	<b>34</b>
<b>Chapter 1</b>	<b>General Introduction – Models Of The Metabolic Syndrome</b>
<b>1.1</b>	<b>Historical Perspective 38</b>
<b>1.2</b>	<b>Definition Of The Metabolic Syndrome 38</b>
<b>1.3</b>	<b>Pathogenesis Of The Metabolic Syndrome 41</b>
<b>1.3.1</b>	<b>Obesity &amp; Abnormal Body Fat Distribution 41</b>
<b>1.3.2</b>	<b>Insulin Resistance &amp; Glucose Intolerance 43</b>
<b>1.3.2.1</b>	<b>The Role Of Obesity In The Pathogenesis Of Insulin Resistance 43</b>
<b>1.3.2.2</b>	<b>Impaired Insulin Receptor Signalling In Insulin Resistance 44</b>
<b>1.3.3</b>	<b>Dyslipidaemia 45</b>
<b>1.3.4</b>	<b>Elevated Blood Pressure 46</b>
<b>1.3.5</b>	<b>Proinflammatory Cytokines &amp; Adiponectin 46</b>
<b>1.4</b>	<b>Prevalence Of The Metabolic Syndrome 47</b>
<b>1.5</b>	<b>Consequences Of The Metabolic Syndrome 48</b>
<b>1.6</b>	<b>Management Of The Metabolic Syndrome 49</b>



1.7	Models Of The Metabolic Syndrome	50
1.8	The Endocannabinoid System (ECS)	51
1.8.1	Role Of The ECS In Contributing To Obesity	51
1.8.2	Cannabinoid Receptors	52
1.8.3	Endogenous Endocannabinoids	53
1.8.4	Exogenous CB <sub>1</sub> Receptor Ligands	54
1.8.4.1	Exogenous CB <sub>1</sub> Agonists	54
1.8.4.2	Exogenous CB <sub>1</sub> Antagonists	54
1.8.5	Endocannabinoid-Mediated Intra-Cellular Signalling	55
1.8.6	Endocannabinoid-Mediated Neuronal Signalling	57
1.8.7	Role Of The ECS In The Modulation Of Energy Regulation	58
1.8.7.1	Animal Studies	58
1.8.7.2	Human Studies	58
1.8.8	Therapeutic Potential Of CB <sub>1</sub> Receptor Ligands In The Management Of Obesity	59
1.9	Polycystic Ovary Syndrome	60
1.9.1	Diagnosis of PCOS	61
1.9.2	Pathogenesis Of PCOS	62
1.9.2.1	Abnormal Pituitary Function	62
1.9.2.2	Abnormal Steroidogenesis	62
1.9.2.3	Insulin Resistance	63
1.9.3	Insulin Resistance And Its Role In Reproductive Abnormalities In PCOS	64
1.9.4	Insulin Resistance And Its Role In Metabolic Abnormalities In PCOS	65
1.9.4.1	Obesity And Central Body Fat Redistribution	66

1.9.4.2	Glucose Intolerance And Type II Diabetes	66
1.9.4.3	Lipids And Lipoprotein Profiles	67
1.9.4.4	Blood Pressure	68
1.9.4.5	Haemostatic Factors	68
1.9.4.6	Inflammation	69
1.9.4.7	Adipocytokine Profiles	69
1.9.4.8	Prevalence Of The Metabolic Syndrome In PCOS	69
1.9.5	Vascular Abnormalities In PCOS	70
1.9.5.1	Endothelial Dysfunction	70
1.9.5.2	Subclinical Atherosclerosis	70
1.9.5.3	Coronary Heart Disease Risk In PCOS	71
1.9.6	The Role Of Metformin In The Treatment of PCOS	71
1.10	Thesis Aims And Objectives	71
<b>Chapter 2</b>	<b>Establishment Of Plasmid Standard Curves For Measurement Of Transcript Expression</b>	
<b>2.1</b>	<b>INTRODUCTION</b>	<b>74</b>
2.1.1	Northern Blot Analysis	74
2.1.2	Ribonuclease Protection Assay	75
2.1.3	cDNA Microarrays	75
2.1.4	Quantitative Real-Time Polymerase Chain Reaction	76
2.1.4.1	Conventional Polymerase Chain Reaction	76
2.1.4.2	Quantitative Polymerase Chain Reaction	78
2.1.4.3	Methods Of Quantification	79
2.1.5	Chapter Aims	80
<b>2.2</b>	<b>MATERIALS AND METHODS</b>	<b>81</b>

2.2.1	Genomic DNA Extraction	81
2.2.2	DNA Quantification	81
2.2.3	Primer Design	82
2.2.4	PCR Amplification	83
2.2.5	Agarose Gel Electrophoresis Of PCR Products	84
2.2.6	PCR Product Purification	84
2.2.7	DNA Concentration Calculation By Agarose Gel Analysis	85
2.2.8	Plasmid Vector Ligation	85
2.2.9	Transformation Of Competent Cells	87
2.2.9.1	Preparation Of Culture Media	87
2.2.9.2	Preparation Of Agar Plates	88
2.2.9.3	Transfection	88
2.2.10	Culture Of Selected Colonies	89
2.2.11	Small-Scale Isolation Of Plasmid cDNA By Alkali Lysis	90
2.2.12	Restriction Digest Analysis Of Purified Plasmid cDNA	90
2.2.13	Agarose Gel Electrophoresis	91
2.2.14	Automated DNA Sequencing	91
2.2.14.1	Sodium Acetate Precipitation	92
2.2.15	Maxiprep	92
2.2.16	Calculation of transcript copy numbers from DNA concentration	93
2.2.17	Storage Of Plasmid DNA Stock Solutions	94
2.2.18	QPCR	94
2.2.18.1	QPCR optimisation	94
2.2.18.2	QPCR Amplification Efficiency & Quality Checks	95
2.2.18.3	QPCR Protocol	96

2.2.19	QPCR Product Verification	96
<b>2.3</b>	<b>RESULTS</b>	98
2.3.1	Genomic DNA concentrations	98
2.3.2	Primer Sequences	98
2.3.3	PCR Amplification	100
2.3.4	Restriction Digest Analysis Of Mini-Preps	100
2.3.5	Measurement of Maxi-Prep DNA Concentration	101
2.3.6	Optimisation Of QPCR Primer Concentrations	102
2.3.7	QPCR Standard Curves	103
2.3.8	DNA Sequencing	107
<b>2.4</b>	<b>DISCUSSION</b>	108
<b>Chapter 3</b>	<b>Effect Of Cannabinoid Receptor Modulation On Proliferation And Differentiation In Pre-Adipocyte Cell Lines</b>	
<b>3.1</b>	<b>INTRODUCTION</b>	110
3.1.1	Cellular Composition Of Adipose Tissue	110
3.1.2	Development Of Adipose Tissue	111
3.1.3	Cellular Development & Transcript Expression During Adipogenesis	111
3.1.4	White & Brown Adipose Tissue	114
3.1.5	Cell Lines	116
3.1.5.1	White Pre-Adipocyte: 3T3-L1	117
3.1.5.2	Brown Pre-Adipocyte: PAZ6	118
3.1.6	Hormonal Induction Of Adipogenesis	118

3.1.7	<i>In Vitro</i> Evaluation Of Pre-Adipocyte Proliferation	119
3.1.7.1	Cell Cycle Analysis	120
3.1.8	<i>In Vitro</i> Assessment Of Adipogenesis	121
3.1.9	Chapter Aims	122
<b>3.2</b>	<b>MATERIALS AND METHODS</b>	123
3.2.1	Cell Populations	123
3.2.2	Reagents	123
3.2.3	Culture Media	124
3.2.4	Routine Maintenance Of Cell Lines	124
3.2.5	Cryopreservation Of Cells	125
3.2.6	Proliferation Studies	125
3.2.6.1	Cell Culture Protocol	125
3.2.6.2	Direct Cell Counting	126
3.2.6.3	Trypan Blue Toxicity Assay	126
3.2.6.4	Cell Cycle Analysis / Flow Cytometry	126
3.2.7	Adipogenesis Studies	127
3.2.7.1	Cell Culture Protocol	127
3.2.7.2	Isolation Of Total RNA From 3T3-L1 & PAZ6	127
3.2.7.3	DNase Treatment Of RNA	128
3.2.7.4	Reverse Transcription	129
3.2.7.5	Conventional PCR	129
3.2.7.6	QPCR Measurement Of Markers Of Adipogenesis	130
3.2.7.7	Oil Red O Staining	131
3.2.8	Statistical Analysis	132
<b>3.3</b>	<b>RESULTS</b>	133
3.3.1	Endogenous CB Agonist Anandamide Stimulates	133

	Proliferation Of 3T3-L1 But Has No Effect On PAZ6	
3.3.2	CB <sub>1</sub> Agonist ACEA Stimulates Proliferation Of 3T3-L1 But Does Not Affect PAZ6	137
3.3.3	Effect Of CB <sub>1</sub> Antagonist AM 251 On Proliferation Of 3T3-L1 And PAZ6	141
3.3.4	CB <sub>2</sub> Agonist JWH 133 Does Not Affect Proliferation Of 3T3-L1 Or PAZ6	145
3.3.5	CB <sub>1</sub> Antagonist AM 251 Inhibition Of Proliferation Is Not Due To Cell Toxicity	149
3.3.6	The Effect Of CB <sub>1</sub> Antagonist AM 251 On The Cell Cycle	149
3.3.7	Summary Of The Effects Of Cannabinoid Receptor Modulation On Preadipocyte Cell Line Proliferation	151
3.3.8	RNA Quality	151
3.3.9	Transcript Expression During 3T3-L1 Pre- adipocyte Differentiation	152
3.3.10	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On Foci Of Differentiation In 3T3-L1	153
3.3.11	Oil Red O Staining	153
3.3.12	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On Terminal Markers Of Adipogenesis In 3T3-L1	155
3.3.13	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On UCP-1 Expression In Differentiated 3T3-L1	157
3.4	DISCUSSION	158

<b>Chapter 4</b>	<b>Effect Of Cannabinoid Receptor Modulation On Proliferation And Differentiation In Human Primary Pre-Adipocytes.</b>	
<b>4.1</b>	<b>INTRODUCTION</b>	<b>161</b>
4.1.1	Human Primary Cultures	162
4.1.2	Adipose Tissue Depot-Specific Differences	163
4.1.3	Adiponectin	163
4.1.3.1	Enzyme-Linked Immunosorbent Assay (ELISA)	164
4.1.4	Chapter Aims	166
<b>4.2</b>	<b>MATERIALS AND METHODS</b>	<b>167</b>
4.2.1	Study Approvals & Patients Studied	167
4.2.2	Reagents And Culture Media	167
4.2.3	Explants	168
4.2.4	Collagenase Digest	168
4.2.5	Routine Maintenance Of Human Primary Pre-Adipocytes	169
4.2.6	Proliferation Studies	169
4.2.6.1	Cell Culture Protocol	169
4.2.6.2	Direct Cell Counting	170
4.2.7	Adipogenesis Studies	170
4.2.7.1	Cell Culture Protocol	170
4.2.7.2	Isolation Of Total RNA & Reverse Transcription To cDNA	171
4.2.7.3	QPCR Measurement Of Markers Of Adipogenesis	171
4.2.7.4	ELISA Measurement Of Adiponectin	171
4.2.8	Statistical Analysis	172

<b>4.3</b>	<b>RESULTS</b>	<b>173</b>
4.3.1	Study Participant Demographics	173
4.3.2	Primary Pre-Adipocyte Cell Culture	173
4.3.3	CB <sub>1</sub> Agonist ACEA Stimulates Subcutaneous Pre- Adipocyte Proliferation	175
4.3.4	CB <sub>1</sub> Agonist ACEA Stimulates Omental Pre- Adipocyte Proliferation	177
4.3.5	CB <sub>1</sub> Antagonist AM 251 Inhibits Subcutaneous Pre- Adipocyte Proliferation	179
4.3.6	CB <sub>1</sub> Antagonist AM 251 Inhibits Omental Pre- Adipocyte Proliferation	181
4.3.7	CB <sub>1</sub> Antagonist AM 251 May Exert A Preferential Effect On Omental Pre-Adipocyte Proliferation	183
4.3.8	Summary Of The Effects Of Cannabinoid Receptor Modulation On Pre-Adipocyte Cell Line Proliferation	184
4.3.9	Adipogenesis In Primary Subcutaneous & Omental Cell Cultures	185
4.3.10	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On LPL Expression In Subcutaneous Adipogenesis	186
4.3.11	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On UCP-1 Expression In Terminally Differentiated Subcutaneous Adipocytes	187
4.3.12	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On LPL Expression In Omental Adipogenesis	188
4.3.13	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM 251 On UCP-1 Expression In Terminally Differentiated Omental Adipocytes	189
4.3.14	The Effect Of CB <sub>1</sub> Agonist ACEA & CB <sub>1</sub> Antagonist AM	190



251 On Adiponectin Production During Subcutaneous &  
Omental Adipogenesis

<b>4.4</b>	<b>DISCUSSION</b>	<b>193</b>
<b>Chapter 5</b>	<b>Effect Of Metformin On Vascular Function, Body Composition &amp; Metabolic Profile In PCOS</b>	
<b>5.1</b>	<b>INTRODUCTION</b>	<b>196</b>
5.1.2	Arterial Stiffness	198
5.1.2.1	Mechanisms Of Arterial Stiffness	198
5.1.2.2	Arterial Pressure Waveform	199
5.1.2.3	Arterial Stiffness & Cardiovascular Risk	200
5.1.3	Non-Invasive Assessment Of Arterial Stiffness	201
5.1.3.1	Analysis Of Arterial Waveforms	202
5.1.3.2	Measurement Of Pulse Wave Velocity	203
5.1.3.3	Relating Change In Arterial Diameter To Distending Pressure	203
5.1.3.4	Comparison Of Non-Invasive Measures Of Arterial Stiffness	204
5.1.4	Vascular Endothelium & Endothelial Dysfunction	205
5.1.5	Non-Invasive Assessment Of Endothelial Function	207
5.1.6	Clinical Trial Design	207
5.1.7	Chapter Aims	208
<b>5.2</b>	<b>MATERIALS AND METHODS</b>	<b>209</b>
5.2.1	Trial Approval & Funding	209
5.2.2	Trial Participants – Inclusion & Exclusion Criteria	209

5.2.3	Consent	210
5.2.4	Treatments & Interventions	210
5.2.5	Measurements	211
5.2.5.1	Measurement Of Arterial Stiffness & Endothelial Function	212
5.2.5.2	Anthropometric Measurements	214
5.2.5.3	Metabolic Biochemistry Measurements	214
5.2.6	Randomisation & Blinding	216
5.2.7	Outcome Measures	216
5.2.8	Sample Size & Power Calculation	216
5.2.9	Statistical Methods	217
5.2.10	Procedures & Instructions	217
5.2.10.1	Adverse Event Reporting	217
5.2.10.2	Emergency Procedure For Unblinding	218
5.2.10.3	End Of Study Unblinding	219
5.2.11	Project Management & Administrative Procedures	219
5.2.11.1	Auditing Procedure	220
5.2.11.2	Handling Of Study Medication	220
5.2.12	Intra-Observer Variability	220

<b>5.5</b>	<b>RESULTS</b>	<b>222</b>
5.3.1	Subject Recruitment And Trial Completion	222
5.3.2	Baseline Demographic & Anthropometric Data	223
5.3.3	Baseline Vascular Parameters	224
5.3.4	Baseline Metabolic Biochemical Parameters	225
5.3.5	Prevalence Of Features Of The Metabolic Syndrome In Study Population	225
5.3.6	Treatment Compliance & Adverse Events	226

5.3.7	Effect Of Metformin On Vascular Function	227
5.3.8	Effect Of Metformin On Anthropometric Measurements	230
5.3.9	Effect Of Metformin On Metabolic Biochemical Parameters	230
<b>5.4</b>	<b>DISCUSSION</b>	<b>232</b>
<b>Chapter 6</b>	<b>General Discussion</b>	
6.1	Background	237
6.2	Thesis Aims	237
6.3	Current Pharmacological Therapies For The Management Of Obesity	238
6.4	The ECS As A Therapeutic Target In The Management Of Obesity & The Metabolic Syndrome	240
6.4.1	The Role Of CB <sub>1</sub> Receptors In The Regulation Of Metabolism	240
6.4.2	<i>In Vitro</i> Studies Supporting A Role Of Peripheral CB <sub>1</sub> Receptors	241
6.4.3	Adverse Events Associated With Rimonabant	243
6.4.4	Future Drug Development Targeting The ECS	245
6.5	Metformin In PCOS – An <i>In Vivo</i> Model Of The Metabolic Syndrome	246
6.5.1	Action Of Metformin In Adipose Tissue	247
6.5.2	Action Of Metformin In The Vascular Endothelium	248
6.5.3	Direct Effect Of Adiponectin On Endothelial Function	249
6.5.4	Future Studies	249

<b>6.6</b>	<b>Conclusion</b>	<b>250</b>
<b>Appendix 1</b>	<b>Patient Information Sheet</b>	<b>251</b>
	Physiological and pharmacological modulation of adipose/connective tissue remodelling	
<b>Appendix 2</b>	<b>Consent Form</b>	<b>255</b>
	Physiological and pharmacological modulation of adipose/connective tissue remodelling	
<b>Appendix 3</b>	<b>Patient Information Sheet</b>	<b>257</b>
	Effects of metformin on vascular function in PCOS	
<b>Appendix 4</b>	<b>Consent Form</b>	<b>263</b>
	Effects of metformin on vascular function in PCOS	
<b>Appendix 5</b>	<b>Case Report Form</b>	<b>264</b>
	Effects of metformin on vascular function in PCOS	
<b>References</b>		<b>271</b>

## **SUMMARY**

### **BACKGROUND**

Owing to the long-term health risks associated with increased adiposity and the limited efficacy of existing anti-obesity agents, there is an urgent need for further development of alternative therapeutic options to serve as an adjunct to lifestyle measures to address global cardiometabolic risk and thus reduce the risk of developing obesity-related illnesses such as type II diabetes and cardiovascular disease.

### **AIMS & METHODS**

The studies presented in this thesis aimed to investigate the effects of novel (CB<sub>1</sub> antagonist) and existing (metformin) pharmacological agents on components of the metabolic syndrome using *in vitro* and *in vivo* models. This was undertaken with *in vitro* studies of the effect of CB<sub>1</sub> receptor modulation on white, brown and primary (subcutaneous and omental) pre-adipocyte proliferation, adipogenesis and adipokine production; as well as a randomised, double-blind cross-over trial of the effects of metformin on vascular function and metabolic profile in young women with polycystic ovary syndrome (*in vivo*).

### **RESULTS**

CB<sub>1</sub> receptor antagonism inhibited white and primary pre-adipocyte proliferation and increased expression of terminal markers of adipogenesis while promoting adiponectin production. In young women with PCOS, short term metformin therapy improved arterial stiffness and endothelial function, resulted in modest weight loss and an elevation in serum adiponectin. There is increasing evidence for the key role the latter plays in metabolic processes and vascular health, and these increases in adiponectin levels may underlie some of the mechanisms mediating the changes observed. Therefore treatments targeting a switch in the adipokine profile as the therapeutic goal represent a new approach to addressing global cardiometabolic risk.

## **ACKNOWLEDGEMENTS**

First and foremost I would like to express my gratitude to my supervisors, Dr Aled Rees and Dr Marian Ludgate, for the generous support and guidance provided throughout the course of this project. I would also like to thank Dr Sam Rice for his supervision in vascular techniques as well as his endless help and advice. I am grateful to the surgical department at the University Hospital of Wales, including Mr Malcolm Puntis and Mr Nagappan Kumar (Department of Hepatobiliary Surgery), Mr Brian Rees (Department of Colorectal Surgery), and Mr David Scott-Coombes (Department of Endocrine Surgery) who provided the adipose tissue. My thanks also to Drs Lei Zhang and Martyn Bullock for their patience and tutoring in the laboratory as well as provision of plasmid cDNA stocks for human markers of adipogenesis, Mr Barrie Francis (Genomics Facility, School of Medicine) for his help with DNA sequencing, and Dr Kate Craig and her team for their help with patient care in the Cardiff Clinical Research Facility.

I would like to thank Professor Maurice Scanlon (Department of Endocrinology), and Dr Maria Gonzalez (Department of Dermatology) for allowing access to their patients. I am deeply indebted to all the patients who volunteered to participate in this study, without whom this work would not have been possible.

This project was undertaken during my tenure of a Lewis Thomas Gibbon Jenkins of Britton Ferry Fellowship granted by the Royal College of Physicians, and later by a Clinical Research Fellowship funded by the National Assembly for Wales New Deal Task Force. I am grateful to both these bodies for their financial support.

Lastly, I wish to thank my parents for their unfaltering support and encouragement over the years, my husband Vikas for his humour in the darkest hours and prolonged tolerance whilst writing this thesis, and finally my daughter Aashi for the joy and happiness she has brought to our lives.

## **PUBLICATIONS AND PRESENTATIONS**

### **Publications Arising From Research**

Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA: **Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.**

*Journal of Clinical Endocrinology & Metabolism* 2010, **95**(2):722-730.

Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA: **Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.**

*Obstetrical & Gynaecological Survey* 2010, **65**(6):381-382

### **Presentations To Learned Societies**

N Agarwal, SPL Rice, H Bolusani, SD Luzio, G Dunseath, ME Ludgate, DA Rees. **The effect of metformin on vascular function in PCOS.**

Society for Endocrinology, April 2009. Harrogate. (Oral presentation/abstract)

N Agarwal, SPL Rice, H Bolusani, SD Luzio, G Dunseath, ME Ludgate, DA Rees. **The effect of metformin on vascular function in PCOS.**

Welsh Endocrine & Diabetes Society Meeting, May 2009, Newport. (Oral presentation/abstract – David Q Borseley prize)

N Agarwal, S Rice, L Zhang, DA Rees, and ME Ludgate. **Comparison of the effects of cannabinoid receptor modulation on adipogenesis in human primary preadipocytes and a murine cell line.**

Society for Endocrinology, April 2008. Harrogate. (Poster/abstract)

N Agarwal, DA Rees, ME Ludgate. **Cannabinoid Receptors in proliferation and differentiation of white and brown adipose tissues.** Welsh Endocrine and Diabetes Society, Newport. May 2007. (Oral presentation)

N Agarwal, DA Rees, ME Ludgate. **Comparison of the effects of cannabinoid receptor modulation in human primary preadipocytes and a murine cell line.**  
Society for Endocrinology, Birmingham. March 2007. (Poster/Abstract)

N Agarwal, DA Rees, ME Ludgate. **Cannabinoid Receptors in proliferation and differentiation of white and brown adipose tissues.**  
Society for Endocrinology, London. November 2006. (Poster/Abstract)

This work has also been presented locally at Cardiff University Annual Research Days and at Cardiff University Interdisciplinary Research Group meetings.



## **ABBREVIATIONS**

<b>µg</b>	<b>Microgrammes</b>
<b>µl</b>	<b>Microlitres</b>
<b>17-OHP</b>	<b>17-hydroxyprogesterone</b>
<b>2-AG</b>	<b>2-arachidonylglycerol</b>
<b>5-HT</b>	<b>5-hydroxytryptamine</b>
<b>A</b>	<b>Adenosine</b>
<b>A<sub>260</sub></b>	<b>Absorbance at wavelengths of 260 nanometres</b>
<b>A<sub>280</sub></b>	<b>Absorbance at wavelengths of 280 nanometres</b>
<b>AACE</b>	<b>American Association of Clinical Endocrinology</b>
<b>ACE</b>	<b>Angiotensin converting enzyme</b>
<b>ACTH</b>	<b>Adrenocorticotrophic hormone</b>
<b>AEA</b>	<b>Anandamide</b>
<b>AIx</b>	<b>Augmentation index</b>
<b>AMPK</b>	<b>Adenosine monophosphate-activated protein kinase</b>
<b>Amp<sup>r</sup></b>	<b>ampicillin resistance</b>
<b>AP</b>	<b>Active – Placebo</b>
<b>Apo B</b>	<b>Apoprotein B</b>
<b>APRT</b>	<b>adenosine phosphoribosyltransferase</b>
<b>aPWV</b>	<b>Aortic pulse wave velocity</b>
<b>ARP</b>	<b>acidic ribosomal phosphoprotein</b>
<b>ATII</b>	<b>angiotensin-II</b>
<b>BAT</b>	<b>Brown adipose tissue</b>
<b>BLAST</b>	<b>Basic Local Alignment Search Tool</b>
<b>BMI</b>	<b>Body mass index</b>
<b>bp</b>	<b>Base pairs</b>
<b>BP</b>	<b>Blood pressure</b>

<b>bPWV</b>	<b>Brachial pulse wave velocity</b>
<b>BSA</b>	<b>bovine serum albumin</b>
<b>Buffer AW</b>	<b>Wash buffer</b>
<b>C</b>	<b>Cytosine</b>
<b>C/EBP</b>	<b>CCAAT-enhancer-binding proteins</b>
<b>C/EBP<math>\beta</math></b>	<b>CCAAT-enhancer-binding protein <math>\beta</math></b>
<b>CAD</b>	<b>Coronary artery disease</b>
<b>cAMP</b>	<b>Cyclic adenosine monophosphate</b>
<b>CB<sub>1</sub></b>	<b>Cannabinoid receptor 1</b>
<b>CB<sub>2</sub></b>	<b>Cannabinoid receptor 2</b>
<b>cDBP</b>	<b>Central diastolic blood pressure</b>
<b>cDNA</b>	<b>complementary DNA</b>
<b>CHD</b>	<b>Coronary heart disease</b>
<b>CHOP</b>	<b>C/EBP homologous protein</b>
<b>CiAP2</b>	<b>cellular inhibitor of apoptosis2</b>
<b>CIMT</b>	<b>Carotid intima media thickness</b>
<b>cm</b>	<b>centimetre</b>
<b>CNP</b>	<b>C-type natriuretic peptide</b>
<b>COX</b>	<b>cyclooxygenase</b>
<b>CRP</b>	<b>C-reactive protein</b>
<b>cSBP</b>	<b>Central systolic blood pressure</b>
<b>Ct</b>	<b>threshold cycle</b>
<b>CVD</b>	<b>Cardiovascular disease</b>
<b>dATP</b>	<b>Deoxyadenosine triphosphate</b>
<b>dCTP</b>	<b>Deoxycytosine triphosphate</b>
<b>dGTP</b>	<b>Deoxyguanosine triphosphate</b>
<b>DHEA</b>	<b>Dehydroepiandrosterone</b>
<b>DM</b>	<b>Differentiation medium</b>

DMEM	Dulbecco's modified eagle medium
DMSO	dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DNase	Deoxyribonuclease
dNTPs	Deoxynucleotide triphosphates
dNTPs	deoxynucleotide triphosphates
DPP	Diabetes prevention programme
dTTP	Deoxythymidine triphosphates
E. Coli	<i>Escherichia coli</i>
ECS	Endocannabinoid system
EDHF	endothelium-derived hyperpolarizing factor
EDTA	Ethylenediaminetetraacetic acid
EGIR	The European Group for the study of Insulin Resistance
EMA	European medicines agency
eNOS	endothelium NOS
ET-1	endothelin-1
FA	Fatty acid
FAAH	Fatty acid amide hydrolase
FAH	Functional adrenal hyperandrogenism
FAI	Free androgen index
FAS	Fatty acid synthase
FCS	Fetal calf serum
FDG PET	2-[ <sup>18</sup> F]fluoro-2-deoxy-glucose positron emission tomography
FDPT	Finnish diabetes prevention trial
FFA	Free fatty acids
FOH	Functional ovarian hyperandrogenism
FSH	Follicle stimulating hormone
G	Grammes

G	Guanine
G <sub>0</sub>	Gap 0 cell cycle phase
G <sub>1/2</sub>	Gap 1 or 2: cell growth phase
GATA	glutamyl amino transferidase subunit A
GH1	Growth Hormone 1
GHR	Growth Hormone Receptor
GLUT4	glucose transporter 4
GnRH	Gonadotrophin releasing hormone
GPDH	glycerol-3-phosphate dehydrogenase
GTN	Glyceryl trinitrite
H <sub>2</sub> O	Pure water
HAART	highly active antiretroviral therapy
HBSS	Hank's balanced salt solution
HDL	High density lipoprotein
HIV	Human Immunodeficiency Virus
HOMA	Homeostasis model assessment
HOMA-IR	Homeostasis model assessment - Insulin Resistance
HRP	Horseradish-peroxidase
hsCRP	High sensitivity C-reactive protein
IBMX	3-isobutyl-1-methylxanthine
IDF	International Diabetes Federation
IGF	Impaired fasting glucose
IGF-1	Insulin-like growth factor 1
IGT	Impaired glucose tolerance
IL-6	Interleukin-6
IMP	investigational medicinal product
iNOS	inducible NOS
IP <sub>3</sub>	inositol triphosphate 3

<b>IQR</b>	<b>Inter Quartile Range</b>
<b>IR</b>	<b>Insulin resistance</b>
<b>IRS</b>	<b>Insulin receptor substrate</b>
<b>ISRCTN</b>	<b>International Standard Randomised Controlled Trial Number</b>
<b>K<sup>+</sup><sub>A</sub></b>	<b>A-type potassium channels</b>
<b>Kb</b>	<b>Kilo base</b>
<b>kg</b>	<b>Kilogram</b>
<b>KLF</b>	<b>Krupple-like factors</b>
<b>L</b>	<b>Litre</b>
<b><i>LacZ</i></b>	<b>β-galactosidase</b>
<b>LB</b>	<b>Luria Bertani</b>
<b>LDL</b>	<b>Low density lipoprotein</b>
<b>LH</b>	<b>Luteinising hormone</b>
<b>LPL</b>	<b>Lipoprotein lipase</b>
<b>M</b>	<b>Molar</b>
<b>MAP</b>	<b>mitogen-activated protein</b>
<b>mg</b>	<b>Milligrams</b>
<b>MgCl<sub>2</sub></b>	<b>Magnesium chloride</b>
<b>MHRA</b>	<b>Medicines and Healthcare Products Regulatory Authority</b>
<b>ml</b>	<b>Millilitres</b>
<b>mM</b>	<b>Millimolar</b>
<b>MMLV</b>	<b>Moloney murine leukemia virus</b>
<b>mmol</b>	<b>Millimoles</b>
<b>MRI</b>	<b>Magnetic Resonance Imaging</b>
<b>mRNA</b>	<b>Messenger RNA</b>
<b>NCEP-ATP III</b>	<b>National Cholesterol Education Program Third Adult Treatment Panel</b>
<b>ng</b>	<b>Nanograms</b>
<b>NHANES</b>	<b>National Health and Nutrition Examination Survey</b>

<b>nM</b>	<b>Nanomolar</b>
<b>NO</b>	<b>Nitric oxide</b>
<b>NOS</b>	<b>NO synthases</b>
<b>OD<sub>49</sub></b>	<b>Optical density at 49 nm</b>
<b>PA</b>	<b>Placebo Active</b>
<b>PAI-1</b>	<b>Plasminogen activator inhibitor-1</b>
<b>PBS</b>	<b>Phosphate buffered saline</b>
<b>PCOS</b>	<b>Polycystic ovary syndrome</b>
<b>PCR</b>	<b>Polymerase chain reaction</b>
<b>pDBP</b>	<b>Perioheral diastolic blood pressure</b>
<b>pg</b>	<b>Picogrammes</b>
<b>PGI<sub>2</sub></b>	<b>Prostacyclin</b>
<b>PGK1</b>	<b>phosphoglycerate-1-kinas</b>
<b>PI3K</b>	<b>phosphoinositide 3 kinase</b>
<b>PKA</b>	<b>Protein kinase A</b>
<b>PKC</b>	<b>Protein kinase C</b>
<b>PLC</b>	<b>phopholipase C</b>
<b>pmol</b>	<b>Picomoles</b>
<b>pmol</b>	<b>Picomoles</b>
<b>PPAR<math>\gamma</math></b>	<b>Peroxisome proliferator-activated receptor-<math>\gamma</math></b>
<b>Pref-1</b>	<b>Pre-adipocyte factor 1</b>
<b>pSBP</b>	<b>Peripheral systolic blood pressure</b>
<b>PWA</b>	<b>Pulse wave analysis</b>
<b>PWV</b>	<b>Pulse wave velocity</b>
<b>QPCR</b>	<b>Quantitative real time polymerase chain reaction</b>
<b>RIO</b>	<b>Rimonabant in obesity</b>
<b>RNA</b>	<b>Ribonucleic acid</b>
<b>RNase</b>	<b>Ribonuclease</b>

RPA	ribonuclease protection assay
rpm	Revolutions per minute
RSq	correlation coefficient
S	DNA synthesis phase
SAE	Serious adverse event
SEM	Standard error of mean
SHBG	Sex-hormone binding globulin
siRNA	small interfering RNA
SNP	sodium nitroprusside
SREBP1c	Sterol response element binding protein 1c
T <sub>10</sub> E <sub>1</sub>	(10 mM Tris-HCl, 1 mM EDTA, pH 8.0)
T2DM	Type II diabetes mellitus
TAE	Tris-Acetate-EDTA
TC	Total cholesterol
TG	Triglycerides
TGF- $\beta$	transforming growth factor- $\beta$
T <sub>m</sub>	melting temperature
TNF- $\alpha$	Tumour necrosis factor-alpha
t-PA	Tissue plasminogen activator inhibitor
T <sub>R</sub>	Time to inflection point
Tris.HCl	Tris(hydroxymethyl)aminomethane hydrochloride
U	Units
UCP-1	uncoupling protein-1
UHW	University Hospital of Wales
UV	Ultraviolet
VLDL	Very low-density lipoprotein
v/v	Volume/volume
w/v	Weight/volume

WAT	White adipose tissue
WHO	World Health Organisation
WHR	Waist hip ratio
X-gal	5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside
$\Delta^9$ -THC	$\Delta^9$ -tetrahydrocannabinol
$\mu\text{m}$	Micrometre
$\mu\text{M}$	Micromolar



## LIST OF FIGURES

Figure №	Title	Page №
1.1	The Role Of Obesity & Insulin Resistance In The Pathogenesis Of The Metabolic Syndrome	44
1.2	Prevalence Of The Metabolic Syndrome From NCEP ATP III Definition	47
1.3	Schematic Representation of Human CB1 and CB2 Receptors	52
1.4	Schematic Representation Of The Endocannabinoids	53
1.5	Exogenous CB1 Receptor Ligands	55
1.6	Effects Of CB1 Activation On Intracellular Signalling Cascades	56
1.7	Endocannabinoid-Mediated Neurotransmitter Signalling	57
1.8	Ovarian Steroid Biosynthesis Pathways	63
1.9	Consequences Of Insulin Resistance In PCOS	65
1.10	Increased Insulin Resistance In PCOS	67
1.11	Prevalence Of The Metabolic Syndrome In PCOS	70
2.1	Schematic Diagram Of The PCR Cycle	77
2.2	Schematic Representation Of SYBR® Green QPCR	79
2.3	pGEM®-T Easy Plasmid Vector Map & Sequence Reference Points	86
2.4	Selection Of Bacterial Colonies Containing Plasmid Vector	89
2.5	Human and Murine CB PCR Products	100
2.6	Human CB <sub>1</sub> Mini-Prep Restriction Digest Products	101
2.7A	SYBR Green® QPCR Standard Curve & Amplification Plots for Human CB <sub>1</sub>	104
2.7B	SYBR Green® QPCR Standard Curve & Amplification Plots for Murine CB <sub>1</sub>	104

2.7C	SYBR Green® QPCR Standard Curve & Amplification Plots for Human CB <sub>2</sub>	105
2.7D	SYBR Green® QPCR Standard Curve & Amplification Plots for Murine CB <sub>2</sub>	105
2.8A	Dissociation Curve For Human CB <sub>1</sub>	106
2.8B	Dissociation Curve For Murine CB <sub>1</sub>	106
2.8C	Dissociation Curve For Human CB <sub>2</sub>	107
2.8D	Dissociation Curve For Murine CB <sub>2</sub>	107
3.1	Transcriptional Regulation Of Adipogenesis	114
3.2	White & Brown Fat Development From The Mesenchymal Stem Cell	116
3.3	Murine 3T3-L1 White Pre-Adipocytes	117
3.4	Human PAZ6 Brown Pre-Adipocytes	118
3.5	Stages Of The Cell Cycle	121
3.6	The Effect Of Anandamide On 3T3-L1 Proliferation At 24 Hours	133
3.7	The Effect Of Anandamide On 3T3-L1 Proliferation At 72 Hours	134
3.8	The Effect Of Anandamide On PAZ6 Proliferation At 24 Hours	135
3.9	The Effect Of Anandamide On PAZ6 Proliferation At 72 Hours	136
3.10	The Effect Of ACEA On 3T3-L1 Proliferation At 24 Hours	137
3.11	The Effect Of ACEA On 3T3-L1 Proliferation At 72 Hours	138
3.12	The Effect Of ACEA On PAZ6 Proliferation At 24 Hours	139
3.13	The Effect Of ACEA On PAZ6 Proliferation At 72 Hours	140
3.14	The Effect Of AM 251 On 3T3-L1 Proliferation At 24 Hours	141
3.15	The Effect Of AM 251 On 3T3-L1 Proliferation At 72 Hours	142
3.16	The Effect Of AM 251 On PAZ6 Proliferation At 24 Hours	143
3.17	The Effect Of AM 251 On PAZ6 Proliferation At 72 Hours	144
3.18	The Effect Of JWH 133 On 3T3-L1 Proliferation At 24 Hours	145
3.19	The Effect Of JWH 133 On 3T3-L1 Proliferation At 72 Hours	146

3.20	The Effect Of JWH 133 On PAZ6 Proliferation At 24 Hours	147
3.21	The Effect Of JWH 133 On PAZ6 Proliferation At 72 Hours	148
3.22	Trypan Blue Staining Of 3T3-L1 After 72 Hours Exposure To AM 251	149
3.23	Histograms Illustrating Effect Of AM 251 On 3T3-L1 Cell Cycle Progression	150
3.24	The Effect Of AM 251 On 3T3-L1 Cell Cycle	150
3.25	Agarose Gel Electrophoresis Of 3T3-L1 RNA	151
3.26	Transcript Expression During 3T3-L1 Adipogenesis	152
3.27	Adipogenesis In 3T3-L1	153
3.28	Oil Red O Staining In Mature 3T3-L1 Adipocytes	154
3.29	Box-and-Whisker Representation Of The Effect Of CB <sub>1</sub> Agonist ACEA & Antagonist AM 251 On Oil Red O Staining in Mature 3T3-L1 Adipocytes	154
3.30	The Effect Of AM 251 On GPDH Expression In 3T3-L1 During Adipogenesis	155
4.1	Association Of Reduced Serum Adiponectin With Features Of The Metabolic Syndrome In Males & Females As Defined By The IDF Criteria	164
4.2	Schematic Representation Of The ELISA Technique	165
4.3	Isolation Of Primary Pre-Adipocytes Using Collagenase Digest Followed By Centrifugation Through Phthalic Acid Dionyl Ester.	169
4.4A	Subcutaneous Pre-Adipocytes	174
4.4B	Omental Pre-Adipocytes	174
4.5	Effect Of ACEA On Subcutaneous Pre-Adipocyte Proliferation At 72 Hours	175
4.6	Effect Of ACEA On Subcutaneous Pre-Adipocyte Proliferation At 168 Hours	176

4.7	The Effect Of ACEA On Omental Pre-Adipocyte Proliferation At 72 Hours	177
4.8	The Effect Of ACEA On Omental Pre-Adipocyte Proliferation At 168 Hours	178
4.9	Effect Of AM251 On Subcutaneous Pre-Adipocyte Proliferation At 72 Hours	179
4.10	Effect Of AM251 On Subcutaneous Pre-Adipocyte Proliferation At 168 Hours	180
4.11	The Effect Of AM 251 On Omental Pre-adipocyte Proliferation At 72 Hours	181
4.12	Effect Of AM 251 On Omental Pre-Adipocyte Proliferation At 168 Hours	182
4.13A	Effect Of 500 nM AM 251 On Primary Preadipocyte Proliferation	183
4.13B	Effect Of 10 $\mu$ M ACEA On Primary Preadipocyte Proliferation	184
4.14A	Subcutaneous Adipocytes	185
4.14B	Omental Adipocytes	185
4.15	Effect Of ACEA & AM251 On Subcutaneous Adipogenesis	187
4.16	Effect Of ACEA & AM251 On Omental Adipogenesis	189
4.17	Effect Of ACEA & AM251 On Omental Adiponectin Production	191
4.18	Effect Of ACEA & AM251 On Subcutaneous Adiponectin Production	191
5.1	Age-Adjusted Prevalence Of Features Of The Metabolic Syndrome In Women With PCOS, Age-Matched Controls And Women From the NHANES Study	196
5.2	Schematic Representation Of The Arterial Pressure Waveform	199
5.3	Schematic Representation Of Healthy & Stiffened Arterial Waveforms	200
5.4	Schematic Representation Of Applanation Tonometry	202
5.5	Modulators Of Vascular Tone	206

5.6	Summary Of Clinical Trial Design	211
5.7	Example Of SphygmoCor™ Generated PWA	213
5.8	Flow Of Participants Through Each Phase Of The Clinical Trial	222
5.9	Effect Of Metformin Therapy On Augmentation Index In PCOS	227
5.10	Effect Of Metformin Therapy On Brachial & Aortic PWV In PCOS	228
5.11	Effect Of Metformin Therapy On Peripheral BP In PCOS	228
5.12	Effect Of Metformin Therapy On Central Systolic BP In PCOS	229
5.13	Effect Of Metformin Therapy On Adiponectin In PCOS	231

## LIST OF TABLES

Table №	Title	Page №
1.1	Definitions Of The Metabolic Syndrome	39
1.2	IDF Worldwide Definition Of The Metabolic Syndrome	40
1.3	Proteins Secreted By Adipocytes	42
1.4	Benefits Of 10kg Weight Loss	50
1.5	Potential Sites And Therapeutic Effects Of CB <sub>1</sub> Antagonists	60
2.1	PCR Reagents For Amplification From Genomic DNA	83
2.2	PCR Thermal Cycling Protocol	84
2.3	Protocol For pGEM®-T Easy Vector Ligation With PCR Amplicons	87
2.4	PCR Protocol For DNA Sequencing	92
2.5	Primer Concentrations Used In The Primer Matrix Test	95
2.5	QPCR Thermal Cycling Protocol	97
2.7	Quantification Of Genomic DNA Concentration	98
2.8A	Primer Sequences for Human CB Receptors and Markers Of Adipogenesis	99
2.8B	Primer Sequences for Murine CB Receptors and Markers Of Adipogenesis	99
2.9	Maxi-Prep DNA Concentrations	101
2.10	Transcript Copy Numbers Determined From Maxi-Prep DNA Concentration	102
2.11	Human CB <sub>1</sub> Primer Matrix Test	103
2.12	Optimised Concentrations For All QPCR Primers	103

3.1	Cellular Development And Transcript Expression In Adipogenesis	112
3.2	Summary Of CB Receptor Modulators	123
3.3	Constituents Of Cell Culture Media	124
3.4	Reverse Transcription Thermal Cycling Protocol	129
3.5	PCR Reagents For Amplification From Genomic DNA	130
3.6	PCR Thermal Cycling Protocol	130
3.7	QPCR Thermal Cycling Protocol	131
3.8	Mean, Median & IQR For 3T3-L1 Treated With Anandamide For 24 Hours	133
3.9	Mean, Median & IQR For 3T3-L1 Treated With Anandamide For 72 Hours	134
3.10	Mean, Median & IQR For PAZ6 Treated With Anandamide For 24 Hours	135
3.11	Mean, Median & IQR For PAZ6 Treated With Anandamide For 72 Hours	136
3.12	Mean, Median & IQR For 3T3-L1 Treated With ACEA For 24 Hours	137
3.13	Mean, Median & IQR For 3T3-L1 Treated With ACEA For 72 Hours	138
3.14	Mean, Median & IQR For PAZ6 Treated With ACEA For 24 Hours	139
3.15	Mean, Median & IQR For PAZ6 Treated With ACEA For 72 Hours	140
3.16	Mean, Median & IQR For 3T3-L1 Treated With AM 251 For 24 Hours	141
3.17	Mean, Median & IQR For 3T3-L1 Treated With AM 251 For 72 Hours	142
3.18	Mean, Median & IQR For PAZ6 Treated With AM 251 For 24 Hours	143
3.19	Mean, Median & IQR For PAZ6 Treated With AM 251 For 72 Hours	144
3.20	Mean, Median & IQR For 3T3-L1 Treated With JWH 133 For 24 Hours	145
3.21	Mean, Median & IQR For 3T3-L1 Treated With JWH 133 For 72 Hours	146
3.22	Mean, Median & IQR For PAZ6 Treated With JWH 133 For 24 Hours	147
3.23	Mean, Median & IQR For PAZ6 Treated With JWH 133 For 72 Hours	148
3.24	The Effect Of AM 251 On GPDH Expression In 3T3-L1 During	156

## **Adipogenesis**

<b>4.1</b>	<b>Anthropometric Data Of Study Participants</b>	<b>173</b>
<b>4.2</b>	<b>Mean, Median &amp; IQR For Subcutaneous Cells Treated With ACEA For 72 Hours</b>	<b>175</b>
<b>4.3</b>	<b>Mean, Median &amp; IQR For Subcutaneous Cells Treated With ACEA For 168 Hours</b>	<b>176</b>
<b>4.4.</b>	<b>Mean, Median &amp; IQR For Omental Cells Treated With ACEA For 72 Hours</b>	<b>177</b>
<b>4.5</b>	<b>Mean, Median &amp; IQR For Omental Cells Treated With ACEA For 168 Hours</b>	<b>178</b>
<b>4.6</b>	<b>Mean, Median &amp; IQR For Subcutaneous Cells Treated With AM 251 For 72 Hours</b>	<b>179</b>
<b>4.7</b>	<b>Mean, Median &amp; IQR For Subcutaneous Cells After AM 251 For 168 Hours</b>	<b>180</b>
<b>4.8</b>	<b>Mean, Median &amp; IQR For Omental Cells Treated With AM 251 For 72 Hours</b>	<b>181</b>
<b>4.9</b>	<b>Mean, Median &amp; IQR For Omental Cells Treated With AM 251 For 168 Hours</b>	<b>182</b>
<b>4.10</b>	<b>Effect Of ACEA &amp; AM251 On LPL Expression In Subcutaneous Adipogenesis</b>	<b>186</b>
<b>4.11</b>	<b>Effect Of ACEA &amp; AM251 On LPL Expression In Omental Adipogenesis</b>	<b>188</b>
<b>4.12</b>	<b>Effect Of ACEA &amp; AM251 On Omental Adiponectin Production</b>	<b>190</b>
<b>4.13</b>	<b>Effect Of ACEA &amp; AM251 On Subcutaneous Adiponectin Production</b>	<b>192</b>
<b>5.1</b>	<b>Advantages &amp; Disadvantages Of Non-Invasive Measures Of Arterial Stiffness</b>	<b>204</b>
<b>5.2</b>	<b>Biochemical Assay Information</b>	<b>215</b>



5.3	Intra-Operator Variability	221
5.4	Baseline Demographic & Anthropometric Characteristics	223
5.5	Baseline Vascular Parameters Of Study Participants	224
5.6	Baseline Metabolic Biochemical Parameters Of Study Participants	225
5.7	Prevalence Of Features Of The Metabolic Syndrome In PCOS Based On the 2006 IDF Criteria	226
5.8	Effect Of Metformin vs. Placebo On Vascular Outcome In PCOS	229
5.9	Effect Of Metformin vs. Placebo On Anthropometric Measurements In PCOS	230
5.10	Effect Of Metformin vs. Placebo On Metabolic Markers In PCOS	231

# **CHAPTER 1:      GENERAL INTRODUCTION - MODELS OF THE METABOLIC SYNDROME**

## **1.1              Historical Perspective**

The concept of the metabolic syndrome, or a clustering of metabolic abnormalities arising from the increasing prevalence of obesity, has existed since the 1920s, when the Swedish physician Kylin first described an association between hypertension, hyperglycaemia and hyperuricaemia [1]. A correlation with upper body adiposity (android or male-type obesity) was acknowledged by Vague in the 1940s [2] while the association with insulin resistance was made towards the end of the 1980s [3]. Since then numerous labels have been applied including the “deadly quartet,” “syndrome X” and the “insulin resistance syndrome” eventually leading to today’s terminology of the metabolic syndrome referring to the coexistence of glucose intolerance and insulin resistance, central obesity, dyslipidaemia and hypertension [4]. These are all well recognised risk factors predisposing individuals to the development of type II diabetes and cardiovascular disease, both associated with increased morbidity and mortality. With a growing worldwide prevalence, addressing the metabolic syndrome has therefore become a global public health challenge.

## **1.2              Definition Of The Metabolic Syndrome**

Over recent years numerous expert groups have attempted to develop an internationally accepted and unified definition of the metabolic syndrome (Table 1.1), including the World Health Organisation (WHO), the European Group for the Study of Insulin Resistance (EGIR), and the National Cholesterol Education Program Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults - Third Adult Treatment Panel (NCEP-ATP

III), as well as position statements from the American Association of Clinical Endocrinology (AACE) and the International Diabetes Federation (IDF) [4, 5].

**Table 1.1: Definitions Of The Metabolic Syndrome**

	WHO 1999 [6]  Impaired glucose tolerance or diabetes and/or insulin resistance AND two of the following:	EGIR 1999 [7]  Insulin resistance AND two of the following:	NCEP ATP III 2001 [8]  Three or more of the following risk factors:	AACE 2003 [9]
<b>Central obesity</b>	Waist hip ratio ≥ 0.9 ♂ ≥ 0.85 ♀ or BMI > 30 kg/m <sup>2</sup>	Waist circumference ≥ 94 cm ♂ ≥ 80 cm ♀	Waist circumference ≥ 102 cm ♂ ≥ 88 cm ♀	BMI > 25 kg/m <sup>2</sup>
<b>Dysglycaemia (mmol/l)</b>	Fasting glucose ≥ 6.1 or 2 hours post glucose challenge ≥ 7.8	Fasting glucose ≥ 6.1	Fasting glucose ≥ 6.1 (modified to ≥ 5.6 in 2004)	Fasting glucose ≥ 6.1 or 2 hours post glucose challenge ≥ 7.8
<b>Insulin resistance</b>	Glucose uptake below lowest quartile measured under hyperinsulinaemic euglycaemic conditions	Top 25% of fasting insulin values among the non-diabetic population	Not applicable	Not applicable
<b>Blood Pressure (mmHg)</b>	≥ 140/90	≥ 140/90 or treated hypertension	> 130/85 or treated hypertension	> 130/85
<b>Triglycerides (mmol/l)</b>	≥ 1.7	> 2.0	≥ 1.7	≥ 1.7
<b>HDL cholesterol (mmol/l)</b>	♂ < 0.9 ♀ < 1.0	< 1.0 or on treatment	♂ < 1.03 ♀ < 1.29	♂ < 1.03 ♀ < 1.29
<b>Other factors</b>	Microalbuminuria (urinary albumin excretion rate > 20 µg/min or albumin: creatinine ratio > 30 mg/g)	Not applicable	Not applicable	Family history of type II DM Polycystic Ovary Syndrome Sedentary lifestyle Increasing age Ethnicity

While all groups are in agreement over the core components of obesity, hyperglycaemia, hypertension and dyslipidaemia, considerable confusion and controversy exists regarding the specific criteria and cut-off points for each individual component, and the applicability of these criteria to differing populations. The assessment of obesity has been most difficult, with older definitions failing to account for ethnic variations in body mass index (BMI) and waist circumference, though this has been addressed in the 2005 IDF consensus statement recommending an updated global definition for the metabolic syndrome (Table 1.2). By accounting for ethnic variations in the measurement, and implications, of central obesity, the IDF definition should enable physicians internationally to identify and treat at risk individuals, whilst also allowing comparison of the prevalence and health outcomes of this syndrome in differing populations [5]. This definition also requires the presence of central obesity for the diagnosis, thus recognising the strong correlation with other features of the metabolic syndrome.

**Table 1.2: IDF Worldwide Definition Of The Metabolic Syndrome [5]**

Clinical Parameter	Eligibility Criteria (Ethnicity specific central obesity plus 2 other factors)	
<b>Triglycerides (mmol/l)</b>	≥ 1.7 or treated hypertriglyceridaemia	
<b>HDL cholesterol (mmol/l)</b>	♂ < 1.03    ♀ < 1.29	
<b>Blood pressure (mmHg)</b>	Systolic ≥ 135 or diastolic ≥ 85	
<b>Dysglycaemia (mmol/l)</b>	Fasting glucose ≥ 5.6 or previously diagnosed type II DM	
<b>Ethnicity specific central obesity (waist circumference - cm)</b>	Europeans	♂ ≥ 94 cm    ♀ ≥ 80 cm
	USA (Caucasians)	♂ ≥ 102 cm    ♀ ≥ 88 cm
	South Asians	♂ ≥ 90 cm    ♀ ≥ 80 cm
	Chinese	♂ ≥ 90 cm    ♀ ≥ 80 cm
	Japanese	♂ ≥ 90 cm    ♀ ≥ 80 cm
	South & Central Americans	Use South Asian values till further data available
	Sub-Saharan Africans Eastern Mediterraneans Middle Easterns	Use European values till further data available

### **1.3 Pathogenesis Of The Metabolic Syndrome**

The complex pathogenesis of the metabolic syndrome and its key components is still to be fully elucidated. Both insulin resistance together with central or visceral adiposity are the dominant causative factors recognised to date. The global obesity epidemic is thought to be the most important driving force for the increasing prevalence of both insulin resistance and the metabolic syndrome [5]. Environmental factors which include cigarette smoking and sedentary lifestyles also contribute to the development of many of the major metabolic disturbances [4].

#### **1.3.1 Obesity & Abnormal Body Fat Distribution**

Epidemiological studies have demonstrated a clear association between increasing body weight, measured by the body mass index (BMI), and all-cause mortality [10]. Furthermore, amongst individuals with similar BMI values, those with greater abdominal adiposity (as assessed by measurement of waist circumference or waist-hip ratio), are at greater risk of developing type II diabetes mellitus (DM), hypertension and cardiovascular disease (CVD) [11, 12]. This excess in visceral, as compared to subcutaneous, accumulation of adipose tissue has been shown to be associated with adverse and potentially atherogenic metabolic disturbances in both men and women, including fasting hypertriglyceridaemia, reduction in high-density lipoprotein (HDL), and elevations in both fasting and post-prandial insulin and glucose levels [13].

The hypotheses which link central obesity with components of the metabolic syndrome have arisen from the recent understanding of the function of adipose tissue as not only an energy store, but an endocrine organ capable of secreting adipocytokines, growth factors and other bio-active substances (Table 1.3) known to impair the action of insulin. These include free fatty acids (FFA) and the inflammatory mediators tumour necrosis factor-alpha (TNF- $\alpha$ ) and

interleukin-6 (IL-6) [14]. TNF- $\alpha$  has been shown to promote insulin resistance, stimulate lipolysis and thus increase FFA release, and inhibit peripheral glucose uptake while IL-6 increases hepatic glucose production & triglyceride synthesis. Excess visceral adipose tissue is also associated with a reduction in the insulin-sensitising cytokine adiponectin, and thus a loss of its anti-diabetic, anti-inflammatory, and anti-atherosclerotic properties [14]. These pathogenic processes are illustrated further in Figure 1.1.

**Table 1.3: Proteins Secreted By Adipocytes [15]**

Molecule	Effect
<b>Adiponectin</b>	Insulin sensitisation Improved fatty acid transport and utilisation
<b>Leptin</b>	Hypothalamic energy regulation Maturation of reproductive function
<b>Resistin</b>	Impairs insulin sensitivity
<b>Tumour necrosis factor alpha</b>	Mediator of the acute phase response Increased insulin resistance ( $\downarrow$ lipogenesis, $\uparrow$ lipolysis, $\downarrow$ insulin-induced glucose uptake)
<b>Interleukin 6</b>	Increases hepatic glucose production & triglyceride synthesis
<b>Plasminogen activator inhibitor 1</b>	Potent inhibitor of the fibrinolytic system
<b>Angiotensinogen</b>	Regulator of blood pressure & electrolyte homeostasis
<b>Transforming growth factor beta</b>	Regulator of growth & differentiation
<b>Insulin like growth factor 1</b>	Stimulates cell proliferation and mediates many effects of growth hormone
<b>Adipsin</b>	? link between activation of the complement pathway and adipose tissue metabolism
<b>Acylation Stimulating Protein</b>	Activates diacylglycerol acyltransferase Inhibits lipase Stimulates Glucose transporter 4 translocation to cell surface
<b>Tissue factor</b>	Initiator of the coagulation cascade
<b>PGI2 PGF2alpha</b>	Implicated in blood clotting, ovulation & menstruation
<b>Migration inhibitory factor</b>	Involved in proinflammatory processes & immunoregulation
<b>Adipocyte protein 2</b>	Involved in intracellular trafficking and targeting of fatty acids
<b>Agouti protein</b>	? induces insulin resistance through increasing intracellular free calcium concentrations Increases appetite & decreases energy expenditure

### **1.3.2 Insulin Resistance & Glucose Intolerance**


There is clear evidence supporting a major role of insulin resistance in the development of the metabolic syndrome, though the exact underlying mechanism is not yet fully understood. It is present in the majority of individuals meeting the criteria for the metabolic syndrome with a strong association with the other dominant components, as well as the correlation with the development of type II DM and CVD [5]. The Bruneck study examined the prevalence of insulin resistance in random subjects from the general population aged between 40 and 79 years by the homeostasis model assessment (HOMA), and demonstrated a clear correlation between increasing degrees of insulin resistance and the number of co-existing metabolic abnormalities [16]. Meta-analysis of previous data has shown hyperinsulinaemia in non-diabetic men and women to be an independent risk factor for CVD, especially in non-white populations, though this does still require further study [17].

#### **1.3.2.1 The Role Of Obesity In The Pathogenesis Of Insulin Resistance**

An overabundance of FFAs, derived predominantly from lipolysis of triglyceride stores within adipose tissue, is thought to be a main contributor to the development of insulin resistance [4]. Insulin itself has important antilipolytic properties, thus further compounding the problem in the setting of insulin resistance. The excess FFAs further antagonise the actions of insulin by stimulating hepatic gluconeogenesis thus contributing to hyperglycaemia, whilst also suppressing peripheral skeletal muscle glucose transport leading to reduced muscle glycogen synthesis and glycolysis [18]. The increasing and prolonged exposure to the resultant elevated concentrations of insulin eventually leads to the development of frank type II DM, deterioration in pancreatic  $\beta$ -cell function and therefore a fall in insulin secretion with worsening hyperglycaemia [19]. These pathogenic processes are illustrated further in Figure

1.1.

**Figure 1.1: The Role Of Obesity & Insulin Resistance In The Pathogenesis Of The Metabolic Syndrome [4, 20, 21]**



### 1.3.2.2 Impaired Insulin Receptor Signalling In Insulin Resistance

Insulin binding induces tyrosine phosphorylation of the insulin receptor, resulting in the binding of a number of intracellular proteins such as the insulin receptor substrates (IRS-1



and IRS-2) [22]. Phosphorylated tyrosine residues on these proteins serve as docking sites for the recruitment and binding of downstream signalling proteins such as phosphoinositide 3 kinase (PI3K) and Akt, a family of genes encoding serine/threonine-specific protein kinases, eventually regulating responses including glucose transport, protein and glycogen synthesis [22].

In obese states, lipid accumulation can occur in ectopic sites outside of adipose tissue due to excess fat intake, fatty acid synthesis and reduced fatty acid disposal. Moreover lipid accumulation within myocytes and hepatocytes is strongly associated with increased insulin resistance [18]. Accumulation of excess lipid within skeletal muscle and the liver inhibits tyrosine phosphorylation of IRS-1, which in turn follows serine phosphorylation therefore inhibiting PI3K binding and activation and thus reducing insulin-stimulated glucose transport [23]. Candidate proteins implicated in this serine phosphorylation include the protein kinase C family which may be activated by accumulation of lipid, as well as inflammatory intermediaries such as TNF $\alpha$  and IL-6 which may be activated within adipose tissue in obese states [23].

### **1.3.3 Dyslipidaemia**

The dyslipidaemic profile seen in the metabolic syndrome tends to be characterised by the pro-atherogenic pattern of raised triglycerides (TG) and low HDL, as well as other lipoprotein changes including elevated small dense low-density lipoprotein (LDL) and apolipoprotein B (Apo B) [24]. As discussed previously, obesity gives rise to excess FFAs which in turn exacerbate insulin resistance. As well as stimulating hepatic gluconeogenesis, FFAs also increase hepatic TG synthesis and the production of Apo B-containing, triglyceride-rich very low-density lipoprotein (VLDL) [25]. TGs are also primarily responsible for an associated remodelling of HDL by a process of reverse cholesterol transport and cholesterol esterification leading to a reduction in the cholesterol content of HDL [26].

#### **1.3.4 Elevated Blood Pressure**

Hypertension is closely associated with obesity and insulin resistance and is associated with a two-fold increase in CVD risk for every 20/10 mmHg increment in blood pressure commencing at 115/75 mmHg [27, 28]. Several mechanisms have been postulated linking insulin resistance with the development of elevated blood pressure. For instance, there is evidence indicating increased renal sodium reabsorption in the metabolic syndrome, especially in Caucasian populations [29], as well a loss of vasodilatory effects of insulin observed in a normal physiological setting [30]. Furthermore insulin also stimulates sympathetic nervous activity [31] while FFAs themselves mediate a relative vasoconstrictive effect [32].

#### **1.3.5 Proinflammatory Cytokines & Adiponectin**


Numerous other parameters have also been demonstrated to feature in individuals with the metabolic syndrome including a pro-inflammatory state, as indicated by elevated plasma TNF- $\alpha$ , IL-6 and C-reactive protein (CRP), markers of a pro-thrombotic state, the most common being plasminogen activator inhibitor-1 (PAI-1), and adverse adipocytokine profiles, especially low circulating adiponectin [5]. The latter is a cytokine produced almost exclusively by adipocytes and enhances insulin sensitivity and inhibits numerous steps in the inflammatory process [33]. In the liver it suppresses endogenous glucose production while improving glucose transport and fatty acid oxidation in skeletal muscle [34, 35]. Furthermore, TNF $\alpha$  is also over expressed in adipose tissue and induces insulin resistance through acute and chronic effects on insulin-sensitive tissues [36]. As discussed previously, the increase in proinflammatory cytokines probably reflects over-production by the expanded adipose tissue mass seen in these individuals. However, these features have not been incorporated into current definitions of the metabolic syndrome to date.

## 1.4 Prevalence Of The Metabolic Syndrome

Due to differences in the existing definitions of the metabolic syndrome, there are varying reports of its prevalence depending on the definition used and the ethnic group studied. Most studies suggest a prevalence of 10-30% in the general adult population in developed countries and urban areas of developing countries (Figure 1.2) [37].

**Figure 1.2: Prevalence Of The Metabolic Syndrome From NCEP ATP III Definition**

Adapted from Cameron et al [4, 37]



The prevalence of the metabolic syndrome, as defined by the NCEP ATP III criteria, was evaluated in 8814 adults in the United States in the third National Health and Nutrition Examination Survey (NHANES III). The overall prevalence was shown to be 22 percent, with an age-dependent increase and higher prevalence rates seen in Mexican and African subgroups [38]. Data from NHANES 1999-2000 confirms that the prevalence has continued to increase, particularly in women [39]. The prevalence of the metabolic syndrome by NCEP ATP III criteria was also assessed in a middle-aged cohort of 3323 Framingham Heart Study

participants who did not have diabetes or cardiovascular disease at an initial examination in the early 1990s. At baseline, the prevalence of the metabolic syndrome was 26.8 percent in men and 16.6 percent in women. Following an eight year period there was an age-adjusted 56 percent increase in prevalence among men and a 47 percent increase among women [40].

## **1.5 Consequences Of The Metabolic Syndrome**

There is considerable controversy and dispute about the concept of the metabolic syndrome – some believe that this label adds little practical clinical value to individual patient management whilst others value the metabolic syndrome as a screening tool to detect and target those at high risk of diabetes and CVD [41, 42]. Components of the metabolic syndrome are associated with an increased risk of type II DM and CVD, and there are now numerous studies indicating the presence of the metabolic syndrome itself as a predictor of future diabetes, though this is not surprising given the presence of insulin resistance and glucose intolerance in the defining criteria [43]. Furthermore, an increased mortality has been demonstrated by meta-analysis in non-diabetic individuals meeting the WHO criteria for the metabolic syndrome [44]. The overall hazard ratios for all-cause and cardiovascular mortality in persons with the metabolic syndrome compared with persons without it were respectively 1.44 and 2.26 in men and 1.38 and 2.78 in women after adjustment for age, blood cholesterol levels, and smoking. Application of the NCEP ATP III criteria to 10537 participants from the NHANES III study also indicated a significant relationship between the syndrome and both myocardial infarction and stroke in men and women [45].

Apart from type II DM and CVD, the metabolic syndrome is also associated with several other disorders all of which demonstrate a clear link with obesity, including non-alcoholic steatohepatitis [46], chronic kidney disease [47], polycystic ovary syndrome [48], obstructive sleep apnoea [49] and cognitive decline, though this is by no means an exhaustive list.

Other studies have disputed whether application of the metabolic syndrome provides any additional information over and above the individual well-established CVD risk factors which may in part reflect the inadequacies and inconsistencies in the definitions used [50]. It is not clear whether the metabolic syndrome simply reflects the increasingly sedentary lifestyle and dietary habits of today's society or if accumulating excess central fat deposits was associated with survival benefits in the past. There is however clear evidence that the metabolic syndrome, considered either as a separate disease entity or a constellation of risk factors, predisposes to cardiovascular risk [51-53]. These individuals represent an at-risk population and require further attention.

## **1.6 Management Of The Metabolic Syndrome**

The metabolic syndrome represents a common cluster of metabolic disturbances associated with increased risk of type II DM and CVD, predominantly arising from the increasing prevalence of obesity. In 2003 a report from the American Heart Association and the National Institutes of Health recommended two main therapeutic goals for the management of the metabolic syndrome [54]. Firstly this involves lifestyle modification to treat the underlying causes of obesity and physical inactivity by intensifying weight management and increasing physical activity. This should be followed by treatment of cardiovascular risk factors if they persist despite lifestyle modification, and includes treatment with insulin sensitising agents, anti-hypertensive and lipid-lowering drugs. However, at present there is no direct evidence supporting the attempts to prevent type II DM and CVD by treating the metabolic syndrome and no trials comparing the lifestyle modifying vs. pharmacological approaches in improving outcome.

Weight loss, regardless of how this is accomplished, improves metabolic parameters, reduces cardiovascular risk and improves disease outcome (Table 1.4). However, sustained weight loss is challenging to achieve, and most individuals find lifestyle modifications difficult to

adhere to long-term. The few existing drugs that have been used for the treatment of obesity do help achieve modest weight loss in the short-term but many patients return to their pre-treatment body weights within a few years of treatment discontinuation. Although the core approach to the treatment of obesity, and thus the metabolic syndrome, encompasses weight reduction and increased physical activity, there may also be a role for pharmacotherapy in reducing the burden of diabetes and cardiovascular disease; hence the adipocyte represents a major molecular target for novel therapeutic agents.

**Table 1.4: Benefits Of 10kg Weight Loss [55]**

Clinical Parameter	Effect
<b>Mortality</b>	20-25% ↓ total mortality 30-40% ↓ diabetes-related deaths 40-50% ↓ Obesity-related cancer deaths
<b>Blood pressure</b>	10 mmHg ↓ systolic pressure 20 mmHg ↓ diastolic pressure
<b>Lipid Profile</b>	10% ↓ total cholesterol 15% ↓ LDL cholesterol 30% ↓ triglycerides 8% ↑ HDL cholesterol
<b>Glycaemia</b>	>50% ↓ risk of developing diabetes 30-50% ↓ fasting blood glucose 15% ↓ HbA1c
<b>Angina</b>	91% ↓ symptoms 33% ↑ exercise tolerance

## 1.7 Models Of The Metabolic Syndrome

We have chosen to study the effect of pharmacomodulation in two models representing features of the metabolic syndrome: firstly, the endocannabinoid system, as an *in vitro* model of obesity, and secondly, polycystic ovary syndrome (PCOS), as an *in vivo* model for the syndrome itself. We hypothesise that novel (CB<sub>1</sub> antagonist) and existing (metformin)

pharmacotherapy targets may generate new benefits through changes in obesity, and in particular, central adiposity.

## **1.8 The Endocannabinoid System (ECS)**

### **1.8.1 Role Of The ECS In Contributing To Obesity**

The discovery of the ECS can be traced back almost 4000 years when the ancient Indians first described the pleasure-inducing medicinal properties of the plant *Cannabis sativa* [56], though the identification of  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) as the principal active compound of marijuana was not made until the late 20<sup>th</sup> century leading to further characterisation of the cannabinoid receptors and their endogenous ligands [57]. More recent research into the physiology of the ECS has aroused considerable interest, with the recognition of significant effects in the regulation of food intake as well as energy metabolism via central and peripheral mechanisms in both animals and humans [58, 59]. The ECS is therefore emerging as a novel therapeutic target for management of components of the metabolic syndrome.

The elements of the ECS comprise the cannabinoid receptors, the endogenous lipid ligands, the proteins required for their biosynthesis and inactivation, and the affected intracellular signalling pathways. In addition to its role in energy metabolism, the ECS also contributes to numerous other physiological functions including behaviour regulation, neuroprotection, nociception, and immunomodulation [60].




### 1.8.2 Cannabinoid Receptors

Two cannabinoid receptors, namely cannabinoid receptor type 1 (CB<sub>1</sub>) and cannabinoid receptor type 2 (CB<sub>2</sub>), have been identified to date, and form part of the seven transmembrane G protein-coupled family of receptors [60] (Figure 1.3).

**Figure 1.3 : Schematic Representation of Human CB<sub>1</sub> and CB<sub>2</sub> Receptors**

Adapted from Shire et al [61]

(where ● represents amino acids common to both CB<sub>1</sub> & CB<sub>2</sub>)



CB<sub>1</sub> receptors are located extensively throughout the central nervous system particularly specific mesolimbic regions, the pituitary and the hypothalamus, especially in regions known to be involved in the control of calorie intake and satiety, as well as in other organs involved in energy homeostasis including adipose tissue, liver, gastrointestinal tract, pancreas and skeletal muscle. They are also found in the myocardium and vascular endothelium, while CB<sub>2</sub> receptors are predominantly expressed on immune and blood cells [62]. Therefore CB<sub>1</sub> receptor modulation appears to affect metabolic function whereas CB<sub>2</sub> activation has been




implicated in pain and immune modulation. Recent studies from CB<sub>1</sub> and CB<sub>2</sub> receptor knockout mice have also suggested the existence of non-CB<sub>1</sub>, non-CB<sub>2</sub> endocannabinoid receptors but these remain the subject of ongoing study [63]. Given its role in energy homeostasis, this thesis will focus on the effects of CB<sub>1</sub> in the ECS.

### 1.8.3 Endogenous Endocannabinoids

The cannabinoid receptors are activated by a group of naturally occurring, cannabis-like lipids known as the endocannabinoids, the earliest of which to be identified were the arachidonic acid derivatives arachidonylethanolamide (anandamide or AEA) in 1992, followed by 2-arachidonylglycerol (2-AG) [60, 64] (Figure 1.4).

**Figure 1.4 : Schematic Representation Of The Endocannabinoids**

Adapted from Di Marzo et al [65]



More recently other bioactive mediators have also been described including noladin ether, virodhamine and oleamide, though their physiological functions have not yet been fully

established [60]. AEA synthesis occurs via the phosphodiesterase-mediated cleavage of the membrane phospholipid, N-arachidonoyl-phosphatidylethanolamine [66]. Being lipophilic compounds the endocannabinoids cannot be stored in vesicles like other neurotransmitters and are therefore synthesised upon demand from membrane phospholipids by cells at the site of action [64]. Following release and local receptor activation, the products are then rapidly degraded by hydrolysis via fatty acid amide hydrolase (FAAH), thus acting primarily near their site of synthesis by binding to cannabinoid receptors on the neighbouring cell surfaces [64]. Both AEA and 2-AG are capable of binding to CB<sub>1</sub> and CB<sub>2</sub> but with differing affinities and activation efficiencies [60].

#### **1.8.4 Exogenous CB<sub>1</sub> Receptor Ligands**

The exogenous CB<sub>1</sub> receptor ligands can be further classified according to their ability to either activate (agonists) or inactivate (antagonists) CB<sub>1</sub> receptors.

##### **1.8.4.1 Exogenous CB<sub>1</sub> Agonists**

The first exogenous CB ligand to be identified was the *Cannabis sativa* plant-derived Δ<sup>9</sup>-THC, with the ability to activate both CB<sub>1</sub> and CB<sub>2</sub> [57]. The desire for therapeutic potential has led to the development of synthetic CB agonists with selective affinity for either CB<sub>1</sub> or CB<sub>2</sub> receptors depending on the treatment target. HU210, a synthetic derivative of Δ<sup>9</sup>-THC, is one of the most potent CB<sub>1</sub> agonists as is the AEA derivative arachidonyl-2'-chloroethylamide, both with very limited activity on CB<sub>2</sub> (Figure 1.5) [60].

##### **1.8.4.2 Exogenous CB<sub>1</sub> Antagonists**





These compounds represent novel therapeutic agents with the potential for treating components of the metabolic syndrome. These ligands act either as competitive antagonists



of CB<sub>1</sub> receptor activation by endocannabinoids, or as inverse agonists that modulate CB<sub>1</sub> receptor activity by shifting it from an active “on” to an inactive “off” state [60]. The first and most extensively used CB<sub>1</sub> receptor antagonist is SR141716, which has also been developed into the pharmacological agent rimonabant for human use, but other compounds that have been characterised include AM251, AM281, and SR14778 (Figure 1.5) [60].

**Figure 1.5: Exogenous CB<sub>1</sub> Receptor Ligands**

Adapted from Di Marzo et al [67]

<b>CB<sub>1</sub> Receptor Agonists</b>	<p style="text-align: center;"><b>THC</b></p> 	<p style="text-align: center;"><b>HU 210</b></p> 
<b>CB<sub>1</sub> Receptor Antagonists</b>	<p style="text-align: center;"><b>SR 141716</b></p> 	<p style="text-align: center;"><b>AM 251</b></p> 


### 1.8.5 Endocannabinoid-Mediated Intra-Cellular Signalling

Several mechanisms involved in endocannabinoid-mediated signalling have been described over the recent years and some of these signalling cascades have been schematically represented in Figure 1.6. CB<sub>1</sub> receptors are coupled via G-proteins, negatively to adenylate cyclase and positively to mitogen-activated protein kinase, as well as to potassium and

calcium ion channels [68]. G-protein stimulation by CB<sub>1</sub> activation inhibits ATP to cAMP conversion mediated by adenylate cyclase [60]. cAMP is in turn thought to bind to regulatory subunits of protein kinase A (PKA) resulting in the activation of A-type potassium (K<sup>+</sup><sub>A</sub>) channel while G-protein mediated effects on protein kinase C (PKC) can result in activation of inwardly-rectifying potassium (K<sub>ir</sub>) channels and the inhibition of calcium channels [60]. CB<sub>1</sub> activation also stimulates numerous intracellular kinases eventually resulting in gene expression and transcription. It is important to note that these events have been reported in different cell systems and thus may not all occur in the same cell type [60].

**Figure 1.6: Effects Of CB1 Activation On Intracellular Signalling Cascades**

Adapted from Pagotto et al [60]






### 1.8.6

### Endocannabinoid-Mediated Neuronal Signalling

Neurotransmitters released from vesicles within pre-synaptic neurons activate post-synaptic neuronal synthesis and release of endocannabinoids [69]. The endogenous  $CB_1$  ligands diffuse back and bind to  $CB_1$  receptors located on the pre-synaptic nerve terminals resulting in G-protein activation, calcium channel inhibition and eventual inhibition of neurotransmitter release (Figure 1.7) [69].

**Figure 1.7: Endocannabinoid-Mediated Neurotransmitter Signalling**

Adapted from Piomelli et al [69]



## **1.8.7 Role Of The ECS In The Modulation Of Energy Regulation**

### **1.8.7.1 Animal Studies**

The vital function of the ECS in normal physiology is proposed by its evolutionary preservation and presence even in lower-level organisms [70]. Its role in the regulation of energy balance has been demonstrated in animal studies where chronic activation of the ECS increases food intake and promotes weight gain [71]. Conversely, CB<sub>1</sub> blockade in the diet-induced obese mouse reduces fat mass while CB<sub>1</sub> receptor knock-out mice maintain a lean phenotype and are resistant to diet-induced obesity [72]. These feeding experiments suggest that endocannabinoids affect the homeostatic control of body weight, not only through central orexigenic mechanisms at known sites in the hypothalamus and limbic forebrain but also through factors independent of food intake by peripheral effects in the regulation of energy metabolism [58]. These peripheral actions of the ECS include mediation of lipogenesis and modulation of adipocytokine profiles in adipose tissue and the liver, and gluconeogenesis in skeletal muscle [60].

### **1.8.7.2 Human Studies**

A potential link between the ECS and obesity has also been suggested by clinical data in human studies. Higher concentrations of circulating endocannabinoids and CB<sub>1</sub> receptor expression have been noted in obese as compared to lean women [73]. Similarly, both AEA and 2-AG levels are significantly enhanced in individuals with binge eating disorders [74]. Genetic studies have also shown an association between a polymorphism in the gene encoding the main endocannabinoid-degrading enzyme, fatty acid amide hydrolase (FAAH), and elevated BMI in white and black patient groups, though not in subjects of Asian origin [75].






Patients with obesity, or hyperglycaemia associated with type II diabetes, also display greater concentrations of endocannabinoids in visceral fat, or serum, respectively, than corresponding normal-weight, euglycaemic controls [76]. The metabolic effects of the ECS are also borne out in phase III clinical trials of the first selective CB<sub>1</sub> receptor antagonist SR141716, or rimonabant, where treatment promoted significant weight loss and reduction in waist circumference [77]. These have been accompanied by parallel improvements in the metabolic profile, namely reductions in fasting insulin and triglyceride levels, a rise in HDL cholesterol and adiponectin [77-81].

#### **1.8.8 Therapeutic Potential Of CB<sub>1</sub> Receptor Ligands In The Management Of Obesity**

Stimulation of the ECS favours several adverse metabolic processes resulting in weight gain, lipogenesis and impaired glucose metabolism, thus making it a novel therapeutic target for managing features of the metabolic syndrome, principally obesity and its associated cardiovascular sequelae. Furthermore, the observations outlined in the above studies raise the possibility that by reducing central adiposity, CB<sub>1</sub> receptors may exert differential effects in visceral as opposed to subcutaneous fat depots, making both important areas for study. The potential sites of action and proposed therapeutic clinical benefits of CB<sub>1</sub> receptor antagonist treatment have been summarised in Table 1.5.

**Table 1.5 : Potential Sites And Therapeutic Effects Of CB<sub>1</sub> Antagonists**

Adapted from Pagotto et al [82]

Site of Action		Potential Mechanism Of Action	Clinical Implications
	Hypothalamus Nucleus Accumbens	Anorexigenic effect ↓ Food intake	Body weight Abdominal obesity
	Adipose tissue	↑ Adiponectin ↓ Lipogenesis	Dyslipidaemia Insulin resistance
	Muscle	↑ Glucose uptake	Insulin resistance
	Liver	↓ Lipogenesis	Dyslipidaemia Insulin resistance
	Gastrointestinal tract	↑ Satiety signals	Body weight Abdominal obesity

### 1.9 Polycystic Ovary Syndrome (PCOS)

PCOS is the commonest endocrinopathy in women of reproductive age, affecting up to 10% of the premenopausal population [83]. It has become increasingly apparent that in addition to its well-established effects on female reproductive health, PCOS also comprises multiple metabolic abnormalities associated with long-term health risks, including glucose intolerance and insulin resistance, type II diabetes, hypertension, dyslipidaemia, visceral adiposity and endothelial dysfunction [84-91]. Although there is a lack of sufficient epidemiological data in regard to absolute cardiovascular event rates, the increased prevalence of the above cardiovascular risk factors has been clearly documented. Developing therapeutic strategies to



minimise this vascular burden is therefore important. The recognition of insulin resistance as a factor in the pathogenesis of PCOS had resulted in the widespread and accepted use of insulin-sensitising agents in the treatment of this condition. Despite evidence for increased presence of surrogate markers of cardiovascular disease, it is still unclear whether this is associated with accelerated atherosclerosis and endpoint data are lacking, an issue we aim to address in this study.

### **1.9.1           Diagnosis of PCOS**

Patients with PCOS present with a multitude of complaints ranging from hirsutism, acne, menstrual irregularities and infertility, and are therefore seen by a variety of healthcare professionals including primary care physicians, endocrinologists, dermatologists, and gynaecologists, making a clear consensus for diagnosis vital. The first international conference on PCOS was held at the National Institutes of Health in 1990, when three key features were identified by majority opinion as necessary for the diagnosis of PCOS [92]:

1. Clinical and/or biochemical hyperandrogenism
2. Chronic anovulation
3. Exclusion of other endocrine disorders including congenital adrenal hyperplasia, hyperprolactinaemia, Cushing's syndrome, thyroid dysfunction, and androgen-secreting tumours.

The most recent consensus statement from the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM)-sponsored PCOS workshop group in Rotterdam in 2003 revised the criteria for diagnosis to include two from the following three features in addition to the exclusion of other endocrine diseases [93]:

1. Clinical and/or biochemical hyperandrogenism

2. Oligomenorrhoea or chronic anovulation
3. Radiological evidence of polycystic ovaries

Despite the increasing awareness of insulin resistance and other metabolic abnormalities associated with PCOS, no aspects of these features are included in the current definition.

### **1.9.2 Pathogenesis Of PCOS**

The exact aetiology of PCOS remains unknown though multiple genetic and extrinsic factors contribute towards the phenotypic expression. PCOS was originally thought to arise as a result of abnormal pituitary function and androgen excess; however there is now increasing evidence for insulin resistance as an additional pathogenetic factor.

#### **1.9.2.1 Abnormal Pituitary Function**


One of the first laboratory abnormalities identified in PCOS is excessive pituitary secretion of luteinising hormone (LH) relative to follicle stimulating hormone (FSH), associated with increased pulses of hypothalamic gonadotrophin releasing hormone (GnRH); this implicated in the pathogenesis of PCOS by increasing ovarian theca cell androgen synthesis [94]. However, abnormal pituitary function alone does not account for all cases as not all women with PCOS exhibit elevated LH concentrations [95].

#### **1.9.2.2 Abnormal Steroidogenesis**

Elevated androgen levels in PCOS are thought to result from the dysregulation of steroidogenesis arising from either functional ovarian hyperandrogenism (FOH) or functional adrenal hyperandrogenism (FAH). FOH is found in about 70% of subjects with PCOS characterised by excessive secretion of 17-hydroxyprogesterone (17-OHP) in response to

GnRH agonist stimulation and failure of dexamethasone to suppress free plasma testosterone [95]. FAH is found in approximately 50% of patients with PCOS and can be demonstrated by increased secretion of dehydroepiandrosterone (DHEA) in response to adrenocorticotrophic hormone (ACTH) [95]. The most likely cause of the excessive androgen secretion in both glands may be dysregulation of the 17-hydroxylase and 17,20-lyase activities of P-450c17, the rate-limiting steps in androgen biosynthesis (Figure 1.8) [95]. The cause of this abnormal regulation remains unknown, though hyperinsulinaemia may play a role in many cases.

**Figure 1.8: Ovarian Steroid Biosynthesis Pathways [95]**  
(Adapted from Rosenfield et al)



### 1.9.2.3 Insulin Resistance

A link between abnormal insulin action and reproductive abnormalities was first described in 1921 by Achard and Thiers in their case of "diabète des femmes à barbe" (diabetes in a

bearded woman) [96], and later described as an association between amenorrhoea, cystic ovaries and masculinisation by Stein and Leventhal in the 1930s leading to the term Stein-Leventhal syndrome [97]. This association with hyperandrogenism and PCOS was eventually confirmed in the early 1980s [98, 99]. There is evidence for insulin resistance prevalent from an early age in PCOS and at a level disproportionate to that expected from BMI [100]. Up to 10% of women with PCOS will have type II diabetes by the age of 40, and approximately one-third will have an abnormal glucose tolerance test – both rates significantly higher than in matched controls [84]. Also, PCOS is often accompanied by acanthosis nigricans, a dermatological marker of insulin resistance [101]. Although excess androgen levels can cause modest reductions in glucose tolerance as seen in anabolic steroid users, in PCOS the predominant abnormality is thought to be stimulation of ovarian and adrenal steroidogenesis as a result of insulin excess [95, 102].

### **1.9.3 Insulin Resistance And Its Role In Reproductive Abnormalities In PCOS**

Despite resistance to insulin action in adipose tissue and skeletal muscle, the ovary and adrenal glands appear to remain relatively sensitive, if not hypersensitive to the effects of insulin. Both insulin and insulin-like growth factor (IGF) have stimulating effects on androgen production resulting in abnormal ovarian follicular development (Figure 1.8) [95]. This phenomenon is not just restricted to obese women with PCOS, as even lean subjects have been shown to display ovarian insulin hypersensitivity and hypersecretion in the setting of otherwise normal insulin sensitivity [103]. Also, states of hyperinsulinaemia and hyperandrogenism are associated with reduced circulating levels of sex-hormone binding globulin (SHBG), resulting in further elevations in free androgen concentrations [104]. These processes contribute to the clinical manifestations of increased androgen activity in the form of hirsutism, acne, alopecia, as well as ovarian dysfunction and menstrual irregularity [105].


### 1.9.4

### Insulin Resistance And Its Role In Metabolic Abnormalities In PCOS

Insulin resistance in PCOS is not only linked with the reproductive abnormalities discussed above, but also with a wide spectrum of metabolic abnormalities that are known to predate type II diabetes and cardiovascular disease (Figure 1.9).

**Figure 1.9: Consequences Of Insulin Resistance In PCOS**

Adapted from Sattar et al [105]



#### **1.9.4.1 Obesity And Central Body Fat Redistribution**

Obesity is an extremely common clinical feature in PCOS with 50-60% women having a BMI > 25 kg/m<sup>2</sup> [105]. Numerous studies have also illustrated body fat redistribution with a greater tendency towards accumulation of central adiposity. This is evidenced by greater waist circumference measurements and waist:hip ratios in PCOS independent of BMI [106], and two-fold higher visceral and pre-peritoneal fat thickness in women with PCOS compared to BMI-matched controls [107]. This increased central obesity has also been shown to correlate with higher insulin resistance rates as well as elevated fasting insulin and triglyceride levels in this population, further supporting the growing evidence for a pivotal role of visceral fat tissue in the development of adverse metabolic profiles [107, 108].

#### **1.9.4.2 Glucose Intolerance And Type II Diabetes**


Obesity is one of the strongest predictors for type II diabetes as demonstrated by the Bruneck study which identified a rising incidence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and frank diabetes proportional to rising BMI [109]. The higher incidence of obesity in PCOS therefore contributes to the excess risk seen in this population. However, studies have also demonstrated that women with PCOS have a greater risk for altered glucose metabolism even after accounting for total adiposity (Figure 1.10) [105].

One American study identified overall prevalence rates of IGT at 31.1% and of type II diabetes at 7.5% in PCOS women aged 14-44 years, and in the non-obese PCOS population (BMI < 27 kg/m<sup>2</sup>) the prevalence of IGT was 10.3% and diabetes 1.5% [85]. These rates were significantly higher than in controls matched for age, weight and ethnicity even at this young age. Overall, current clinical evidence suggests an overall increased risk of IGT/type II diabetes of two to four-fold in women with PCOS compared to age and weight matched controls [105].



**Figure 1.10: Increased Insulin Resistance In PCOS**

Adapted from Sattar et al [105]



#### **1.9.4.3 Lipids And Lipoprotein Profiles**

Dyslipidaemia is the most common metabolic abnormality observed in women with PCOS affecting up to 70% of this population [110]. The atherogenic lipid profile associated with PCOS mirrors that seen in type II diabetes and is generally characterised by elevated serum triglycerides and VLDL, a reduction in HDL concentration and a modest rise in LDL [89, 111]. These findings are present in both obese and lean PCOS subjects and remain significant when compared to matched controls. These studies have also demonstrated an association of the adverse lipid profile with both elevated insulin levels in non-diabetic women as well as an unsurprising correlation with the presence of diabetes.

Insulin is a major positive regulator of lipoprotein lipase, suppresses lipolysis and increases free fatty acid mobilisation from adipose tissue stores, therefore the elevations in triglycerides and reduction in HDL may be more closely related to insulin resistance [112]. 24-40% of women with PCOS also display qualitative changes in LDL which may contribute to an increase in cardiovascular risk in PCOS [113, 114]. The LDL lipoprotein phenotype

reported is an increase in LDL density with a common finding being type III or type IV LDL subclasses (LDL III, density range = 1.033–1.038 g/ml; LDL IV and LDL V in the density range = 1.038–1.050 g/ml) [115]. These variations in LDL are less dependent on changes in body weight and insulin resistance, and may partly be related to hyperandrogenism [112, 116].

#### **1.9.4.4 Blood Pressure**

There is currently no convincing data confirming excess risk of hypertension in PCOS compared to a control population, though the current evidence is limited by the availability of only a restricted number of small studies addressing this issue [111]. Zimmerman et al found no differences in 24-hour ambulatory blood pressure or left ventricular mass between subjects with PCOS and normal controls, despite significant differences in insulin resistance [117]. However, Fridstrom and colleagues further evaluated the effect of pregnancy on blood pressure in PCOS by means of a case-control trial and demonstrated an increased risk of hypertension in the third trimester and during labour [118]. Whether PCOS therefore represents a high risk state for hypertension still requires further clarification. A large long-term follow-up study by Wild and colleagues, suggested an increased prevalence of hypertension in patients with PCOS, but with no absolute evidence of increased risk of mortality and morbidity from coronary heart disease [119].

#### **1.9.4.5 Haemostatic Factors**

There is now increasing evidence linking raised plasma levels of haemostatic factors (including PAI-1, tissue plasminogen activator inhibitor (t-PA) and fibrinogen) with risk for coronary heart disease (CHD). Furthermore PAI-1 is positively associated with insulin resistance and predictive of T2DM in the general population [120, 121]. PAI-1 has been shown to be elevated in PCOS correlating directly with obesity and inversely with insulin sensitivity [87].



#### **1.9.4.6 Inflammation**

Chronic, low grade inflammation, as reflected by an increase in surrogate markers such as CRP, independently predicts those at risk for CHD and type 2 diabetes [122]. Women with PCOS have higher circulating CRP concentrations in comparison to controls [91, 123]. These elevations are independent of BMI and are also associated with greater insulin resistance. Preliminary genetic studies have also suggested a potential link between polymorphisms in the genes encoding TNF- $\alpha$  and IL-6 with hyperandrogenism and PCOS [124, 125].

#### **1.9.4.7 Adipocytokine Profiles**


Studies evaluating serum concentrations of adiponectin, an insulin sensitising cytokine, have shown a clear correlation with BMI and central obesity. Obese women with PCOS demonstrate reduced levels of adiponectin though no difference has been seen in comparison to weight-matched controls [126].

#### **1.9.4.8 Prevalence Of The Metabolic Syndrome In PCOS**

As discussed previously, the metabolic syndrome represents a potential means of identifying individuals at elevated risk of future CVD. Women with PCOS have a greater prevalence of the metabolic syndrome of 15-50% depending on the criteria used to define the syndrome [127-129]. Dokras et al found a 47.3% prevalence rate of the metabolic syndrome, according to the WHO criteria, in PCOS in contrast to 4.3% in an age-adjusted control population and 23.4% in the NHANES study group (Figure 1.11) [127]. These studies also highlight an increased prevalence of the individual components of the syndrome compared to control populations and this has also been demonstrated in the preceding sections.

**Figure 1.11: Prevalence Of The Metabolic Syndrome In PCOS**

Adapted from Dokras et al [127]



### **1.9.5 Vascular Abnormalities In PCOS**

#### **1.9.5.1 Endothelial Dysfunction**

Endothelial dysfunction, a marker of vascular damage, has recently been linked to the development of atherosclerosis and is now considered to be an independent predictor of future CVD events [130]. Numerous studies have shown early impairment of endothelial structure and function in PCOS, affecting even the young, normal-weight, non-dyslipidaemic, non-hypertensive women [91, 131]. Whether therapeutic interventions to improve endothelial function translate into any clinical benefit with reduced CVD events however, remains unknown.

#### **1.9.5.2 Subclinical Atherosclerosis**

There are a growing number of studies highlighting an increased vascular risk in PCOS based on surrogate end-points of CVD, including carotid intima media thickness (CIMT), and coronary artery calcification. In women undergoing coronary angiography, those with more extensive coronary artery disease (CAD) were more likely to have polycystic ovaries on

ultrasound associated with androgenic and metabolic abnormalities [132]. Also, coronary artery and aortic calcification is more prevalent in PCOS than in obese and non-obese women of a similar age and is comparable to the rates seen in men at the same age [128, 133]. Women over the age of 45 years with PCOS have significantly greater CIMT compared to age and BMI-matched controls suggesting premature carotid atherosclerosis [134]. Moreover, women with PCOS also display altered vascular function, as measured by surrogate markers of arterial stiffness including brachial pulse wave velocity, which may be associated with a functional defect in the vascular action of insulin [135].

#### **1.9.5.3 Coronary Heart Disease Risk In PCOS**

Despite a clear association between PCOS and an increased prevalence of adverse metabolic features and elevated markers of vascular risk, there is limited evidence confirming an absolute

increase in CVD events in this group and larger studies are still required to elucidate the actual risk. A long-term retrospective cohort study comparing women with PCOS to age-matched controls demonstrated that a history of nonfatal cerebrovascular disease and cardiovascular risk factors including diabetes are more prevalent among women with PCOS [136]. However, this study has been criticised for identifying cases of PCOS based only upon histopathology records from women who had undergone ovarian surgery and thus not truly representing the PCOS population. The Nurses' Health Study is one of the largest studies assessing the risk for CHD and stroke associated with a history of irregular menstrual cycles [137]. 82 439 female nurses were followed prospectively for 14 years and women reporting usually irregular or very irregular cycles had an increased risk for both nonfatal and fatal CVD as well as a non-significant increase in overall stroke risk [137]. Since 80-90% of women reporting menstrual irregularity have PCOS, these data suggested a 50% excess CHD risk in PCOS compared to age and BMI matched controls, in keeping with the greater prevalence of the metabolic syndrome in this group [105].

### **1.9.6 The Role Of Metformin In The Treatment of PCOS**

The mainstay of treatment for PCOS is lifestyle modification. However, if cardiovascular risk remains a concern despite measures to address diet, exercise and smoking cessation, then the insulin sensitiser, metformin, is increasingly being used in the therapeutic adjunct in the management of PCOS. While metformin exerts its predominant metabolic and glucoregulatory action in the liver, considerable interest in its use has arisen by the recognition of its pleiotropic actions on several tissues affected by insulin resistance, including adipose tissue and the endothelium [138]. In subjects with PCOS, metformin not only improves insulin sensitivity [139], but also reduces circulating concentrations of endothelin-1, a marker of endothelial dysfunction [140]. This potential action on the vascular endothelium will be evaluated further in this thesis.

### **1.10 Thesis Aims And Objectives**

The metabolic syndrome comprises a cluster of disturbances, including central obesity, dyslipidaemia and hypertension, centred around insulin resistance. Affected individuals are at increased risk of type II diabetes and CVD, therefore developing novel therapeutic strategies to minimise this is a priority public health challenge.

The adipocyte represents a major molecular target for novel therapeutic agents. CB<sub>1</sub> receptors are expressed in adipocytes, and early trials of a CB<sub>1</sub> antagonist (SR141716) confirm the potential value of this compound in the metabolic syndrome. Some of its effects may be mediated via inhibition of preadipocyte proliferation and differentiation as well as a change in adipocytokine production.

PCOS is the commonest endocrinopathy in young women with well-established effects on reproductive and metabolic health. It is also apparent that PCOS is a vascular disorder

associated with insulin resistance. Metformin therapy improves insulin sensitivity in PCOS but there is limited evidence to support whether these benefits improve vascular risk or indeed whether they represent a direct effect of the drug on the vasculature, or an indirect action mediated through adipokine production or other factors relating to adipose mass.

When the present study was originally designed, the aim had been to investigate the pharmacological effects of a single agent, a CB<sub>1</sub> receptor antagonist, on aspects of the metabolic syndrome using *in vitro* and *in vivo* models. This was however not feasible due to number of factors. Being a novel therapeutic drug, it was not possible to obtain this for independent study in a clinical trial setting at the time this project was commenced. Furthermore the agent was subsequently withdrawn from clinical use shortly afterwards for reasons that will be detailed in the final chapter. Therefore, whilst CB<sub>1</sub> receptor modulators were utilised in the *in vitro* experiments, metformin was chosen as an alternative investigational medicinal product for the *in vivo* studies.

The overall hypothesis for this thesis is that existing (metformin) and novel (CB<sub>1</sub> antagonist) pharmacological agents that target components of the metabolic syndrome may exert their benefits not only by improving insulin sensitivity and obesity, but also through indirect mechanisms involving a switch in the adipokine profile. This hypothesis will be tested using appropriate models of the metabolic syndrome *in vitro* (adipogenesis) and *in vivo* (PCOS) as follows:

1. To evaluate the actions of cannabinoid receptors on proliferation, differentiation and adipokine production in models of *in vitro* adipogenesis.
2. To determine the *in vivo* effects of metformin therapy on arterial stiffness, endothelial function, adipokine profile and insulin sensitivity in young women with PCOS.

## **CHAPTER 2: ESTABLISHMENT OF PLASMID STANDARD CURVES FOR MEASUREMENT OF TRANSCRIPT EXPRESSION**

### **2.1 INTRODUCTION**

Analysis of the activation or inactivation of gene expression has long been used to provide insight into the understanding of the regulation of cellular function and thus the pathophysiology of disease processes. As DNA is transcribed to mRNA and the latter translated to produce functional proteins, quantification of mRNA levels can be used to study gene expression [141]. Numerous techniques have been developed to allow such study including Northern blot analysis, ribonuclease protection assay, microarrays, serial analysis of gene expression as well as conventional and quantitative real time polymerase chain reaction. An overview of some of these methods, including their advantages and limitations, is discussed below.

#### **2.1.1 Northern Blot Analysis**

The technique of Northern blotting was developed by James Alwine et al at Stanford University in 1977, and refers to a process by which electrophoretically separated bands of RNA are transferred to a nylon or nitrocellulose membrane, and specific transcripts subsequently detected by hybridisation to radio-labelled DNA probes followed by autoradiography. <sup>32</sup>P-labelled probes have been conventionally used but non-radioactive systems have now also become available [142, 143].

Northern blotting allows mRNA size determination and can thus be useful to demonstrate alternatively spliced transcripts or mutations that result in modified mRNA sizes [144]. While this method allows detection of highly specific RNA bands, it supplies information about

tissue distribution, but not cellular location of target RNA, and is further limited by the requirement for large quantities of total RNA from whole tissue. This technique has been superseded, in recent years, by the development of more modern techniques that have increased sensitivity, are less time-consuming and provide more quantitative results.

### **2.1.2 Ribonuclease Protection Assay**

The ribonuclease protection assay (RPA) is a highly sensitive and specific method for detecting RNA and its subsequent quantification. RNA extracted from cells is hybridised with RNA probes, synthesised with the aid of bacteriophage-derived RNA polymerases, containing sequences complementary to those of the gene of interest allowing the formation of double-stranded RNA. Single stranded RNA is then cleaved by RNase resulting in residual fragments specific to the gene of interest [144, 145]. Based on the quantity of target RNA present in the study sample, information can be derived concerning levels of gene expression. The simultaneous use of multi-probe RNA systems has the advantage of allowing the absolute quantification of multiple species of RNA in a single specimen enabling their comparison, but the method is limited by the large volume of source material required.

### **2.1.3 cDNA microarrays**

In a cDNA array, multiple gene-specific oligonucleotides derived from RNA transcripts are individually arranged on a single matrix which is then probed with fluorescently tagged cDNA representations from total RNA pools [144, 146]. The relative amount of transcript present can therefore be determined by the type of fluorescent signal generated. A single array can contain tens of thousands of probes, therefore this high-throughput method enables the simultaneous study of multiple genes and also allows comparison of gene expression profiles in different settings, for example, in experiments studying the effects of the presence or absence of a specific drug [144]. The main disadvantages include cost, as well as the

challenge of accurate statistical analysis and interpretation of the vast quantities of data generated.

#### **2.1.4 Polymerase Chain Reaction**

##### **2.1.4.1 Conventional Polymerase Chain Reaction [147]**

Polymerase Chain Reaction (PCR) allows highly sensitive detection and amplification of short (approximately 100-500 base pairs), target sequences of a larger DNA molecule in a relatively short period of time in an *in vitro* setting. A typical PCR reaction will require a sample of target (genomic or plasmid) DNA, a thermostable DNA polymerase, forward and reverse oligonucleotide primers to recognise the target DNA sequence, deoxynucleotide triphosphates (dNTPs), reaction buffer and magnesium. The reaction mix is then placed in an automated thermal cycler that proceeds through stages at different temperature settings for different periods of time, each series of which is referred to as a single cycle of amplification. Each individual PCR cycle will theoretically double the quantity of the target DNA sequence. Therefore ten cycles will multiply the sequence by a factor of about one thousand, and twenty cycles by a factor of more than a million in just a few hours.


The PCR process occurs in three main stages. The first stage is the initial DNA denaturation step which separates the two intertwined strands of DNA from each other producing single-stranded DNA templates necessary for the DNA polymerase. The complete denaturation of the DNA template at the start of the PCR reaction is of key importance as incomplete denaturation of DNA results in inefficient utilisation of the DNA template in the first amplification cycle and thus poor yield of PCR product (amplicon). This initial denaturation should be performed over an interval of 1 to 5 minutes at 95°C.



The next stage includes the actual amplification cycles and occurs in three steps. The first step denatures the DNA at the start of each cycle. This also occurs at 95°C but lasts for 30 seconds to 2 minutes. Since the PCR product synthesized in the first amplification cycle is significantly shorter than the template DNA, it is completely denatured under these conditions. This is followed by the primer annealing step for which the temperature is reduced to 40-60°C for 30-60 seconds. At this temperature, the oligonucleotide primers can form stable associations (annealing) with the separated target DNA strands and enable the third step of the cycle, i.e. DNA synthesis by a thermostable DNA polymerase performed at 70-75°C lasting 1-2 minutes. The number of times this cycle of denaturation, annealing and DNA synthesis is repeated depends upon the amount of template DNA and expected yield of the PCR product. Usually 25-40 cycles are performed.

After the last cycle, the samples are incubated at 72°C for 5-15min for the final extension stage to fill-in the protruding ends of newly synthesized amplicons. The reactions are then held at 4°C until required for further analysis of e.g. size, quantity and sequence, or for use in further experimental procedures such as cloning in plasmid vectors. A schematic representation of the PCR cycle is given in Figure 2.1.

**Figure 2.1: Schematic Diagram Of The PCR Cycle**



PCR can be used for semi-quantitative measurement of transcript expression if the number of cycles is kept within the logarithmic phase of amplification. The PCR product amount is then determined by densitometric analysis of ethidium bromide fluorescence upon gel electrophoresis and co-amplification of the transcript of interest with internal controls can allow comparison between different samples.


#### **2.1.4.2 Quantitative Polymerase Chain Reaction (QPCR)**

QPCR is a highly sensitive technique for studying gene expression by amplification of defined sequences of target RNA. Extracted RNA is initially reverse transcribed to complementary DNA (cDNA), followed by PCR amplification. Quantification of the PCR product occurs during the exponential phase allowing both absolute and relative measurement of the gene of interest. QPCR has the advantage of allowing the simultaneous analysis of multiple samples by standardising data to a known calibrator (housekeeper gene), thus enabling the direct comparison of samples collected from separate populations and different points in time [144]. The most sensitive QPCR machines use glass capillaries and are able to detect transcript copy numbers as low as multiples of ten, whereas the higher throughput machines utilise 96 well plates with sensitivity for transcript numbers in the hundreds. It is, therefore, also a useful technique in circumstances where source material is limited. However, the validity of this procedure is dependent upon careful optimisation of all reaction components as well as accurate quantification of the amplification product.

QPCR is identical to conventional PCR but also allows real time monitoring of the reaction process by including a fluorescent reporter molecule either in the form of a double-stranded DNA-binding dye e.g. SYBR® Green (Figure 2.2), or dye-labelled probes e.g. Taqman®. The SYBR® based assays are relatively easier to design and optimise compared to the probe based techniques and have been used to study gene expression for the purposes of the present study. SYBR® Green has a strong affinity for dsDNA and upon binding there is a

1000-fold increase in its fluorescence (Figure 2.2). As the PCR proceeds the quantity of dsDNA synthesised rises which further augments SYBR® binding and thus fluorescence. The first cycle at which the ambient background fluorescence can be distinguished from that generated by PCR amplification is termed the threshold cycle (Ct). This Ct value is directly proportional to the quantity of DNA present in the initial template.

**Figure 2.2: Schematic Representation Of SYBR® Green QPCR**



#### 2.1.4.3 Methods Of Quantification

QPCR enables both absolute and relative measurement of mRNA.

Absolute quantification measures the total quantity of the target sequence and is usually expressed as the number of copies of mRNA present in a given sample. The gene of interest can be cloned in a plasmid vector allowing measurement of plasmid DNA concentration. A QPCR standard curve can then be generated by amplification of serial dilutions of the plasmid DNA and plotting the log of the initial known template copy number against the Ct value obtained for each corresponding dilution. Therefore copy numbers in experimental samples can be determined by comparison of their Ct values to this standard curve.

Relative quantification allows gene expression to be reported relative to that of an endogenous control or housekeeper gene whose expression is constant in all samples [144]. This process helps control for differences between samples that may have arisen during RNA extraction and reverse transcription. Gene expression can also be expressed as fold-changes relative to a calibrator, such as Day 0 in time-course experiments or by comparison to an untreated, negative control.

A combination of both the above QPCR methods was utilised in this study. Absolute mRNA copy numbers were determined for each sample following which the results were normalised to housekeeper gene expression.

#### **2.1.5 Chapter Aims**

This chapter aims to describe the methods used to produce a series of plasmid cDNA standards and optimise QPCR conditions to allow measurement of transcript expression for human and murine CB<sub>1</sub> and CB<sub>2</sub> receptors, and markers of adipogenesis. The transcriptional control of adipogenesis and details of these individual genes is discussed in further depth in Chapter 3.

## **2.2 MATERIALS AND METHODS**

All centrifugation steps were performed in a Rotina 46R Hettich Zentrifugen (Patterson Scientific, Luton, UK), unless otherwise stated.

### **2.2.1 Genomic DNA Extraction**

Ethical approval was obtained to extract genomic DNA from human and mouse whole blood samples which was undertaken with the use of the QIAamp DNA Blood Mini Kit (QIAGEN Ltd, Crawley, UK) as per the manufacturer's instructions. 200 µl of whole blood was combined with 20 µl 20 mg/ml RNase A (Promega UK Ltd, Hampshire, UK), 25 µl Proteinase K and 200 µl Buffer AL (lysis buffer), incubated at 70°C for 10 minutes then mixed with 210 µl of absolute ethanol by vortexing. The sample was transferred to a QIAamp spin column placed within a 2 ml collection tube, and centrifuged at 8000 rpm for 1 minute. The column was then transferred to a clean 2 ml collection tube and the previous sample discarded. 500 µl of Buffer AW (wash buffer) was added and the column centrifuged at 8000 rpm for 1 minute. The column was again placed in a fresh 2 ml collection tube, combined with another 500 µl of Buffer AW and centrifuged at 13000 rpm for a further 3 minutes. The column was then transferred to a clean 1.5ml Eppendorf tube and DNA eluted with 200 µl of ultra pure water preheated to 70°C, by centrifugation at 8000 rpm for 1 minute.

### **2.2.2 DNA Quantification**

DNA concentration was quantified by measuring absorbance at 260nm ( $A_{260}$ ) and 280nm ( $A_{280}$ ) using a Gene Quant Pro spectrophotometer (Gene Quant, GE Healthcare), and purity of the sample assessed by the  $A_{260}/A_{280}$  ratio.

### 2.2.3 Primer Design

Primers are short nucleic acid chains usually 15-30bp in length, specific to the gene of interest, and serve as a starting point for DNA replication. Longer primers provide higher specificity. The primer should not be complementary to itself or to any other primer in the reaction mixture in order to avoid the formation of primer-dimers and hairpins. All possible sites of binding between primers and the template DNA should be noted to ensure correct identification of the target DNA sequence.

Nucleotide mRNA sequences were obtained for the genes encoding human and murine CB<sub>1</sub> and CB<sub>2</sub> receptors, murine markers of adipogenesis - preadipocyte factor 1 (Pref-1), CCAAT-enhancer-binding protein  $\beta$  (C/EBP $\beta$ ), peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ), and glycerol-3-phosphate dehydrogenase (GPDH); and house keeper gene acidic ribosomal phosphoprotein (ARP), from the online database GenBank available at the National Centre for Biotechnology Information website (<http://www.ncbi.nlm.nih.gov/>). Based on these published sequences, primers were designed using the online PRIMER3 software available at [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3\\_www.cgi](http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Ideally primers should be designed to hybridise to different exons to avoid amplification from contaminating genomic DNA, however this was not always possible as the genes encoding CB receptors were all noted to contain a single exon.

Once designed, specificity of the primer sequences was analysed with a BLAST (Basic Local Alignment Search Tool) search (<http://www.ncbi.nlm.nih.gov/blast>) to ensure no cross-reactivity with other genes. Primer sequences were manufactured by Invitrogen (Invitrogen Ltd, Paisley, UK). Plasmid cDNA standards for the human markers of adipogenesis - C/EBP $\beta$ , PPAR $\gamma$ , lipoprotein lipase (LPL) and uncoupling protein-1 (UCP-1); and the housekeeper gene adenosine phosphoribosyltransferase (APRT), were kindly provided by Dr Lei Zhang (Centre for Endocrine & Diabetes Sciences, Cardiff University).

## 2.2.4 PCR Amplification

PCR was performed in compatible 500 µl polypropylene tubes using a Techne Genius DNA Thermal Cycler (Techne Cambridge Ltd, Cambridge, UK). A reagent master mix was prepared to increase reaction consistency and minimise pipetting error. Each reaction contained approximately 100 ng of genomic DNA (human or mouse), 1 µl forward primer (10 pmol/l), 1 µl reverse primer (10 pmol/l), 1 µl dNTPs, 2.5 µl 10x reaction buffer, 0.4 µl (5 units/µl) Taq DNA polymerase (Promega, Southampton, UK), and ultra pure water to complete a total of 25 µl per reaction. Higher magnesium concentrations were required in the reactions containing mouse DNA and primers. This was achieved by using a magnesium-free buffer supplemented with 5 µl of 25 mM MgCl<sub>2</sub>. A single reaction containing all reagents except genomic DNA was also performed as the negative control to confirm the absence of contamination. The PCR reagents and thermal cycling settings are shown in Tables 2.1 and 2.2.

**Table 2.1: PCR Reagents For Amplification From Genomic DNA**

Reagents	Volume per reaction
<b>Sterile H<sub>2</sub>O</b>	to complete final volume of 25 µl
<b>10x Taq DNA polymerase buffer</b> (100 mM Tris-HCl, 500 nM KCl, 15 mM MgCl <sub>2</sub> )	2.5 µl
<b>dNTP mix</b> (10mM each dATP, dCTP, dGTP, dTTP)	1 µl
<b>Forward primer (10 pmol/l)</b>	1 µl
<b>Reverse primer (10 pmol/l)</b>	1 µl
<b>Taq DNA polymerase (5 units/µl)</b>	0.4 µl
<b>Genomic DNA</b>	100 ng
<b>Total volume</b>	25 µl



**Table2.2: PCR Thermal Cycling Protocol**

	Temperature	Time	Nº of cycles
<b>Initial Denaturation</b>	95°C	5 minutes	1
<b>Denaturation</b>	95°C	1 minute	40
<b>Annealing</b>	60°C	30 seconds	
<b>DNA synthesis</b>	72°C	1 minute	
<b>Final extension</b>	72°C	5 minutes	1

### **2.2.5 Agarose Gel Electrophoresis Of PCR Products**

Following PCR the product size was verified using agarose gel electrophoresis. A 2% gel was prepared with 40 ml TAE 1x buffer (Tris-Acetate-EDTA), 0.8 g agarose and 2 µl of 10mg/ml ethidium bromide (Sigma). (To make 50x TAE buffer add 121g Tris base in 250ml H<sub>2</sub>O. stir to dissolve. add 28.6mL acetic acid. add 50ml 0.5M EDTA pH 8.0) The same concentration of ethidium bromide i.e. 0.5 µg/ml, was maintained in the TAE running buffer. The solution was heated in a conventional microwave to enable the agarose to dissolve completely and then allowed to set by cooling at room temperature for 20 minutes in the minigel apparatus. 10 µl of each amplicon and 2 µl of 6x loading dye (Promega, UK) were placed in individual wells with 5 µl of 100 bp DNA ladder (Promega) and 1 µl 6x loading dye in the final lane for comparison. The gel apparatus was run at 150 volts for 30 minutes and then visualised under an ultraviolet light source connected to a computer using an Alpha Imager™ gel documentation system (Alpha Innotech, San Leandro, California, USA).

### **2.2.6 PCR Product Purification**

This protocol and reagents provided by QIAGEN (QIAGEN Ltd, Crawley, UK), was followed to purify each PCR product from primers, dNTPs, DNA polymerase and salts present in the PCR reaction, resulting in pure DNA for use in the subsequent experimental procedures.



3 volumes of Buffer QG (solubilisation and binding buffer) was added to 1 volume of the PCR reaction product and mixed thoroughly by vortexing. Before proceeding it was necessary to ensure yellow colouration of the mixture indicating a pH  $\leq 7.5$ , i.e. optimal for DNA adsorption to the QIAquick membrane. The solution was transferred to a QIAquick spin column placed within a 2 ml collection tube and centrifuged at 13000 rpm for 1 minute. 0.75mls of Buffer PE (wash buffer) was applied to the column and centrifuged again for 1 minute. The flow-through was discarded, column centrifuged for an additional minute and then placed in a clean collection tube. DNA was eluted by the addition of 50  $\mu$ l of Buffer EB (Elution buffer - 10mM Tris·Cl, pH 8.5) to the column and a final centrifugation step at 13000 rpm for 1 minute.

#### **2.2.7 DNA Concentration Calculation By Agarose Gel Analysis**

The purified PCR product size was verified by agarose gel electrophoresis as described in section 2.2.5. The quantity of the PCR product was estimated by comparison of the signal intensity against standard quantitative molecular weight markers on a 1 kb and 100 bp DNA ladder (Promega) allowing calculation of DNA concentration within the purified product using the following formula:

$$\frac{\text{Estimated weight (ng)}}{\text{Volume of PCR product loaded in gel apparatus } (\mu\text{l})} = \text{DNA concentration (ng}/\mu\text{l})$$


#### **2.2.8 Plasmid Vector Ligation**

A plasmid is a DNA molecule capable of autonomous replication. Insertion of the gene to be replicated and then transfection into competent cells allows large scale DNA amplification by bacterial culture. The commercially available pGEM®-T Easy plasmid vector (Promega, Southampton, UK) contains genes encoding ampicillin resistance (Amp<sup>r</sup>) as well as the  $\alpha$ -

subunit of *LacZ* ( $\beta$ -galactosidase) allowing later selection of suitably transformed cell colonies. The bacterial host DNA encodes the remaining  $\Omega$ -subunit thus forming functional  $\beta$ -galactosidase upon successful transformation of competent cells. Key features of the vector are illustrated in Figure 2.3 including the multiple cloning region contained within the *LacZ* coding region which is flanked by recognition sites for restriction enzymes e.g. *EcoR*I, which can be used to verify the presence of an insert, providing the insert itself has no *EcoR*I site, in which case 1 or more of the other restriction enzymes would be used for digestion.

**Figure 2.3: pGEM®-T Easy Plasmid Vector Map & Sequence Reference Points**

(adapted from Promega technical manual available at [www.promega.com/tbs](http://www.promega.com/tbs))



Purified PCR amplicons were ligated with the pGEM®-T Easy plasmid in vector-insert ratios of 1:1, 1:3, and 3:1 based on molarity. The amount of PCR product (insert) to be included in each reaction was calculated using the following formula obtained from the Promega website at [www.promega.com/tbs](http://www.promega.com/tbs):

$$\frac{\text{ng of vector} \times \text{kb size of insert}}{\text{kb size of vector}} \times \text{vector : insert molar ratio} = \text{ng of insert}$$

Each reaction contained 50 ng vector, 5 µl of 2x ligase buffer, 1 µl (0.1 units) T4 bacteriophage-derived DNA ligase (Promega), either 1, 3 or 9 ng insert DNA, and ultrapure water to complete a total of 10 µl per reaction, and then incubated at room temperature for 6 hours prior to transfection into competent cells. This protocol has been summarised in table 2.3.

**Table 2.3: Protocol For pGEM®-T Easy Vector Ligation With PCR Amplicons**

Reagents	Vector:Insert base pair ratio		
	1:1	1:3	3:1
<b>Ultrapure water</b>	2 µl	1 µl	0 µl
<b>2 x ligase buffer</b>	5 µl	5 µl	5 µl
<b>pGEM®-T Easy Vector DNA</b>	50 ng	50 ng	50 ng
<b>Insert DNA (PCR product)</b>	3 ng	9 ng	1 ng
<b>T4 DNA Ligase (0.1 units per µl)</b>	1 µl	1 µl	1 µl
<b>Total volume</b>	10 µl	10 µl	10 µl

## 2.2.9 Transformation Of Competent Cells

### 2.2.9.1 Preparation Of Culture Media

Luria Bertani (LB) medium (USB, Cleveland, Ohio) was prepared for use as bacterial growth medium by adding 5 g LB to 200 mls distilled water and autoclaving for 1 hour. The medium

was then cooled to 55°C before being supplemented with 200 µl of 100 mg/ml ampicillin for a final concentration of 100 µg / ml.

10 mls of sterile modified SOC solution (super-optimal broth with catabolic repressor) was prepared by combining 10mls LB with 100 µl of 2M glucose solution (3.6 g glucose dissolved in 10 mls distilled water and filter sterilised) for a final concentration of 20mM glucose.

100 mg X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) was dissolved in 2mls dimethylformamide for a stock solution concentration of 50 mg/ml and stored sheltered from light at -20°C.

#### **2.2.9.2 Preparation Of Agar Plates**

14.8g LB-agar was added to 400mls distilled water and autoclaved for 1 hour. The solution was then incubated at 55°C for 2 hours and supplemented with 400 µl of 100 mg/ml ampicillin (final concentration 100 µg/ml) and 640 µl of 50 mg/ml X-gal (final concentration 80 µg/ml). 25mls of the final solution was added to each 10 cm petri dish and allowed to set at room temperature. The agar plates were then stored inverted at 4°C until use.

#### **2.2.9.3 Transfection**

There are two main methods for preparing competent bacterial cells for transformation – incubation in cold calcium containing buffers (chemical) or by electroporation. Both these techniques render the cell membranes transiently permeable to extracellular DNA in the environment thus allowing transfection with plasmid DNA. The commercially available chemically competent *Escherichia coli* (*E. Coli*) DH5α (Invitrogen) were used in these experiments. 4 µl of plasmid ligation products were combined with 20 µl aliquots of *E. Coli* DH5α and incubated on ice for 30 minutes. The samples were then heat-shocked at 42°C for


90 seconds and returned to ice for 5 minutes. 1 ml of sterile SOC medium (LB containing 20mM glucose) was added to each sample and incubated at 37°C for 1 hour with gentle shaking at 150 rpm following which the samples were centrifuged at 3000 rpm for 5 minutes. 600 µl of the medium supernatant was discarded and following gentle resuspension, 200 µl of the remaining transformation mix was spread onto LB-agar plates containing 100 µg/ml ampicillin and 80 µg/ml X-gal and incubated, inverted, overnight at 37°C.

#### 2.2.10 Culture Of Selected Colonies

X-gal supplemented in the agar plates is a colourless galactose sugar that is metabolised by  $\beta$ -galactosidase to 5-bromo-4 chloroindole, an insoluble bright blue product. Successful cloning of an insert into the pGEM®-T Easy Vector interrupts the coding sequence of  $\beta$ -galactosidase allowing recombinant clones to be identified by colour screening on indicator plates.

Using this method of blue-white screening, *E.coli* colonies were selected (Figure 2.4) using a micro-inoculator loop and used to inoculate 5 ml of LB medium containing 100 mg/ml ampicillin (Sigma-Aldrich Company Ltd, Dorset, UK). Cultures were grown overnight in an orbital shaking incubator at 200 rpm at 37°C.

**Figure 2.4: Selection Of Bacterial Colonies Containing Plasmid Vector**





### **2.2.11 Small-Scale Isolation Of Plasmid cDNA By Alkali Lysis (Mini-prep)**

1.5 ml of overnight culture fluid containing transformed cells was transferred to a 1.5 ml Eppendorf tube and centrifuged at 13000 rpm for 1 minute. The cell pellet was then resuspended in 1 ml of SET (20% sucrose, 50mM Tris.HCl, 50mM EDTA, pH 7.5) and centrifuged again at 13000 rpm for 1 minute. The supernatant was removed and pellet resuspended in 150  $\mu$ l SET. This was then combined with 5  $\mu$ l of 4mg/ml DNase-free RNase A (Promega UK Ltd, Hampshire, UK) and 350  $\mu$ l of freshly prepared lysis solution (0.2M NaOH, 1% SDS [8.8 ml H<sub>2</sub>O, 0.2 ml 10M NaOH and 1 ml 10% SDS]). Samples were kept on ice for 10 minutes, combined with 250  $\mu$ l 3M sodium acetate (pH 5.2) and mixed by inverting the tube several times and kept on ice for a further 30 minutes. This was followed by centrifugation at 15000 rpm for 5 minutes at 4°C. The supernatant was transferred to a clean tube to which an equal volume of isopropanol was added and then centrifuged at 13000 rpm for 10 minutes at room temperature. The supernatant was discarded and DNA pellet washed with 1 ml 70% v/v ethanol 30 % T<sub>10</sub>E<sub>1</sub> (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and centrifuged for 5 minutes. The supernatant was again discarded and DNA pellets air-dried prior to resuspension in 20  $\mu$ l T<sub>10</sub>E<sub>1</sub> buffer.

DNA concentration was quantified by measuring absorbance at 260nm ( $A_{260}$ ) and 280nm ( $A_{280}$ ) using a Gene Quant Pro spectrophotometer, and purity of the sample assessed by the  $A_{260}/A_{280}$  ratio.

### **2.2.12 Restriction Digest Analysis Of Purified Plasmid cDNA**

Following isolation of plasmid cDNA, a single-enzyme digestion was undertaken with the restriction enzyme *Eco*R1 to allow release of the insert. Each reaction contained 1 $\mu$ l (10 units/  $\mu$ l) *Eco*R1 (Promega), 1  $\mu$ l 10x reaction buffer, approximately 1  $\mu$ g cDNA and made up to 10  $\mu$ l with H<sub>2</sub>O. The samples were then incubated in a 37°C water bath for 2 hours.

### **2.2.13 Agarose Gel Electrophoresis**

Following digestion the product size was verified using agarose gel electrophoresis. A 1.2% gel was prepared with 50 ml Tris-acetate-EDTA (TAE) 1x buffer, 0.6 g agarose and 2.5 µl of 10mg/ml ethidium bromide. The same concentration of ethidium bromide i.e. 0.5 µg/ml, was maintained in the TAE running buffer. The undigested and digested plasmids were compared to 100bp and 1kb DNA ladders. Bands corresponding to the 3 kb plasmid vector were seen in all lanes. Samples which also confirmed the presence of an insert of the expected size, released by restriction digest, were selected for DNA sequencing prior to proceeding to large-scale plasmid DNA preparation.

### **2.2.14 Automated DNA Sequencing**

The plasmid cDNA products resulting from the alkali lysis procedure containing inserts of the expected size were analysed to ensure correct DNA sequence incorporation into the plasmid vectors and successful amplification in bacteria.

The sequencing reactions were performed on a Techne Genius DNA Thermal Cycler (Techne Cambridge Ltd, Cambridge, UK). Two reactions were undertaken for each individual cDNA specimen, one containing the corresponding forward primer, and one with the reverse primer. Each reaction contained 2 µl Big Dye Terminator Cycle Sequencing Ready Reaction (v3.1, ABI Prism, PE Biosystems), 2 µl 5x Big Dye reaction buffer, 1 µl 10 pmol/L primer (Invitrogen), approximately 200 ng cDNA, and made up to 10 µl with H<sub>2</sub>O. The PCR settings used are shown in Table 2.4.

**Table 2.4: PCR Protocol For DNA Sequencing**

Temperature	Time	Nº of cycles
96°C	3 minutes	1
96°C	30 seconds	30
60°C	4 minutes	

#### **2.2.14.1 Sodium Acetate Precipitation**

Following PCR, 1.5 µl of 3M Sodium Acetate, 31.5 µl ice-cold 95% v/v ethanol and 10 µl sterile water was added to each sample. These were incubated at room temperature for 15 minutes and then centrifuged at 15,000 rpm for 20 minutes at 4°C. The supernatant was discarded and the DNA pellet washed with 250 µl ice-cold 70% v/v ethanol and centrifuged further at 15,000 rpm for 5 minutes at 4°C. The supernatant was removed and samples incubated for 1 minute at 95°C prior to being resuspended in 10 µl 70% v/v ethanol and analysed on an ABI 310 Genetic Analyser. The resulting DNA sequences were analysed with a BLAST search to ensure correspondence with the genes of interest and alignment with the initial primer sequences.

#### **2.2.15 Maxiprep**

100 mls of LB medium containing 100 µg/ml ampicillin was inoculated with 1 ml of bacterial culture preserved prior to mini-prep. Cultures were grown in a 200 ml conical flask overnight in an orbital shaking incubator at 250 rpm at 37°C. Plasmid DNA was then extracted using the Qiafilter Plasmid Maxi Kit (Qiagen) according to the following protocol. The bacterial cells were harvested by centrifuging the overnight culture fluid at 3600 rpm for 30 minutes at 4°C and supernatant discarded. The cell pellet was resuspended in 10 mls Buffer P1



(resuspension buffer with RNase A) by vortexing, combined with 10 mls Buffer P2 (alkaline lysis buffer), incubated at room temperature for 5 minutes and then neutralised with 10 mls chilled Buffer P3 (neutralisation buffer). The lysate was poured into the barrel of a QIAfilter cartridge, and incubated at room temperature for a further 10 minutes prior to filtration through a QIAGEN-tip, allowing binding of plasmid DNA to an anion-exchange resin. Protein and RNA impurities were removed by washing with 30mls Buffer QC (medium salt wash) and DNA eluted with 15 mls Buffer QF. DNA was further concentrated and purified by precipitation with 10.5 mls room-temperature isopropanol added to the eluted DNA and centrifugation at 11000 rpm for 30 minutes at 4°C. The supernatant was discarded, DNA pellet washed with 5 mls room temperature 70% v/v ethanol and centrifuged at 11000 rpm for another 10 minutes at 4°C. The DNA pellet was then air-dried for 10 minutes, resuspended in 100 µl sterile water and final DNA yield calculated by measuring absorbance at 260 nm using a Gene Quant Pro spectrophotometer, and purity of the sample examined by the  $A_{260}/A_{280}$  ratio.

The purified plasmid DNA was again analysed by restriction enzyme digest and agarose gel electrophoresis as described in sections 2.2.12 and 2.2.13.

#### **2.2.16 Calculation Of Transcript Copy Numbers From DNA Concentration**

Determination of transcript copy numbers from DNA concentration required use of the following formulae obtained from <http://www.promega.com/biomath>:

1. Conversion of DNA concentration from µg/ml to pmol/ml based on the following formula:

$$\frac{\mu\text{g DNA}}{\text{ml}} \times \frac{\text{pmol}}{660\text{pg}} \times \frac{10^6 \text{ pg}}{1\mu\text{g}} \times \frac{1}{N} = \text{pmol DNA/ml}$$

where:  $N$  = # of nucleotides in plasmid DNA (vector + inserted PCR product)

660pg = average molecular weight of a nucleotide pair.

## 2. Calculation of transcript copy numbers.

Based on the Avogadro constant there are  $6 \times 10^{23}$  copies of a molecule in 1 mole, and 1

pmol =  $10^{-12}$  moles. Therefore:

$$\frac{6 \times 10^{23} \text{ copies} \times \text{pmol DNA/ml}}{10^{12}} \times 10^{-3} = \text{copies}/\mu\text{l}$$

### 2.2.17 Storage Of Plasmid DNA Stock Solutions

Following calculation of transcript copy numbers, the maxi-prep plasmid DNA samples were diluted in sterile water to create stock solutions of  $10^9$  copies per  $\mu\text{l}$  and stored at  $-80^\circ\text{C}$ .

### 2.2.18 QPCR

#### 2.2.18.1 QPCR optimisation

Efficiency of QPCR is dependent upon a number of factors. Primers should be carefully designed and checked for specificity to the gene of interest and where possible primers should span intron-exon boundaries to avoid amplification from contaminating genomic DNA. Amplification efficiency is also affected by differences in the melting temperature ( $T_m$ ) of the forward and reverse primers which in turn is dependent upon the primer's own

concentration within the reaction. Therefore the optimal  $T_m$  for each primer can be achieved by altering the primer concentrations.

The most favourable primer concentrations were determined by performing the primer matrix test (Table 2.5), where QPCR was performed using differing forward and reverse primer concentrations for known copy numbers of plasmid DNA. The optimum primer combination was that which resulted in the lowest  $C_t$  values at both high and low copy numbers of the target gene.

**Table 2.5: Primer Concentrations Used In The Primer Matrix Test**

Reverse Primer	Forward Primer		
	100 nM	300 nM	500 nM
100 nM	100nM Forward 100nM Reverse	300nM Forward 100nM Reverse	500nM Forward 100nM Reverse
300 nM	100nM Forward 300nM Reverse	300nM Forward 300nM Reverse	500nM Forward 300nM Reverse
500 nM	100nM Forward 500nM Reverse	300nM Forward 500nM Reverse	500nM Forward 500nM Reverse

#### **2.2.18.2 QPCR Amplification Efficiency & Quality Checks**

As well as optimising the primer concentrations further quality checks were performed to ensure maximum QPCR efficiency. The  $C_t$  value should occur during the exponential phase of cDNA amplification, therefore the standard curve generated by plotting the  $C_t$  values against the log of the transcript copy numbers should generate a linear graph with a correlation coefficient close to 1.0.

A second quality check is analysis of the melting point ( $T_m$ ), the temperature at which 50% of dsDNA dissociates into single strands. This is identified during QPCR by a significant reduction in fluorescence. The correct DNA product for a specific pair of primers will have the same  $T_m$  dependent on the nucleotide base composition, with GC-rich DNA requiring a higher  $T_m$  than AT-rich DNA. At the end of QPCR amplification, the temperature is therefore increased to the  $T_m$  to identify a single peak representing a single amplified product - the presence of other smaller peaks indicates contaminating DNA, primer-dimers, or alternatively spliced transcripts.

QPCR experiments should also include negative controls where mRNA is used as the nucleic acid template without having undergone reverse transcription (should not yield an amplification product). Another precaution to avoid genomic DNA contamination is to treat mRNA samples with DNase prior to reverse transcription.

### **2.2.18.3 QPCR Protocol**

QPCR was performed using Stratagene's Brilliant® SYBR® Green Master Mix. Each 25  $\mu$ l reaction contained 12.5  $\mu$ l Master Mix, forward and reverse primer (as per optimised concentrations) and ultrapure water. Reactions were set up in Stratagene 96-well PCR plates and centrifuged for 1 minute at 3000 rpm prior to being transferred to the Stratagene MX3000P® thermocycler. The thermal cycling protocol is listed in Table 2.6.

### **2.2.19 QPCR Product Verification**

The QPCR products were analysed by agarose gel electrophoresis, to confirm the presence of products of the expected base-pair size, and by DNA sequencing as described previously to ensure correct sequence amplification.

**Table 2.6: QPCR Thermal Cycling Protocol**

	Temperature	Time	Nº of cycles
<b>Enzyme activation</b>	95°C	10 minutes	1
<b>Denaturation</b>	94°C	30 seconds	40
<b>Annealing</b>	60°C	60 seconds	
<b>Extension</b>	72°C	30 seconds	
<b>Dissociation</b>	95°C	60 seconds	1
	55°C	30 seconds	
	95°C	30 seconds	

## 2.3 **RESULTS**

### 2.3.1 **Genomic DNA concentrations**

The human and genomic DNA concentrations are shown in table 2.7.  $A_{260}$  and  $A_{280}$  are the optical spectrometer measurements of absorbance at the wavelengths of 260 nm and 280 nm respectively.  $A_{260}$  is used to measure nucleic acid concentration and  $A_{280}$  is used to measure protein concentration. A ratio of  $A_{260}/A_{280} > 1.8$  suggests little protein contamination in a nucleic acid sample.

**Table 2.7: Quantification Of Genomic DNA Concentration**

	$A_{260}$	$A_{280}$	Concentration ng/ $\mu$ l	$A_{260}/A_{280}$
<b>Human</b>	0.129	0.065	129	1.985
<b>Murine</b>	0.049	0.028	49	1.75

### 2.3.2 **Primer Sequences**

Tables 2.8A and 2.8B list details of all the human and murine primers used during these experiments, including the primer nucleotide sequence, exon location, expected PCR product size and  $T_m$ . There were difficulties encountered while designing primers and it was not always possible to obtain forward and reverse primers derived from differing exons due to lack of product specificity or failure of PCR amplification.

**Table 2.8A: Primer Sequences for Human CB Receptors and Markers Of Adipogenesis**

Gene		5' to 3' Sequence		Exon	Concent ration	Product size	T <sub>m</sub> (°C)
HUMAN PRIMERS	CB1	Forward	AAG ACC CTG GTC CTG ATC CT	1	100nM	188	60
		Reverse	CGC AGG TCC TTA CTC CTC AG	1	300nM		60
	CB2	Forward	TAG ACA CGG ACC CCT TTT TG	1	100nM	241	60
		Reverse	TTC TCC CAA GTC CCT CAT TG	1	100nM		60
	APRT	Forward	GCT GCG TGC TCA TCC GAA AG	3	100nM	247	60
		Reverse	CTT TAA GCG AGG TCA GCT GC	5	100nM		60
	C/EBP $\beta$	Forward	AAC TTT GGC ACT GGG G	1	100nM	304	60
		Reverse	GGC CCG GCT GAC AGT T	1	100nM		60
	PPAR $\gamma$	Forward	CAG TGG GGA TGT CTC ATA	3	300nM	390	60
		Reverse	CTT TTG GCA TAC TCT GTG AT	5	500nM		60
	LPL	Forward	GAG ATT TCT CTG TAT GGA CC	7	300nM	275	60
		Reverse	CTG CAA ATG AGA CAC TTT CTC	9	300nM		60
	UCP-1	Forward	GGG GCT TCA GCG GCA AAT CAG	2	500 nM	236	60
		Reverse	TAT AAG TCC CCG TGT AGC GAG TT	3	300 nM		60


**Table 2.8B: Primer Sequences for Murine CB Receptors and Markers Of Adipogenesis**

Gene		5' to 3' Sequence		Exon	Concent ration	Product size	T <sub>m</sub> (°C)
MURINE PRIMERS	CB1	Forward	ACA GGG CAG TAC CCC TTC TT	1	100nM	175	60
		Reverse	AGC CCC TGG TGG TAT TCT CT	1	100nM		60
	CB2	Forward	TCA TTG CCA TCC TCT TTT CC	1	500nM	188	60
		Reverse	GAA CCA GCA TAT GAG CAG CA	1	100nM		60
	ARP	Forward	GAG GAA TCA GAT GAG GAT ATG GGA	7	100nM	172	60
		Reverse	AAG CAG GCT GAC TTG GTT GC	7	100nM		60
	Pref-1	Forward	CGT GAT CAA TGG TTC TCC CT	5	300nM	148	60
		Reverse	AGG GGT ACA GCT GTT GGT TG	5	500nM		60
	C/EBP $\beta$	Forward	CAA GCT GAG CGA CGA GTA CA	1	500nM	157	60
		Reverse	CAG CTG CTC CAC CTT CTT CT	1	500nM		60
	PPAR $\gamma$	Forward	TTT TCA AGG GTG CCA GTT TC	6	300nM	220	60
		Reverse	AAT CCT TGG CCC TCT GAG AT	6	300nM		60
	GPDH	Forward	ATG CTC GCC ACA GAA TCC ACA C	8	500nM	124	60
		Reverse	AAC CGG CAG CCC TTG ACT TG	8	500nM		60

### 2.3.3 PCR Amplification

Figure 2.5 illustrates the human and murine CB<sub>1</sub> and CB<sub>2</sub> PCR products visualised on a 2% agarose gel stained with 0.5 µg/ml ethidium bromide. Comparison was made to a 100 bp DNA ladder to ensure the amplified product bands were of the expected size.

**Figure 2.5: Human and Murine CB PCR Products**




### 2.3.4 Restriction Digest Analysis Of Mini-Preps

Figure 2.6 provides an example of two Human CB<sub>1</sub> mini-prep products following *Eco*R1 restriction enzyme digest, visualised on a 1.2% agarose gel stained with 0.5 µg/ml ethidium bromide. Comparison was made to a 1 kb and 100 bp DNA ladder. Bands corresponding to the 3 kb plasmid vector size were seen in both samples but only 1 contained an insert of the expected size, released by restriction digest. This sample was selected for DNA sequencing followed by large-scale plasmid DNA preparation.



**Figure 2.6: Human CB<sub>1</sub> Mini-Prep Restriction Digest Products**



### 2.3.5 Measurement of Maxi-Prep DNA Concentration

Table 2.9 lists the plasmid DNA concentrations determined by spectrophotometer analysis of each maxi-prep. This information was then used to calculate the transcript copy numbers (Table 2.10).

**Table 2.9: Maxi-Prep DNA Concentrations**

	Gene	A <sub>260</sub>	A <sub>280</sub>	Concentration ng/μl	A <sub>260</sub> /A <sub>280</sub>
Human	CB1	0.106	0.055	106	1.927
	CB2	0.331	0.185	331	1.789
Murine	CB1	0.882	0.435	882	2.028
	CB2	1.727	0.879	1727	1.965
	ARP	0.398	0.208	398	1.913
	Pref-1	1.639	0.845	1639	1.94
	C/EBPβ	0.760	0.412	760	1.845
	PPARγ	2.371	1.277	2371	1.857
	GPDH	1.256	0.623	1256	2.016

**Table 2.10: Transcript Copy Numbers Determined From Maxi-Prep DNA Concentration**

	Gene	DNA $\mu\text{g/ml}$	DNA $\text{pmol/ml}$	Copies/ $\mu\text{l}$
<b>Human</b>	<b>CB1</b>	106	50	$3 \times 10^{10}$
	<b>CB2</b>	331	156	$1 \times 10^{11}$
<b>Murine</b>	<b>CB1</b>	882	419	$2.5 \times 10^{11}$
	<b>CB2</b>	1727	817	$5 \times 10^{11}$
	<b>ARP</b>	398	189	$1 \times 10^{11}$
	<b>Pref-1</b>	1639	785	$5 \times 10^{11}$
	<b>C/EBP<math>\beta</math></b>	760	363	$2 \times 10^{11}$
	<b>PPAR<math>\gamma</math></b>	2371	1110	$6.5 \times 10^{11}$
	<b>GPDH</b>	1256	606	$4 \times 10^{11}$

Plasmid DNA standards for the human markers of adipogenesis (C/EBP $\beta$ , PPAR $\gamma$ , LPL) and housekeeper (APRT) were kindly provided by Dr Lei Zhang (Centre for Endocrine & Diabetes Sciences, Cardiff University).

### 2.3.6 Optimisation Of QPCR Primer Concentrations

Table 2.11 lists the Ct values obtained for the primer matrix test when applied to human CB<sub>1</sub> and the optimum primer combination which resulted in the lowest Ct values at both high ( $10^6$ ) and low ( $10^2$ ) copy numbers. Table 2.12 lists the optimised primer concentrations for all the genes of interest for this study.

**Table 2.11: Human CB<sub>1</sub> Primer Matrix Test**

(The Ct values presented are the mean of a single QPCR reaction performed in triplicate. The lowest values have been highlighted indicating the optimum primer combination)

Ct Values for 10 <sup>6</sup> copies				Ct Values for 10 <sup>2</sup> copies			
For Rev	100nM	300nM	500nM	For Rev	100nM	300nM	500nM
100nM	14.37	15.01	15.62	100nM	27.02	28.63	29.03
300nM	14.03	16.44	15.33	300nM	26.94	28.93	30.18
500nM	14.78	14.85	16.81	500nM	27.56	27.83	30.25

**Table 2.12: Optimised Concentrations For All QPCR Primers**


Human gene	Forward primer nM	Reverse primer nM	Murine gene	Forward primer nM	Reverse primer nM
CB1	100	300	CB1	100	100
CB2	100	100	CB2	500	100
APRT	100	100	ARP	100	100
C/EBPβ	100	100	Pref-1	300	500
PPARγ	300	500	C/EBPβ	500	500
LPL	300	300	PPARγ	300	300
			GPDH	500	500

### 2.3.7 QPCR Standard Curves

In order to allow estimation of copy numbers of the genes of interest in unknown samples, standard curves for reference were generated for each gene by QPCR analysis of samples with known copy numbers determined by serial dilutions of plasmid DNA stock solutions. The standard curves were obtained by plotting the Ct values against the log of the transcript copy

numbers to produce a linear graph with a correlation coefficient (RSq) close to 1.0 and amplification efficiency approaching 100%. Representative examples of the QPCR standard curves and amplification plots for human and murine CB<sub>1</sub> and CB<sub>2</sub> are given in Figures 2.7A-D.

**Figure 2.7A: SYBR Green® QPCR Standard Curve & Amplification Plots for Human CB<sub>1</sub>**



**Figure 2.7B: SYBR Green® QPCR Standard Curve & Amplification Plots for Murine CB<sub>1</sub>**






Figure 2.7C: SYBR Green® QPCR Standard Curve & Amplification Plots for Human CB<sub>2</sub>






Figure 2.7D: SYBR Green® QPCR Standard Curve & Amplification Plots for Murine CB<sub>2</sub>




Figures 2.8A-D illustrate the dissociation curves produced during melting point analysis performed after QPCR for human and murine CB<sub>1</sub> and CB<sub>2</sub> with a single peak denoting a single gene product and the absence of primer dimers.

**Figure 2.8A: Dissociation Curve For Human CB<sub>1</sub>**




**Figure 2.8B: Dissociation Curve For Murine CB<sub>1</sub>**






**Figure 2.8C: Dissociation Curve For Human CB<sub>2</sub>**



**Figure 2.8D: Dissociation Curve For Murine CB<sub>2</sub>**



### 2.3.8 DNA Sequencing

Direct DNA sequencing was performed after mini-prep and repeated with the QPCR products after primer optimisation. The resulting sequences were analysed with a BLAST search to ensure correspondence with the genes of interest and alignment with the initial primer sequences.

Numerous factors need to be considered when studying gene expression in order to choose the most sensitive and specific approach for monitoring these transcriptional events. This largely depends upon the quantity of tissue available as well as the level of gene expression. With PCR-based techniques, it is also essential that a number of quality control measures are employed in order to obtain meaningful data. These include designing primers specific to the target genes of interest, confirming the absence of genomic DNA by the use of primers that span intron/exon junctions and DNase treatment following reverse transcription, utilisation of either exogenous or endogenous standards or positive controls to assess reproducibility, and the use of negative controls to verify the absence of contamination.

A number of challenges were encountered during the course of the experiments outlined in this chapter. Ideally when designing primers it is preferable to obtain sequences spanning intron/exon junctions to help differentiate PCR amplicons from genomic products in subsequent experiments. This was however not always possible as a number of the genes of interest only contained a single exon. In other instances, such as with PPAR $\gamma$ , primers were originally designed to contain sequences from different exons but resulted in amplification of non-specific sequences as well. Nevertheless, with careful optimisation of QPCR conditions there are benefits of using absolute quantification. The results obtained for the gene of interest can be compared to transcript expression of housekeeper genes and can thus take into account efficiency of the reverse transcription step, DNase treatment and QPCR amplification itself. This does require the use of housekeeper genes whose expression is constant in the samples to be studied, and this can be quite a challenge when inducing differentiation.

QPCR with SYBR Green® is a sensitive and reproducible method for quantification of transcript expression during adipogenesis. There are, however, limitations with this



technique as well. Even higher sensitivity for detection of transcript numbers can be achieved with the use of capillary tubes within a Light Cycler heated with hot air instead of QPCR using 96-well plates heated on thermal blocks but the number of samples which can be run simultaneously is reduced. Another shortcoming with QPCR is that detection of transcripts does not necessarily correlate with the translated functional protein being present in the cell. Therefore alternative ways of verifying these results should also be employed. For example, in the pre-adipocyte differentiation experiments undertaken in the following chapters adipogenesis is confirmed not only by measurement of mature adipocyte-specific transcript expression, but also by morphological appearance on Oil red O staining and ELISA measurement of adiponectin. Alternative methods, such as the use of hydrolysis probes or cDNA arrays can provide simultaneous information about multiple genes in a large number of samples but can be more complex to design and are accompanied by increased expense.

This chapter has described the techniques used to clone purified PCR products from human and murine genomic DNA and optimise QPCR conditions, eventually resulting in a series of standard curves for measurement of CB<sub>1</sub> and CB<sub>2</sub> receptor expression as well as markers of differentiation in both species. This method was subsequently applied to quantify transcript expression in response to CB receptor modulation during *in vitro* adipogenesis using cell lines and human primary cultures as detailed in the following chapters.

## **CHAPTER 3:      EFFECT OF CANNABINOID RECEPTOR MODULATION ON PROLIFERATION AND DIFFERENTIATION IN PRE- ADIPOCYTE CELL LINES.**

### **3.1              INTRODUCTION**

As previously discussed in Chapter 1, excess adipose tissue is associated with clinical features of insulin resistance and the metabolic syndrome, therefore the adipocyte represents a major molecular target for novel pharmacotherapies aiming to reduce this burden associated with long-term risk of diabetes and CVD. Whereas adipose tissue was initially considered to be a passive connective tissue store of excess energy in the form of triglycerides, it is now also recognised as an endocrine organ capable of metabolic signalling [148]. This was first highlighted in the mid-1980s when research published by the Spiegelman and Flier laboratories demonstrated that adipocytes are an abundant source of a circulating serine protease-adipsin [149]. Since this time numerous other adipocyte secretory proteins, known as the adipocytokines, have been described including Acrp30 or adiponectin [150, 151], TNF $\alpha$  [152], leptin [153], resistin [154], and visfatin [155]. These have been shown to play key roles in energy homeostasis, regulation of appetite and satiety, reproduction, and insulin sensitivity as well as influencing vascular and immunological functions and have been discussed further in Chapter 1 [148].

#### **3.1.1              Cellular Composition Of Adipose Tissue**

The predominant cell-type found in adipose tissue is the adipocyte though numerous additional cells are also present, collectively known as the 'stromal vascular cells' which include pluripotent stem cells and pre-adipocytes both of which possess the ability for

adipogenesis, as well as endothelial cells, pericytes and macrophages all of which help support normal adipose tissue function [156].

### **3.1.2 Development Of Adipose Tissue**

The embryonic development of adipose tissue begins in the second trimester when mesenchymal cells with adipogenic potential form clusters at various sites in close proximity to vascular structures, predominantly at the neck, shoulder and pelvis as well as surrounding essential organs including the heart and kidneys [157, 158]. Adipose tissue has been shown to secrete specific growth factors including transforming growth factor- $\beta$  (TGF- $\beta$ ) which modulate angiogenesis, suggesting a developmental link with adipogenesis [157]. Adipose tissue is present from birth and retains the potential for growth at all stages of life dependent upon the site of the fat depot, the nature of the diet, environmental and genetic factors. Adipose tissue growth occurs by both ongoing lipid accumulation in existing mature adipocytes resulting in cells varying from 25 to 200  $\mu\text{m}$  in diameter, but also by further proliferation and differentiation of pre-adipocytes present within the adipose store [159].







### **3.1.3 Cellular Development & Transcript Expression During Adipogenesis**

The sequence of events occurring during adipogenesis has been studied at length in *in vitro* models and appears to follow a well recognised temporal sequence illustrated in Table 3.1 [160]. Adipocytes are derived from multipotent mesenchymal stem cells which have multiple differentiation capabilities including adipogenesis, osteogenesis, chondrogenesis and myogenesis. Therefore the early stages in adipogenesis involves determination and commitment to the adipocyte lineage by conversion of the multipotent stem cell to a unipotent adipoblast and then a pre-adipocyte [148]. Though morphologically similar to its precursors this cell acquires the machinery that is necessary for lipid transport and synthesis, insulin sensitivity and the secretion of adipocyte-specific proteins [161]. The molecular

regulation of these early events is not yet clearly understood but the latter stages have been more extensively characterised.

**Table 3.1: Cellular Development And Transcript Expression In Adipogenesis**

(adapted from Schaffler et al [148] & Ailhaud et al [157])

Stage		Cell		Gene expression profile
I	Determination		Mesenchymal stem cell (multipotential)	-
II	Cell commitment		Adipoblast (unipotential)	-
III	Mitosis & Clonal expansion		Pre-adipocyte I (no lipid)	<b>EARLY</b> Pref-1 Krox 20
IV			Pre-adipocyte II (lipid-containing)	<b>INTERMEDIATE</b> C/EBPs PPAR $\gamma$
V	Growth arrest		Immature adipocyte (lipid-containing, multilocular)	<b>LATE</b> Lipolytic & lipogenic enzymes e.g. LPL, FAS & GPDH
VI	Terminal differentiation		Mature adipocyte (lipid-filled, unilocular)	<b>VERY LATE</b> Adiponectin Leptin Resistin Visfatin

During *in vitro* adipogenesis using murine models, pre-adipocytes undergo a proliferative phase and clonal expansion eventually followed by growth arrest at the G<sub>1</sub>/S phase of the cell cycle secondary to cell-to-cell contact inhibition, though this step is not essential in primary cultures [162]. This process is associated with the downregulation of early differentiation

markers including Pref-1, a known repressor of adipogenesis [163]. The subsequent stages of adipocyte maturation are associated with a cascade of expression of intermediate adipogenic factors including CCAAT-enhancer-binding proteins (C/EBP  $\alpha$ ,  $\beta$  &  $\delta$ ) and peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) [161]. C/EBP $\beta$  & C/EBP $\delta$  are amongst the earliest seen and are implicated in the induction of adipogenesis by inducing PPAR $\gamma$  expression through C/EBP binding sites in the PPAR $\gamma$  promoter [158, 164]. PPAR $\gamma$  has been described as the 'master regulator' of adipogenesis and is essential for both adipogenesis itself and maintenance of the differentiated state [165]. PPAR $\gamma$  is the most conserved member of the PPAR family and controls gene expression through heterodimerisation with the retinoic X receptor (RXR). There are 3 PPAR $\gamma$  isoforms derived from the same gene through the use of alternate promoters [166, 167]. PPAR $\gamma$ -1 and PPAR $\gamma$ -3 encode for the same protein and are found in numerous cell types including adipose tissue, macrophages and colonic epithelium whereas PPAR $\gamma$ -2 is adipose tissue-specific though the precise roles of these differing isoforms of PPAR $\gamma$  are yet to be established [166, 167]. Numerous studies have demonstrated the critical role for PPAR $\gamma$  in pre-adipocyte differentiation. For instance *in vitro* experiments by Tontonoz et al have shown that PPAR $\gamma$  overexpression in isolation is sufficient to induce adipogenesis [168]. Conversely PPAR $\gamma$  knockout mice exhibit reduced adipose tissue mass while dominant-negative mutations in the human PPAR $\gamma$  gene have been described in subjects with partial lipodystrophy [169-172]. *In vivo* studies in murine models have demonstrated inducible knockout of PPAR $\gamma$  to be associated with adipocyte death [160, 173], whereas PPAR $\gamma$  over-expression alone can induce adipogenesis [168].

The transcriptional cascade regulating adipogenesis is centred around PPAR $\gamma$  itself whose expression is mediated by several pro-adipogenic and anti-adipogenic factors as illustrated in Figure 3.1 [161]. These include the Kruppel-like factors (KLF) which can both promote adipocyte differentiation (KLF 5 & 15) and enhance glucose transport mediated through increased expression, and translocation to the cell membrane, of glucose transporter 4 (GLUT4) [174, 175], as well as inhibit the process by inhibiting PPAR $\gamma$  expression (KLF2)




[176]. PPAR $\gamma$  expression, and thus adipogenesis, is also enhanced indirectly by Krox20, a C/EBP $\beta$  promoter [177], as well as directly by sterol response element binding protein 1c (SREBP1c) [178]. Conversely, adipogenesis can be inhibited by reduced C/EBP expression by the transcription factor homologous to C/EBP (CHOP) [161], as well as PPAR $\gamma$  promoter inhibition by the glutamyl amino transferidase subunit A transcription factors (GATA) [179].

The terminal stages of adipocyte maturation are associated with expression of enzymes required for adipocyte function including lipoprotein lipase (LPL), fatty acid synthase (FAS) and glycerol-3-phosphate dehydrogenase (GPDH) and eventual adipocytokine production [148, 157].

**Figure 3.1: Transcriptional Regulation Of Adipogenesis**

(adapted from Rosen et al [161])



### 3.1.4 White & Brown Adipose Tissue

Two types of adipocytes are found in mammals: the white and brown adipocyte. Whereas white adipose tissue (WAT) serves as an energy reservoir, the function of brown adipose tissue (BAT) is to dissipate energy in the form of heat by non-shivering thermogenesis [180].


Brown adipocytes store less lipid and contain more mitochondria than white adipocytes, and although brown adipocytes have virtually the same enzymatic machinery as white fat cells, the accumulated lipid in BAT is predominantly used as a source of fatty acids for oxidation in these mitochondria, as opposed to acting as a systemic energy storage depot [158]. Brown adipocytes have a similar gene expression profile to white adipocytes but also express some distinct genes, including the uncoupling protein-1 (UCP-1) which allows energy conversion to heat [161]. Whereas WAT is present in humans throughout life, until recently BAT was not thought to be found beyond the neonatal period where its location is limited to surrounding the great vessels in the thoracic cavity and interscapular regions [158]. Recent studies using 2-[<sup>18</sup>F]fluoro-2-deoxy-glucose (taken up by members of the glucose transporter family e.g. GLUT4) positron emission tomography (FDG PET), initially to trace tumour metastases, have identified BAT deposits in adult humans between the anterior neck and thorax [181, 182]. Further studies have also demonstrated that these areas of BAT are metabolically active, particularly in response to cold exposure [183, 184]. Other studies have utilised sensitive PCR-based techniques to demonstrate UCP-1 mRNA expression in WAT suggesting the presence of brown fat cells in small numbers within human WAT depots [185]. WAT is distributed throughout the body but preferentially accumulates in the subcutaneous and visceral depots. An accumulation of the latter reflects central adiposity and is associated with increased metabolic risk [3].

White and brown adipocytes are derived from mesenchymal stem cells (Figure 3.2) via the concerted action of extracellular signals and intrinsic transcription factors. Questions surround several issues in BAT development, including the identity of specific factors that promote brown fat adipogenesis, and whether BAT and WAT share common fat precursor cells or derive separately from stem cells via brown- and white-specific pre-adipocytes [158]. The mechanism by which these stem cells become committed to either white or brown adipocyte differentiation, and the extent to which white and brown adipocytes can be

transdifferentiated to one another, has not yet been fully elucidated, but represents a potential physiological and pharmacological target for anti-obesity interventions.

**Figure 3.2: White & Brown Fat Development From The Mesenchymal Stem Cell**

(adapted from Rosen et al [158])



### 3.1.5 Cell Lines

The diffuse nature of adipose tissue differentiation limits the potential to use *in vivo* and *ex vivo* analyses to study adipogenesis, therefore a series of adipoblast cell lines have been developed that differentiate into adipocytes when treated with appropriate hormonal inducers, and thus allow *in vitro* studies to take place [160]. One of the most commonly used cell lines that readily differentiates into WAT is 3T3-L1 which has been used in the present



study [186], but others have also been developed including 3T3-F442A and Ob 17 [187]. A BAT model was also studied using a cell line derived from simian virus transformation of human brown pre-adipocytes known as PAZ6 [188], though the physiological significance of BAT in adult humans remains controversial.

#### **3.1.5.1 White Pre-Adipocyte: 3T3-L1**

The 3T3 cell line, derived from embryonic fibroblasts harvested from the Swiss mouse, was established by George Todaro and Howard Green in the early 1960s, followed by development of 3T3-L1 cells, a similar and highly resilient cell line with an exaggerated ability to accumulate lipid [186, 189]. 3T3-L1, illustrated in Figure 3.3, are grown in standard culture conditions until proliferation is inhibited by cell-to-cell contact, at which point the cells accumulate lipid droplets and mature into adipocytes, a process which can be influenced by the hormonal environment. The 3T3-L1 cell line was obtained from the American Type Culture Collection ([www.atcc.org](http://www.atcc.org)).

**Figure 3.3: Murine 3T3-L1 White Pre-Adipocytes**

(magnification 200x)




### 3.1.5.2 Brown Pre-Adipocyte: PAZ6

The PAZ6 cell line was kindly provided by Vladimir Zilberfarb (Université Paris Descartes) and is illustrated in Figure 3.4.

**Figure 3.4: Human PAZ6 Brown Pre-Adipocytes**

(magnification 200x)



The PAZ6 cell line was established by transfection of stromal cells derived from human infant BAT with simian virus-40 antigen under control of the vimentin promoter and, in the appropriate hormonal environment, differentiates into mature BAT as confirmed by morphological changes of lipid droplet accumulation and QPCR detection of LPL (mature adipocyte marker) and UCP-1 (mature brown adipocyte marker) expression [188].

### 3.1.6 Hormonal Induction Of Adipogenesis

Over the years a number of agents have been empirically selected to induce *in vitro* adipogenesis and this evidence has been used to establish a differentiation protocol within our lab at the Centre for Endocrine and Diabetes Sciences at Cardiff University. One of the

earliest observations for efficient adipocyte differentiation has been the requirement for insulin to increase both the number of cells recruited for differentiation as well as enhance lipid accumulation [190]. However pre-adipocytes express few insulin receptors and the insulin effect has been shown to be mediated by cross-activation of the insulin-like growth factor-1 (IGF-1) receptor [191]. Further supplementation of the differentiation medium with fetal calf serum rich in IGF-1 therefore also promotes adipogenesis [192]. The glucocorticoid dexamethasone has also been used to inhibit pre-adipocyte proliferation *in vitro* and induces differentiation by inhibiting expression of Pref-1 and inducing C/EBP $\delta$  [164, 193, 194]. Given the crucial role of PPAR $\gamma$  in the regulation of adipogenesis, it is unsurprising that PPAR $\gamma$  agonists such as the thiazolidinedione pioglitazone, have also been used to stimulate differentiation [195].

Another compound known to induce adipogenesis is 3-isobutyl-1-methylxanthine (IBMX), a compound thought to act by increasing intracellular cAMP as well as C/EBP $\beta$  expression [196]. Numerous other hormones have also been used as components of *in vitro* differentiation protocols, though their roles *in vivo* may not be as well established. These include the addition of growth hormone [197], thyroid hormone [198], retinoic acid [199], and prostacyclin [200].

### **3.1.7            *In Vitro* Evaluation Of Pre-Adipocyte Proliferation**

As previously discussed, adipose tissue accumulates by both pre-adipocyte proliferation and differentiation, as well as mature adipocyte hyperplasia. Therefore a study of both these processes is required when investigating modulators of adipose tissue. The first of these, cell proliferation, represents a change in cell numbers arising from cell division or mitosis. Stimulators of cell proliferation will increase the rate at which cells divide, whereas inhibitors will cause either growth arrest or a reduction in the rate of cell division. Therefore the effect



any compound may exert on cellular proliferation can be investigated by determining absolute cell numbers before and after a treatment period.


Several techniques are recognised as validated methods of assessing proliferation. The first and simplest method is direct visual counting with the use of instruments such as a haemocytometer to estimate the number of cells per volume of culture suspension. However such methods are limited by both the laborious nature and potential for observer bias, and have thus been superseded by the development of electric particle counters [201]. Other techniques include radioactive isotope labelling of DNA in dividing cells such as the  $^3\text{H}$ -thymidine incorporation assay, where radioisotope accumulation in samples undergoing increased proliferation can be measured by scintillography [202].

Where a reduction in cell proliferation is observed in response to treatment exposure, it is important to exclude cell toxicity as a cause of the decrease in cell numbers. This was performed in the present studies by staining with trypan blue, a dye taken up by cells where membrane integrity has been lost due to cell necrosis or apoptosis, and by analysis of the cell cycle.

#### **3.1.7.1 Cell Cycle Analysis**

The cell-division cycle refers to the series of events leading to cell division and thus proliferation. The cell cycle can be divided into four phases as illustrated in Figure 3.5, the first three of which are collectively known as the interphase: Gap 1 ( $G_1$ ) phase for cell growth, DNA synthesis phase (S), Gap 2 phase for further cell growth ( $G_2$ ), and mitosis (M) [203]. Cells can either permanently or temporarily exit the cycle at  $G_1$  and become quiescent in a Gap 0 ( $G_0$ ) phase, and it is at this point that adipogenesis can occur in pre-adipocytes. Checkpoints also exist at  $G_1/S$  and  $G_2/M$  to block cell division if adverse environmental factors are present or if cell repair is required [204].

**Figure 3.5: Stages Of The Cell Cycle**



The amount of DNA present in a cell varies according to the stage of the cell cycle. Therefore, if cells undergoing investigation are fixed in ethanol and stained with a DNA stain such as propidium bromide, the amount of DNA present in any cellular sample can be quantified. Plotting this value against the known cell number can provide an indication of the distribution of cells throughout the cell cycle in a given sample, and thus enable the effect of compounds on cell proliferation and the cell cycle to be studied.

### **3.1.8 *In Vitro* Assessment Of Adipogenesis**

Numerous techniques have been established for assessment of adipogenesis. This can be performed by simple direct inspection under light microscopy to observe for morphological features of adipocyte maturation, predominantly a rounding up of cell shape and the acquisition of lipid droplets, coupled with a count of the number of foci of differentiation per high powered microscopic field. This method is again limited by observer bias thus the more robust and objective methods outlined below have been employed in this study.

Oil red O staining can be used to quantify the amount of lipid accumulation within a sample by firstly applying the stain, then extracting the absorbed stain in 100% isopropanol and measurement using colourimetry [205]. Another more specific technique is the measurement

of the expression of transcript specific to the target cell, e.g. terminal adipocyte markers LPL and GPDH, by real-time QPCR as described in Chapter 2. Here, RNA is extracted from differentiating cells during the adipogenesis protocol and reverse transcribed to cDNA. QPCR can then be performed on these samples to quantify the degree of receptor expression and thus the influence, if any, of a treatment upon fat cell differentiation.

### **3.1.9 Chapter Aims**

The ECS plays an important role in regulating weight and energy balance in humans and this system is activated to a greater extent in obese individuals. In animal studies, the administration of exogenous and endogenous cannabinoids is associated with robust increases in food intake and can promote weight gain, an effect believed to be mediated through activation of the CB<sub>1</sub> receptor. Conversely, animal studies of CB<sub>1</sub> blockade have demonstrated reductions in food intake and weight loss with repeated compound administration. These reductions in body weight appear to be greater in obese animals and may be the result of a dual effect on both food intake and metabolic processes. Clinical trials of SR141716 treatment in humans have also demonstrated significant reductions in body weight, waist circumference and improvement of lipid and glucose metabolism. Accordingly, the ECS represents an important pharmacological target for modulation of adipose tissue biology.

This chapter aims to study an *in vitro* model of pharmacological modulation of a key component of the metabolic syndrome – adipose tissue. To this end the actions of CB<sub>1</sub> and CB<sub>2</sub> receptors on proliferation and adipogenesis will be studied using *in vitro* models of both WAT and BAT.

## 3.2 **MATERIALS AND METHODS**

### 3.2.1 **Cell Populations**

The murine white preadipocyte cell line, 3T3-L1, was readily available in the department and the human brown preadipocyte cell line, PAZ6, was kindly provided by Vladimir Zilberfarb (Université Paris Descartes).

### 3.2.2 **Reagents**

CB receptor modulators (Table 3.2) were purchased from Tocris Bioscience (Bristol, UK). All reagents were initially reconstituted in ethanol, and further dissolved in culture medium to produce stock solutions of  $10^{-2}$  molar. The maximum concentration of ethanol in any experiment was 0.1% and this concentration was maintained in all control samples. All other culture medium constituents were obtained from BioWhittaker (Belgium) unless otherwise stated.

**Table 3.2: Summary Of CB Receptor Modulators [206]**

Compound	Description	Binding affinity (Ki)
<b>Anandamide</b>	Endogenous CB <sub>1</sub> and CB <sub>2</sub> agonist	CB <sub>1</sub> – 89 nM CB <sub>2</sub> – 371 nM
<b>ACEA</b>	CB <sub>1</sub> agonist (>1400-fold CB <sub>1</sub> selectivity over CB <sub>2</sub> )	1.4 nM
<b>AM 251</b>	CB <sub>1</sub> antagonist (306-fold CB <sub>1</sub> selectivity over CB <sub>2</sub> )	7.49 nM
<b>JWH 133</b>	CB <sub>2</sub> agonist (200-fold CB <sub>2</sub> selectivity over CB <sub>1</sub> )	3.4 nM

### 3.2.3 Culture Media

Both the 3T3-L1 and PAZ6 cell lines were routinely cultured in complete medium (CM), the contents of which are listed in Table 3.3.

**Table 3.3: Constituents Of Cell Culture Media**

Reagent	3T3-L1	PAZ6
<b>Dulbecco's modified eagle medium (DMEM)</b>	80 mls	82 mls
<b>Ham's F12</b>	80 mls	82 mls
<b>Fetal calf serum (FCS)</b>	10%	8%
<b>Sodium pyruvate</b>	2 mls	2 mls
<b>1.5% Sodium bicarbonate</b>	3 mls	n/a
<b>Hepes buffer</b>	n/a	3mls
<b>Penicillin (Cambrex, Berkshire, UK)</b>	100 u/ml	100 u/ml
<b>Streptomycin (Cambrex, Berkshire, UK)</b>	100 µg/ml	100 µg/ml

### 3.2.4 Routine Maintenance Of Cell Lines

All cell culture experiments were performed in sterile conditions at 37°C in an atmosphere containing humidified 5% CO<sub>2</sub> in air. Both 3T3-L1 and PAZ6 preadipocytes were grown in 75 cm<sup>2</sup> Nunclon™ delta surface flasks (Nunc, Roskilde, Denmark). Culture medium was changed every 48 hours and upon reaching approximately 80% confluence, the cells underwent passage. This was done by aspirating the culture medium and washing the cellular monolayer with 2 mls of 1% w/v trypsin (Cambrex, Berkshire, UK) pre-heated to 37°C. The trypsin was immediately aspirated and the cells were subsequently incubated with a further 2 mls of 1% w/v trypsin until the cells had detached from the flask and were free in suspension, as



confirmed by microscopy. A further 8 mls of culture medium was added to the solution to inactivate the trypsin and the total 10 mls solution was transferred to a universal container and centrifuged at 1000 rpm for 5 minutes. The resultant cell pellet was resuspended in culture medium and transferred either to fresh flasks or plated for experiments.

### **3.2.5 Cryopreservation Of Cells**

At every passage a proportion of cells were used to restock the cell bank. Cells were trypsinised as described above and the cell pellet obtained after centrifugation was resuspended in 0.5 ml of culture medium combined with 0.5 ml of freezing mix (FCS containing 20% dimethyl sulfoxide (DMSO), Sigma-Aldrich Company Ltd, Dorset, UK), and transferred to a 2 ml sterile cryotube. The cryotubes were placed within an insulated polystyrene freezing box containing isopropanol (Fisher Scientific UK Ltd, Leicestershire, UK) to enable a slow cooling rate of 1°C / minute and kept at -80°C for 24 hours prior to long-term storage in liquid nitrogen at -190°C.

### **3.2.6 Proliferation Studies**

#### **3.2.6.1 Cell Culture Protocol**

Both 3T3-L1 and PAZ6 preadipocytes were grown to confluence and trypsinised as described previously. The approximate number of cells per ml solution was calculated with the aid of a haemocytometer (Camber counter, Weber Scientific International Ltd, Middlesex, UK). Cells were subsequently diluted and seeded at  $1 \times 10^3$  per well in 24 well plates (Nunc<sup>TM</sup> delta surface, Nunc, Roskilde, Denmark) and incubated at 37°C overnight to enable optimal attachment. Cells were then incubated in culture medium alone, or supplemented with increasing concentrations of Anandamide ( $10^{-9}$  to  $10^{-5}$  molar), ACEA ( $10^{-9}$  to  $10^{-5}$  molar),

AM251 ( $10^{-9}$  to  $10^{-5}$  molar), or JWH133 ( $10^{-9}$  to  $10^{-5}$  molar). Each experiment was completed in quadruplicate and performed at least twice.

#### **3.2.6.2 Direct Cell Counting**

The pre-adipocytes were collected for direct cell counting after 24 and 72 hours of treatment. Each well was washed with 0.5 mls of 1% w/v trypsin and then incubated with a further 0.5 mls of 1% w/v trypsin until cells were free in suspension. The contents of individual wells were transferred to corresponding cell counting cuvettes containing 10 mls each of Coulter Isoton II Diluent (Beckman Coulter, GmbH, Germany). Cell densities were measured using a Coulter particle counter (Z2, Beckman Coulter GmbH, Germany) with particle size set between 3.8 nm and 9.0nm. Each sample was counted twice and the average value used for statistical analysis.

#### **3.2.6.3 Trypan Blue Toxicity Assay**

3T3-L1 and PAZ6 pre-adipocytes were seeded at  $1 \times 10^3$  per well in 24 well plates as described previously and incubated for 72 hours in culture medium (CM) alone, or supplemented with increasing concentrations of AM251 ( $10^{-9}$  to  $10^{-5}$  molar). Cells were then trypsinised and the resultant cell suspensions were centrifuged at 1000 rpm for 5 minutes and resuspended in 50  $\mu$ l CM combined with 50  $\mu$ l 0.1% Trypan blue (Sigma-Aldrich Company Ltd, Dorset, UK). The cells were examined for positive staining, indicating toxic injury, under a light microscope with the aid of a haemocytometer.

#### **3.2.6.4 Cell Cycle Analysis / Flow Cytometry**

3T3-L1 and PAZ6 pre-adipocytes were seeded at  $1 \times 10^4$  per well in 6 well plates as described previously and incubated for 24 hours in CM alone, followed by a further 48 hour incubation

in CM alone or supplemented with increasing concentrations of AM251 ( $10^{-8}$  to  $10^{-6}$  molar). The cell contents of individual wells were trypsinised as described above, centrifuged at 1000 rpm for 5 minutes, fixed in 1 ml cold ( $4^{\circ}\text{C}$ ) 70% v/v ethanol and stored overnight at  $-20^{\circ}\text{C}$ . The samples were again centrifuged at 1000 rpm for 10 minutes, ethanol aspirated and the cell pellet washed twice with PBS. Following this the samples were incubated for a further 20 minutes at  $37^{\circ}\text{C}$  with propidium iodide ( $50\mu\text{g}/\text{mL}$  in PBS) and RNase A ( $50\mu\text{g}/\text{mL}$ ) and subsequently analysed with a FACSCalibur flow cytometer. The FACSCalibur flow cytometer operation was kindly undertaken by Dr E. Wang, Department of Immunology, School of Medicine, Cardiff University.

### **3.2.7 Adipogenesis Studies**

#### **3.2.7.1 Cell Culture Protocol**

3T3-L1 and PAZ6 cells were plated in 6 well plates and adipogenesis induced in confluent populations of pre-adipocytes by replacing CM with differentiation medium (DM) containing 5% FCS,  $33\mu\text{M}$  biotin (Sigma Aldrich),  $17\mu\text{M}$  panthothenate (Sigma Aldrich),  $1\text{ nM}$  T3 (Sigma Aldrich),  $100\text{ nM}$  dexamethasone (Sigma Aldrich),  $1\mu\text{M}$  thiazolidinedione (Takeda) and  $500\text{ nM}$  insulin (Sigma Aldrich). Cells were maintained in DM alone, or supplemented with  $100\text{ nM}$  ACEA or  $100\text{ nM}$  AM251, for 12 days with DM changes occurring on days 3, 5, 7, 9 and 12. Morphological changes of differentiation were monitored by microscopic examination.

#### **3.2.7.2 Isolation Of Total RNA From 3T3-L1 & PAZ6**

Samples for RNA extraction were collected on days 0, 3, 5, 7, 9 and 12. Culture medium was removed from individual wells and cells washed 3 times with 1 ml PBS. Total RNA was isolated using Invitrogen's TRIzol reagent according to the manufacturer's instructions. Cells were lysed by adding 1 ml TRIzol to each well pipetting the lysate several times and complete

cell lysis confirmed by inspection under a light microscope. The contents of individual wells were transferred to 1.5 ml tubes and stored at -80°C until further use.

To continue RNA isolation, 200 µl chloroform (Fisher) was added to each thawed 1.5 ml tube to separate RNA from DNA and protein. The samples were mixed vigorously and incubated at room temperature for 2 minutes prior to centrifugation at 12000 rpm (Mikro 22R, Heitich Zentrifugen, Germany) for 15 minutes at 4°C. The uppermost RNA-containing aqueous phase was carefully transferred to clean 1.5 ml tubes and the RNA precipitated by adding 0.5 ml isopropanol. The samples were again incubated at room temperature for 10 minutes and centrifuged at 12000 rpm for 10 minutes at 4°C. The supernatant was removed, the remaining RNA pellet washed with 1 ml 75% v/v ethanol (Fisher) and centrifuged for a further 5 minutes at 4°C at 7500 rpm. The RNA pellet was air dried and redissolved in 20 µl nuclease-free water (Promega) by incubating at 60°C for 10 minutes.

The RNA concentration and quality was assessed by spectrophotometry (GeneQuant, GE Healthcare) and analysis on a 1.2% agarose gel. Samples were stored at -80°C until further use.

### **3.2.7.3 DNase Treatment Of RNA**

To avoid contamination of subsequent experiments with residual traces of genomic DNA, the isolated RNA was treated with Promega's RNase-free DNase according to the manufacturer's instructions. 1 µg RNA, 1 µl DNase 10x buffer, 1 µl DNase were combined in a 200 µl microtube and made up to 10 µl with nuclease-free water. The mixture was briefly centrifuged and incubated for 30 minutes in a 37°C water-bath prior to terminating the reaction by adding 1 µl Stop Solution and transferring the microtubes to a heating block for 10 minutes at 65°C.

#### 3.2.7.4 Reverse Transcription

RNA was reverse transcribed to complementary DNA (cDNA) for use in subsequent QPCR to measure transcript expression using the Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega). Each reaction contained 4 µl 5x First-Strand buffer (Promega), 1 µl 40 U/µl RNase inhibitor (Promega), 4 µl 500 ng/µl oligo (dT)<sub>15</sub> (Promega), 4 µl 10 mM dNTPs mix (Sigma-Aldrich), 1 µg DNase-treated RNA pre-heated at 60°C for 10 minutes, 1 µl 20 U/ µl MMLV reverse transcriptase and made up to 20 µl with sterile water. The reaction mixture was centrifuged briefly and transferred to a Techne Genius DNA Thermal Cycler (Techne Cambridge Ltd, Cambridge, UK). The thermal cycling settings are listed in Table 3.4.

**Table 3.4: Reverse Transcription Thermal Cycling Protocol**

	Temperature	Time	Nº of cycles
<b>Reverse transcription</b>	37°C	60 minutes	1
<b>Enzyme inactivation</b>	95°C	5 minutes	1

The resulting cDNA samples were stored at -20°C until further use.

#### 3.2.7.5 Conventional PCR

Standard PCR was performed in a Techne Genius DNA Thermal Cycler (Techne Cambridge Ltd, Cambridge, UK) using primers for the housekeeping gene phosphoglycerate-1-kinase (PGK1). The forward and reverse primers are located on separate exons and can therefore be used to differentiate between PCR products amplified from reverse-transcribed cDNA (250 bp product) and contaminating genomic (650 bp product) when analysed on a 2% agarose gel. The PCR reaction constituents and thermocycling protocol are listed in Tables 3.5 and 3.6.

**Table 3.5: PCR Reagents For Amplification From Genomic DNA**

Reagents	Volume per reaction
Sterile H <sub>2</sub> O	to complete final volume of 25 µl
<b>10x Taq DNA polymerase buffer (100 mM Tris-HCl, 500 nM KCl, 15 mM MgCl<sub>2</sub>)</b>	2.5 µl
<b>dNTP mix (10mM each dATP, dCTP, dGTP, dTTP)</b>	1 µl
<b>Forward primer (10 pmol/l)</b>	1 µl
<b>Reverse primer (10 pmol/l)</b>	1 µl
<b>Taq DNA polymerase (5 units/µl)</b>	0.4 µl
<b>Genomic DNA</b>	100 ng
<b>Total volume</b>	25 µl

**Table 3.6: PCR Thermal Cycling Protocol**

	Temperature	Time	Nº of cycles
<b>Initial Denaturation</b>	95°C	5 minutes	1
<b>Denaturation</b>	95°C	1 minute	40
<b>Annealing</b>	60°C	30 seconds	
<b>DNA synthesis</b>	72°C	1 minute	
<b>Final extension</b>	72°C	5 minutes	1

### 3.2.7.6 QPCR Measurement Of Markers Of Adipogenesis

Real-time QPCR was performed to measure expression of CB<sub>1</sub> and CB<sub>2</sub> receptors in all samples, murine markers of adipogenesis (Pref-1, C/EBPβ, PPARγ, GPDH) and house keeper genes (ARP) in 3T3-L1, and human markers of adipogenesis (C/EBPβ, PPARγ, LPL) and

housekeeper (APRT) in PAZ6 as well as UCP-1 in both cell lines. QPCR was performed using Stratagene's Brilliant® SYBR® Green Master Mix. Each 25 µl reaction contained 12.5 µl Master Mix, forward and reverse primer (as per optimised concentrations detailed in Chapter 2) and ultrapure water. Reactions were set up in Stratagene 96-well PCR plates and centrifuged for 1 minute at 3000 rpm prior to being transferred to the Stratagene MX3000P® thermocycler. The thermal cycling protocol is listed in Table 3.7.

**Table 3.7: QPCR Thermal Cycling Protocol**

	Temperature	Time	No of cycles
<b>Enzyme activation</b>	95°C	10 minutes	1
<b>Denaturation</b>	94°C	30 seconds	40
<b>Annealing</b>	60°C	60 seconds	
<b>Extension</b>	72°C	30 seconds	
<b>Dissociation</b>	95°C	60 seconds	1
	55°C	30 seconds	
	95°C	30 seconds	

### 3.2.7.7 Oil Red O Staining

Oil red O stains were performed to confirm the presence of lipid droplet accumulation and enable foci of differentiation to be counted. 3T3-L1 pre-adipocytes were seeded in 24 well plates and the differentiation protocol conducted as described above. On day 12, 0.5 g of oil red O was dissolved in 100 mls of isopropanol. 12 mls of this solution was combined with 8 mls of sterile water and filtered immediately. Each well was washed with 1 ml PBS, cells fixed with 0.5 ml 60% v/v isopropanol and washed again with 1 ml PBS. 300 µl filtered oil red O was then applied to each well for 15 minutes then aspirated. Each well was washed 3 times with 1 ml sterile water, examined under the light microscope and photographed for illustration. 200 µl of isopropanol was then added to each well and each individual well's

contents were then transferred to corresponding wells in a 96 well plate for analysis in an optical density reader (OpsysMR microplate reader, Dynex Technologies, Chantilly, USA) set at OD<sub>490</sub>.

### **3.2.8 Statistical Analysis**

Data were analysed using the SPSS (version 14.0) statistical software package.

The data generated by the proliferation and adipogenesis studies were not normally distributed (determined by generating Q-Q and P-P plots of data obtained) and therefore analysed according to median and interquartile ranges (IQR) using non-parametric statistical tests. The Friedman's test was performed on each experiment and the Wilcoxon Signed Ranks test was performed on individual treatments relative to control conditions. The QPCR data were analysed as absolute values per input microgram of mRNA and corrected relative to the appropriate housekeeper gene expression.



### 3.3 RESULTS

#### 3.3.1 Endogenous CB Agonist Anandamide Stimulates Proliferation Of 3T3-L1 But Has No Effect On PAZ6


Exposure to the CB agonist anandamide for 24 hours was associated with a concentration-dependent increase in proliferation of 3T3-L1 as illustrated in Table 3.8 and Figure 3.6.

**Table 3.8: Mean, Median & IQR For 3T3-L1 Treated With Anandamide For 24 Hours**

Anandamide concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	4428	4392	4152-4716	n/a
1 nM	4730	4790	4443-4979	0.009
10 nM	4977	4996	4799-5181	<0.001
100 nM	5128	5143	4988-5252	<0.001
1 $\mu$ M	5386	5367	5159-5621	<0.001
10 $\mu$ M	5404	5433	5241-5592	<0.001

**Figure 3.6: The Effect Of Anandamide On 3T3-L1 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.




The significant, concentration-dependent increase in proliferation of 3T3-L1 was also observed after 72 hours exposure to anandamide as illustrated in Table 3.9 and Figure 3.7.

**Table 3.9: Mean, Median & IQR For 3T3-L1 Treated With Anandamide For 72 Hours**

Anandamide concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	35374	35394	35014-35744	n/a
1 nM	36973	36997	36566-37289	<0.001
10 nM	38746	38660	38309-39377	<0.001
100 nM	40867	40978	40048-41616	<0.001
1 $\mu$ M	40280	40430	39820-40712	<0.001
10 $\mu$ M	39984	40039	39480-40511	<0.001

**Figure 3.7: The Effect Of Anandamide On 3T3-L1 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Treatment with the CB agonist anandamide had no significant effect on proliferation of PAZ6 at 24 hours (Table 3.10 and Figure 3.8) or at 72 hours (Table 3.11 and Figure 3.9 ).

**Table 3.10: Mean, Median & IQR For PAZ6 Treated With Anandamide For 24 Hours**

Anandamide concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	3875	3883	3539-4246	n/a
1 nM	3891	4028	3527-4245	0.966
10 nM	3777	3857	3353-4135	0.346
100 nM	3765	3835	3343-4150	0.407
1 $\mu$ M	3868	3872	3504-4171	0.886
10 $\mu$ M	3860	3943	3582-4172	0.797

**Figure 3.8: The Effect Of Anandamide On PAZ6 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.




**Table 3.11: Mean, Median & IQR For PAZ6 Treated With Anandamide For 72 Hours**

Anandamide concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
<b>Control (0.1% ethanol)</b>	21405	21535	20896-21841	n/a
<b>1 nM</b>	21239	21255	20893-21659	0.230
<b>10 nM</b>	21193	21270	20937-21482	0.092
<b>100 nM</b>	21345	21429	20950-21633	0.587
<b>1 <math>\mu</math>M</b>	21239	21195	20864-21721	0.153
<b>10 <math>\mu</math>M</b>	21157	21010	20709-21720	0.067

**Figure 3.9: The Effect Of Anandamide On PAZ6 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.





### 3.3.2 CB<sub>1</sub> Agonist ACEA Stimulates Proliferation Of 3T3-L1 But Does Not Affect PAZ6


Exposure to the CB<sub>1</sub> agonist ACEA for 24 hours was associated with a significant, concentration -dependent increase in proliferation of 3T3-L1 as illustrated in Table 3.12 and Figure 3.10.

**Table 3.12: Mean, Median & IQR For 3T3-L1 Treated With ACEA For 24 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	3736	3736	3560-3900	n/a
1 nM	3867	3811	3752-3961	0.028
10 nM	4021	3991	3906-4155	<0.001
100 nM	4405	4428	4257-4571	<0.001
1 $\mu$ M	4344	4309	4236-4459	<0.001
10 $\mu$ M	4404	4377	4260-4618	<0.001

**Figure 3.10: The Effect Of ACEA On 3T3-L1 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.




The significant, concentration-dependent increase in proliferation of 3T3-L1 was also observed after 72 hours exposure to ACEA as illustrated in Table 3.13 and Figure 3.11.

**Table 3.13: Mean, Median & IQR For 3T3-L1 Treated With ACEA For 72 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
<b>Control (0.1% ethanol)</b>	39835	39805	39230-40355	n/a
<b>1 nM</b>	40717	40624	40290-41121	<b>&lt;0.001</b>
<b>10 nM</b>	41935	41769	41519-42489	<b>&lt;0.001</b>
<b>100 nM</b>	43154	42953	42632-43909	<b>&lt;0.001</b>
<b>1 <math>\mu</math>M</b>	43371	43596	42495-44046	<b>&lt;0.001</b>
<b>10 <math>\mu</math>M</b>	42298	42366	41968-42565	<b>&lt;0.001</b>

**Figure 3.11: The Effect Of ACEA On 3T3-L1 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Treatment with the CB<sub>1</sub> agonist ACEA had no significant effect on proliferation of PAZ6 at 24 hours (Table 3.14 and Figure 3.12) or at 72 hours (Table 3.15 and Figure 3.13).

**Table 3.14: Mean, Median & IQR For PAZ6 Treated With ACEA For 24 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
<b>Control (0.1% ethanol)</b>	3832	3804	3671-3994	n/a
<b>1 nM</b>	3882	3920	3626-4128	0.627
<b>10 nM</b>	3910	3972	3696-4051	0.201
<b>100 nM</b>	3841	3881	3638-4033	0.710
<b>1 <math>\mu</math>M</b>	3868	3851	3727-4025	0.689
<b>10 <math>\mu</math>M</b>	3842	3868	3652-4006	0.886

**Figure 3.12: The Effect Of ACEA On PAZ6 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






**Table 3.15: Mean, Median & IQR For PAZ6 Treated With ACEA For 72 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
<b>Control (0.1% ethanol)</b>	21310	21355	21111-21510	n/a
<b>1 nM</b>	21291	21341	21092-21479	0.732
<b>10 nM</b>	21162	21168	20888-21347	0.063
<b>100 nM</b>	21279	21252	21072-21542	0.648
<b>1 <math>\mu</math>M</b>	21303	21360	21124-21576	0.875
<b>10 <math>\mu</math>M</b>	21347	21431	21124-21576	0.753

**Figure 3.13: The Effect Of ACEA On PAZ6 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.



### 3.3.3 Effect Of CB<sub>1</sub> Antagonist AM 251 On Proliferation Of 3T3-L1 And PAZ6


Exposure to the CB<sub>1</sub> antagonist AM 251 for 24 hours did not affect proliferation of 3T3-L1 as illustrated in Table 3.16 and Figure 3.14.

**Table 3.16: Mean, Median & IQR For 3T3-L1 Treated With AM 251 For 24 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	5433	5443	5302-5537	n/a
1 nM	5414	5390	5313-5522	0.658
10 nM	5401	5356	5317-5480	0.315
100 nM	5442	5462	5341-5523	0.830
1 $\mu$ M	5411	5410	5348-5503	0.511
10 $\mu$ M	5421	5386	5327-5525	0.764

**Figure 3.14: The Effect Of AM 251 On 3T3-L1 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Exposure to AM 251 for 72 hours was associated with a significant, concentration-dependent reduction in proliferation of 3T3-L1 as illustrated in Table 3.17 and Figure 3.15.

**Table 3.17: Mean, Median & IQR For 3T3-L1 Treated With AM 251 For 72 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
<b>Control (0.1% ethanol)</b>	39454	39577	39018-39812	n/a
<b>1 nM</b>	39307	39368	39097-39457	0.137
<b>10 nM</b>	39059	39077	38972-39151	<b>0.001</b>
<b>100 nM</b>	38949	38950	38874-39029	<b>&lt;0.001</b>
<b>1 <math>\mu</math>M</b>	38947	38932	38880-39054	<b>&lt;0.001</b>
<b>10 <math>\mu</math>M</b>	38913	38879	38791-39049	<b>&lt;0.001</b>

**Figure 3.15: The Effect Of AM 251 On 3T3-L1 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.




Treatment with the CB<sub>1</sub> antagonist AM 251 had no significant effect on proliferation of PAZ6 at 24 hours (Table 3.18 and Figure 3.16) or at 72 hours (Table 3.19 and Figure 3.17).

**Table 3.18: Mean, Median & IQR For PAZ6 Treated With AM 251 For 24 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
<b>Control (0.1% ethanol)</b>	3678	3704	3539-3830	n/a
<b>1 nM</b>	3663	3717	3517-3764	0.376
<b>10 nM</b>	3607	3582	3495-3725	0.130
<b>100 nM</b>	3610	3620	3556-3682	0.056
<b>1 <math>\mu</math>M</b>	3594	3605	3450-3662	0.059
<b>10 <math>\mu</math>M</b>	3579	3619	3479-3673	0.081

**Figure 3.16: The Effect Of AM 251 On PAZ6 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






**Table 3.19: Mean, Median & IQR For PAZ6 Treated With AM 251 For 72 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	21689	21763	21328-21951	n/a
1 nM	21639	21643	21225-21988	0.587
10 nM	21587	21559	21353-21793	0.136
100 nM	21539	21588	21239-21912	0.368
1 $\mu$ M	21470	21381	21187-21720	0.058
10 $\mu$ M	21621	21660	21264-21946	0.346

**Figure 3.17: The Effect Of AM 251 On PAZ6 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.



### 3.3.4 CB<sub>2</sub> Agonist JWH 133 Does Not Affect Proliferation Of 3T3-L1 Or PAZ6


Treatment with the CB<sub>2</sub> agonist JWH 133 had no significant effect on proliferation of 3T3-L1 at 24 hours (Table 3.20 and Figure 3.18) or at 72 hours (Table 3.21 and Figure 3.19).

**Table 3.20: Mean, Median & IQR For 3T3-L1 Treated With JWH 133 For 24 Hours**

JWH 133 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	4989	4985	4933-5054	n/a
1 nM	4979	4964	4924-5053	0.511
10 nM	4959	4957	4895-5021	0.260
100 nM	4995	5001	4937-5045	0.954
1 $\mu$ M	4966	4974	4908-5026	0.361
10 $\mu$ M	4939	4926	4869-5013	0.054

**Figure 3.18: The Effect Of JWH 133 On 3T3-L1 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






**Table 3.21: Mean, Median & IQR For 3T3-L1 Treated With JWH 133 For 72 Hours**

JWH 133 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	30167	30120	29572-30778	n/a
1 nM	30049	29866	29273-30869	0.607
10 nM	30249	30385	29451-30860	0.511
100 nM	29995	29840	29198-31045	0.549
1 $\mu$ M	29879	29823	29102-30709	0.304
10 $\mu$ M	29897	29802	29245-30634	0.162

**Figure 3.19: The Effect Of JWH 133 On 3T3-L1 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Treatment with the CB<sub>2</sub> agonist JWH 133 had no significant effect on proliferation of PAZ6 at 24 hours (Table 3.22 and Figure 3.20) or at 72 hours (Table 3.23 and Figure 3.21).

**Table 3.22: Mean, Median & IQR For PAZ6 Treated With JWH 133 For 24 Hours**

JWH 133 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	3991	3980	3853-4107	n/a
1 nM	4005	4018	3916-4107	0.568
10 nM	4017	3992	3887-4145	0.637
100 nM	3997	3985	3848-4135	0.909
1 $\mu$ M	4011	4003	3986-4131	0.543
10 $\mu$ M	3987	3966	3881-4097	0.886

**Figure 3.20: The Effect Of JWH 133 On PAZ6 Proliferation At 24 Hours**

Cells were counted 24 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.




**Table 3.23: Mean, Median & IQR For PAZ6 Treated With JWH 133 For 72 Hours**

JWH 133 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	18324	18373	18073-18534	n/a
1 nM	18318	18243	18108-18575	0.989
10 nM	18246	18199	18007-18544	0.331
100 nM	18299	18252	18017-18642	0.819
1 $\mu$ M	18379	18445	18148-18602	0.399
10 $\mu$ M	18217	18169	17966-18516	0.107

**Figure 3.21: The Effect Of JWH 133 On PAZ6 Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SEM from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






### 3.3.5 CB<sub>1</sub> Antagonist AM 251 Inhibition Of Proliferation Is Not Due To Cell Toxicity

The previous results indicated that treatment with AM 251 had an inhibitory effect on 3T3-L1 proliferation. Overall cell numbers continued to rise between 24 and 72 hours suggesting cell toxicity arising from exposure to AM 251 to be unlikely. Trypan blue staining was undertaken on control and treated samples to confirm this (Figure 3.22). Some dye uptake was noted in all samples and was likely to be a result of manual cell damage that may have occurred during the experimental procedure. Overall toxicity was estimated to be less than 1% in both control and treated samples.

**Figure 3.22: Trypan Blue Staining Of 3T3-L1 After 72 Hours Exposure To AM 251**

(Results are from a single experiment performed in quadruplicate. Magnification 200x)



### 3.3.6 The Effect Of CB<sub>1</sub> Antagonist AM 251 On The Cell Cycle


Cell cycle analysis was undertaken in order to determine whether the inhibition of proliferation observed in 3T3-L1 following treatment with AM 251 was due to interruption of the cell cycle or an increase in cell apoptosis. Figures 3.23 and 3.24 illustrate a significant concentration-related increase in cells in the G<sub>0</sub>/G<sub>1</sub> phase as well as a significant decrease in the number of cells in the S and G<sub>2</sub>+M phases of the cell cycle suggesting a block at G<sub>1</sub>/S. Also



the histograms in Figure 3.23 show no pre-G1 peak, indicating that increased apoptosis was unlikely to be the cause of the reduced cell numbers. Statistical significance was determined by the Kruskal-Wallis test to include both control samples and all treatment concentrations.


**Figure 3.23: Histograms Illustrating Effect Of AM 251 On 3T3-L1 Cell Cycle Progression**

$1 \times 10^4$  cells were plated per well and analysed after 48 hours treatment with control or AM 251 followed by DNA staining with propidium iodide. The x-axis represents the cell cycle and y-axis provides the cell counts. Data are a representative example of 2 independent experiments performed in replicates of six.



**Figure 3.24: The Effect Of AM 251 On 3T3-L1 Cell Cycle**

$1 \times 10^4$  cells were plated per well and analysed after 48 hours treatment with control or AM 251. Results are median values of percentages of gated controls for each cell cycle stage






### 3.3.7 Summary Of The Effects Of Cannabinoid Receptor Modulation On Pre-Adipocyte Cell Line Proliferation

When cultured in ordinary CM, 3T3-L1 were noted to exhibit a population doubling time of approximately 22 hours while this was longer at almost 28 hours for PAZ6 . Treatment with endogenous and exogenous CB<sub>1</sub> agonists resulted in a statistically significant concentration-dependent stimulation of proliferation in 3T3L1 while the CB<sub>1</sub> antagonist had the opposite effect. Further studies with cell cycle analysis and trypan blue staining confirmed that the effect seen was not due to increased apoptosis or toxic effects of the treatments used but may in part be due to cell cycle blockade. CB<sub>2</sub> agonist treatment did not have any effect on 3T3-L1 proliferation Treatment with CB<sub>1</sub> and CB<sub>2</sub> agonists and CB<sub>1</sub> antagonist had no effect on PAZ6 proliferation.

### 3.3.8 RNA Quality

RNA concentration and quality were determined by measuring absorbance at A<sub>260</sub> and A<sub>280</sub> using a Gene Quant Pro spectrophotometer (Gene Quant, GE Healthcare), and purity of the sample assessed by confirming a A<sub>260</sub>/A<sub>280</sub> ratio greater than 1.8 suggesting little protein contamination in the nucleic acid sample. A sample of RNA was also analysed on a 1.2% agarose gel with ethidium bromide staining (Figure 3.25). The presence of bands at 28s and 18s confirmed RNA integrity and suitability for reverse transcription.

**Figure 3.25: Agarose Gel Electrophoresis Of 3T3-L1 RNA**




### 3.3.9 Transcript Expression During 3T3-L1 Pre-adipocyte Differentiation

Figure 3.26 demonstrates transcript expression during adipogenesis in 3T3-L1 cells. While CB<sub>2</sub> expression was largely unaltered, CB<sub>1</sub> receptors were upregulated at the midpoint of the differentiation protocol coincident with PPAR $\gamma$  expression. The increase in GPDH expression, a marker present in mature adipocytes, confirmed successful adipogenesis. Both CB<sub>1</sub> and CB<sub>2</sub> receptor expression was virtually undetectable in PAZ6 with Ct values approaching the limit of detection at the maximum number of programmed PCR cycles and no change was noted during adipogenesis. This may explain the lack of effect of CB modulation on PAZ6 proliferation. Therefore all further differentiation experiments were only performed in 3T3-L1.

**Figure 3.26: Transcript Expression During 3T3-L1 Adipogenesis**

All transcript copy numbers were normalised to the housekeeper gene ARP. Results are presented as fold-changes in comparison to expression on Day 0 & represent two independent experiments performed in triplicate






### **3.3.10      The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On Foci Of Differentiation In 3T3-L1**

One method of assessing adipogenesis is by manually counting separate foci of differentiation occurring within a single observed microscopic field. However, 3T3-L1 differentiation was noted to be so widespread that it was not possible to accurately count foci in order to draw comparisons between control and treatment conditions ((Figure 3.27). These effects were therefore studied by means of oil red O staining and QPCR for terminal markers of adipogenesis.

**Figure 3.27: Adipogenesis In 3T3-L1**

(magnification 200x)




### **3.3.11      Oil Red O Staining**

Lipid droplets are exclusively present in mature adipocytes and stain positive with oil red O (Figure 3.28). Oil red O taken up by the mature adipocytes was dissolved out and assessed by direct colourimetry. Figure 3.29 shows treatment with CB<sub>1</sub> agonist ACEA was associated with an increase in oil red O whereas CB<sub>1</sub> antagonist AM 251 had no significant effect.




**Figure 3.28: Oil Red O Staining In Mature 3T3-L1 Adipocytes**

(magnification 200x)



**Figure 3.29: Box-and-Whisker Representation Of The Effect Of CB<sub>1</sub> Agonist ACEA & Antagonist AM 251 On Oil Red O Staining in Mature 3T3-L1 Adipocytes**

Data represent the median & IQRs expressed as OD<sub>490</sub> from 2 independent experiments performed in quadruplicate. Significance was determined by the Wilcoxon Signed Ranks Test for individual treatments relative to control.




### 3.3.12 The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On Terminal Markers Of Adipogenesis In 3T3-L1

QPCR was performed on cDNA derived from RNA collected on day 0 and day 12 of the differentiation protocol and transcript expression for GPDH was normalised to housekeeper gene (ARP) expression. While exposure to the CB<sub>1</sub> agonist ACEA had no effect on adipogenesis relative to control conditions, supplementation with AM 251 was associated with a significant increase in GPDH expression as illustrated in Figure 3.30 and Table 3.24.

**Figure 3.30: The Effect Of AM 251 On GPDH Expression In 3T3-L1 During Adipogenesis**

Data represent 2 independent experiments performed in triplicate following 12 days culture in DM, ACEA or AM251. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control.



**Table 3.24: The Effect Of AM 251 On GPDH Expression In 3T3-L1 During Adipogenesis**

Data represent 2 independent experiments performed in triplicate following 12 days culture in DM, ACEA or AM251. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control

Sample	GPDH		ARP		Normalised	Mean	P-value
	Ct	Copy	Ct	Copy			
Day 0	25.44	5736	17.51	2187000	26	31	n/a
	26.14	3392	17.04	3175000	11		
	24.37	7842	18.05	1481000	53		
	25.22	6137	17.55	2158000	28		
	26.13	3416	18.70	908100	38		
	26.75	2974	18.56	1012000	29		
Day 12 Control 0.1% ethanol	21.21	138300	18.51	1053000	1313	1095	n/a
	21.41	118900	18.25	1276000	932		
	20.98	164000	18.35	1000000	1640		
	20.71	200600	16.62	3989000	503		
	20.96	166800	18.19	1357900	1228		
	21.15	144900	18.04	1515000	956		
Day 12 100 nM ACEA	19.80	282700	17.21	2739000	1032	1037	0.699
	21.34	120900	17.87	1962000	616		
	20.75	193800	16.98	3472000	558		
	20.03	257500	17.03	3179000	810		
	20.78	192200	18.34	1574000	1221		
	19.66	350100	18.26	1763000	1986		
Day 12 100 nM AM 251	19.70	362000	17.94	1640000	2207	2734	0.015
	20.43	241900	17.88	1976000	1224		
	18.56	517200	17.96	1605600	3221		
	17.91	836000	17.61	2089000	4002		
	18.03	787400	17.43	2184000	3605		
	19.92	423000	17.90	1973000	2144		

### **3.3.13      The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On UCP-1 Expression In Differentiated 3T3-L1**

QPCR was performed on cDNA derived from RNA collected on day 0 and day 12 of the differentiation protocol and transcript expression for UCP-1 was normalised to housekeeper gene (ARP) expression. Transcript expression was at the limit of QPCR detection (Ct values > 35) and did not alter with adipogenesis in control conditions or when supplemented with ACEA or AM 251.



Adipocyte cell proliferation and differentiation represent two closely related cell processes that control adipose tissue homeostasis [207]. In obesity, adipose tissue accumulates as a result of increased pre-adipocyte proliferation (hyperplasia) and differentiation into mature adipocytes, as well as excess lipid droplet accumulation within adipocytes causing cell hypertrophy. The data from the experiments described in this chapter have demonstrated that CB<sub>1</sub> agonist treatment appears to have a stimulatory effect on pre-adipocyte proliferation in the WAT cell line, 3T3-L1, while CB<sub>1</sub> antagonism may inhibit cell proliferation, thus modifying an important step in adipose tissue accumulation. This inhibitory effect does not appear to be due to increased apoptosis and toxicity, but may partly be secondary to cell cycle blockade with growth arrest in the G1 phase. However, though statistically significant, these effects do appear to be relatively small in absolute terms, therefore further work is required to determine their biological significance.

Similar studies published in the literature have also confirmed an anti-proliferative effect, using the CB<sub>1</sub> antagonist SR141716, where the findings have been associated with inhibition of p42/44 mitogen-activated protein (MAP) kinase activity which has been shown to be involved in the CB<sub>1</sub> signalling pathway [207, 208]. The inhibition of proliferation with CB<sub>1</sub> blockade adds evidence to the importance of the ECS in adipocyte physiology and studies by Matias et al have confirmed the presence of the endogenous endocannabinoids 2-AG and AEA in murine white adipocytes *in vitro* [76]. These findings suggest that adipocytes could contribute directly to dysregulation of the ECS affecting obesity.

In the experiments presented here, CB<sub>1</sub> antagonism induced expression of GPDH, a late marker of adipocyte maturation without an associated increase in lipid droplet accumulation measured by oil red O, thus modifying another process in adipose tissue accumulation. These findings are consistent with those published in previous studies. Gary-Bobo et al have also

demonstrated a CB<sub>1</sub> antagonist-induced increase in expression of terminal markers of adipogenesis, GPDH and adiponectin, that was not accompanied by lipid droplet accumulation [207]. The authors hypothesise that CB<sub>1</sub> antagonism may cause an uncoupling of the association between the inhibition of pre-adipocyte proliferation and lipid accumulation through adipogenesis [207]. Though atypical, this property may also account for some of the anti-obesity effects seen with CB<sub>1</sub> blockade but further work is required to clarify this.

CB<sub>2</sub> agonists and antagonists had no effect on 3T3-L1 proliferation. The results from these experiments suggest that CB<sub>2</sub> does not play a significant role in adipocyte biology as modulation of CB<sub>2</sub> in the present studies had no effect on proliferation, and CB<sub>2</sub> transcript expression remained unchanged throughout adipogenesis.

There do not seem to be any previous studies examining the effects of CB modulation in BAT. Neither CB<sub>1</sub> nor CB<sub>2</sub> modulation had any effect on the BAT human pre-adipocyte cell line PAZ6 proliferation, and transcript expression was virtually undetectable for both receptors throughout adipogenesis. These findings, though negative, are novel as there are no published data of similar studies, though further work would be required to confirm this. It is, however, also important to recognise the limitations of the PAZ-6 cell line, which is not always easy to use and does not differentiate as readily in response to environmental stimuli as the 3T3-L1 cell line. These characteristics may also have contributed to the negative findings in the present studies of CB modulation in BAT.

Our experiments did not confirm the presence of the BAT-specific marker, UCP-1, in terminally differentiated 3T3-L1. This is in contrast to a recent study by Perwitz et al who demonstrate that CB<sub>1</sub> blockade with the antagonist SR 141716, or receptor knock down with small interfering RNA (siRNA), induces UCP-1 expression in murine white adipocytes in a time- and concentration-dependent manner at both RNA and the protein level [209]. This was also associated with an augmentation in the number of mitochondria present as

indicated by mitochondria-specific fluorescent staining and electron microscopy. Furthermore, SR 141716 treatment enhanced cytochrome C oxidase activity and increased cellular oxygen consumption [209]. These important findings suggest that CB<sub>1</sub> blockade could promote transdifferentiation of white adipocytes into a BAT phenotype, and may thus contribute to weight loss and improved energy homeostasis. The discrepancy between these studies may be attributed to the different CB<sub>1</sub> antagonists employed or due to possible differences in the WAT cell lines.

The studies described in this chapter suggest that the inhibition of pre-adipocyte proliferation, along with induction of adipocyte maturation, may in part explain the peripheral anti-obesity effects of CB<sub>1</sub> antagonist treatment by a reduction in total body fat mass. However, these data have been obtained from work performed using *in vitro* models of animal-derived cells, and therefore cannot be conclusively applied to human physiology without further study. The next chapter aims to address this by replicating these experiments in a human model with the use of primary pre-adipocytes.

## **CHAPTER 4:      EFFECT OF CANNABINOID RECEPTOR MODULATION ON PROLIFERATION AND DIFFERENTIATION IN HUMAN PRIMARY PRE-ADIPOCYTES.**

### **4.1              INTRODUCTION**

The previous chapter has described the effects of CB receptor modulation on pre-adipocyte proliferation and adipogenesis using *in vitro* models with the 3T3-L1 and PAZ6 cell lines representing WAT and BAT respectively. These studies demonstrated no influence of CB receptor agonism or antagonism on PAZ6 biology, but significant effects, albeit small, were noted in 3T3-L1. However, there are certain limitations associated with conclusions drawn from investigations performed with the use of cell lines. Firstly, 3T3-L1 is a murine cell line therefore any study conclusions have to be applied with caution to human physiology. One difference is that cell lines such as 3T3-L1 undergo one or two cycles of cell division prior to differentiation, whereas human pre-adipocytes can undergo adipogenesis without post-confluence mitosis [161]. Cell lines are specifically developed outside their natural environment with an exaggerated potential for proliferation and lipid accumulation, and are thus not exposed to factors which may influence normal physiology *in vivo*. There is a commercially available immortalised human pre-adipocyte cell line with a preserved differentiating capacity, Chub-S7, derived from the subcutaneous adipose tissue by co-expression of human telomerase reverse transcriptase and papillomavirus E7 oncoprotein genes [210]. The use of this cell line is however, limited by its expense. Furthermore, there is increasing evidence that white pre-adipocytes derived from different locations have distinct molecular and physiological properties. Subcutaneous and visceral adipocytes retain differences in gene expression, adiponectin secretion, and insulin action and signalling, and excess visceral adiposity is associated with an increased risk of DM and CVD [11, 12, 211]. Though 3T3-L1 represents a model of WAT it cannot account for these depot specific

differences that have been observed in humans. In order to address these short-comings it was necessary to repeat some of the previous experiments with human primary cultures derived from both subcutaneous and adipose tissue depots.

#### **4.1.1 Human Primary Cultures**

While the use of human primary cultures may be preferred over non-human cell lines for the reasons discussed above, this is not without its own difficulties. Adipose tissue is an internal organ and therefore obtaining samples requires a surgical procedure. Such a project therefore requires approvals from local Research and Development departments as well as the local Research Ethics Committee. These processes are time-consuming and therefore prolong the duration of any proposed study. Care must also be taken to ensure the study is performed in accordance with the 'Declaration of Helsinki' [212]. Individuals participating in these studies must be approached appropriately and informed consent needs to be obtained, as well as co-operation from surgical colleagues and theatre staff not directly involved in the project. Once isolated, primary pre-adipocytes are more susceptible to contamination due to the methods used for extraction and these cells also exhibit considerably slower rates of proliferation compared to cell lines thus similar experiments require longer periods of study. Unlike the immortalised cell lines, primary cells can enter a period of senescence and thus cells of low passage number (in these studies  $< 2$ ) are required, further limiting the number of experiments possible with any given sample. Despite these drawbacks human primary cultures are still considered the 'gold standard' method for *in vitro* studies and results obtained from such work can be applied to human physiology with greater confidence than cell lines.



#### **4.1.2 Adipose Tissue Depot-Specific Differences**

*In vivo*, WAT is present in a variety of locations, including subcutaneous, omental, pre-orbital, synovial, bone marrow and retroperitoneal depots. Pre-adipocytes isolated from different areas have different adipogenic potential, the basis for which is not fully understood. Individuals with increased visceral adiposity have a greater risk of insulin resistance, dyslipidaemia, and cardiovascular disease than those of equivalent weight but a higher degree of subcutaneous adiposity [3]. Surgical removal of visceral fat by omentectomy improves insulin sensitivity while elimination of subcutaneous fat by liposuction has limited effect on insulin resistance and metabolic abnormalities [213, 214].

Intra-abdominal and subcutaneous adipose tissue exhibit important metabolic differences that may underlie the association of visceral, but not subcutaneous, fat with obesity-related cardiovascular and metabolic problems [215]. Expression of adiponectin and C/EBP $\alpha$  (which regulates adipogenesis and adiponectin gene expression), have been shown to be higher in subcutaneous adipocytes, whereas cellular inhibitor of apoptosis2 (CiAP2) mRNA expression is greater in omental adipocytes [211, 216]. CiAP2 may be involved in the regulation of TNF $\alpha$  signaling, therefore this raises the possibility that depot-specific differences may exist in the regulation of adipocyte apoptosis [216]. Previous studies have also demonstrated a two- to three-fold higher insulin-stimulated glucose uptake in visceral adipocytes as well as exaggerated lipolysis particularly in response to adrenergic stimulation, resulting in higher free fatty acid (FFA) concentrations [211, 217]. Circulating FFAs promote insulin resistance in the liver and muscle, and increase hepatic gluconeogenesis and lipoprotein production.


#### **4.1.3 Adiponectin**

Another hypothesis to explain the physiological mechanism linking excess body fat to adverse metabolic, and thus health, consequences is thought to be via modification of the

adipocytokine profile, the details of which have been discussed in Chapter 1. A reduction in adiponectin or an elevation in  $\text{TNF}\alpha$ , IL-6, and leptin is associated with greater insulin resistance. Previous investigators have illustrated the inverse correlation of adiponectin levels with most components of the metabolic syndrome, defined by the IDF criteria (detailed in Chapter 1), as illustrated in Figure 4.1 [218]. Measurement of this key adipocytokine was therefore included in the present studies of  $\text{CB}_1$  receptor modulation on adipogenesis.

**Figure 4.1: Association Of Reduced Serum Adiponectin With Features Of The Metabolic Syndrome In Males & Females As Defined By The IDF Criteria**

(adapted from Santaniemi et al [218])




#### 4.1.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)

As previously discussed in Chapter 1, adiponectin is found in low and high molecular weight forms with the latter being metabolically more important. Most of the commercially available assays, including Duoset® ELISA (R&D systems, Oxford, UK) used in this study measure total adiponectin using the following method illustrated in Figure 4.2 [219].



**Figure 4.2: Schematic Representation Of The ELISA Technique**



The ELISA technique is based on the principle of an 'antibody sandwich'. First, a capture antibody specific to the analyte of interest is bound to a microtitre plate to create the solid phase. The plate is then washed to remove any unbound antibody and then coated with a blocking reagent. Following a further wash, samples, standards, and controls are then incubated with the solid phase antibody in order to capture the analyte. The plate is then washed again to remove unbound analyte following which a conjugated detection antibody (e.g. biotin-labelled antibody) is added. This detection antibody binds to a different epitope of the molecule being measured, completing the sandwich. This process is again followed by a wash to remove unbound detection antibody, after which a detection reagent (e.g. Horseradish-peroxidase (HRP) conjugated streptavidin) is added. The plate is washed and a substrate solution (e.g. tetramethylbenzidine peroxide) is added. The substrate is converted by the HRP to a blue coloured product in proportion to the amount of bound analyte. Colour development is stopped upon the addition of an acidic solution turning the colour yellow, and

the intensity of the yellow colour is measured by reading the optical density at A450 on a microtitre plate reader.

#### **4.1.4 Chapter Aims**

There have been numerous *in vivo* observational and interventional studies in animal and human populations evaluating the effect of CB receptor influence on adiposity and these have been reviewed in Chapter 1. Most of the published studies of CB receptor influence on pre-adipocyte proliferation and differentiation have been performed with *in vitro* models using non-human cell lines as discussed in the preceding chapter, but there is a scarcity of data from human models. Other investigators have shown that both precursor and mature adipocytes derived from subcutaneous and omental depots express functional plasma membrane CB<sub>1</sub> and CB<sub>2</sub> receptors, though their physiological role has not been directly examined *in vitro* [220].

In order to address some of the uncertainties regarding the extrapolation of cell line data to humans and the depot specific differences seen in WAT physiology, this chapter aims to assess the biological effect of CB<sub>1</sub> receptor agonism and antagonism on proliferation and adipogenesis using human primary cultures, both to confirm or refute the findings from the previous cell line studies, and to compare these effects in cells derived from subcutaneous and omental adipose tissue.

## **4.2 MATERIALS AND METHODS**

### **4.2.1 Study Approvals & Patients Studied**

Approvals were obtained from the Cardiff and Vale NHS Trust Research and Development Office and the South Wales Research Ethics Committee to approach individuals undergoing elective, open abdominal surgery for non-metabolic causes at the University Hospital of Wales, Cardiff. Following admission to the surgical wards, potential study participants were provided with a patient information sheet (Appendix 1). The exclusion criteria applied were pregnancy or treatment with the oral contraceptive pill, oestrogens, androgens, glucocorticoids, growth hormone or thyroxine therapy due to the well-established effects of these hormones on adipocyte function. Patients with lipodystrophy, and subjects receiving highly active antiretroviral therapy (HAART) for HIV infection or other conditions/treatment with a known effect on adipose tissue were also excluded as were diabetics unless treated with dietary therapy alone. Informed consent was obtained (Appendix 2) and data were collected on the individual's age, past medical and drug history, as well as measurements of height, weight, waist and hip circumference, and body fat percentage (Tanita Body fat monitor/scale TBF-538, Tanita corporation, Tokyo, Japan). The surgeons (Mr. M Puntis, Mr. B Rees and Mr. N Kumar) kindly harvested paired subcutaneous and omental adipose tissue samples during surgery for subsequent extraction of pre-adipocytes.

### **4.2.2 Reagents And Culture Media**

The CB receptor modulators, cell culture materials and methods were identical to those used in the cell line experiments with 3T3-L1 as described in the previous chapter. All culture medium constituents were obtained from BioWhittaker (Belgium) unless otherwise stated.



#### **4.2.3 Explants**


Adipose tissue samples were cut into small fragments (0.5-1 mm diameter), placed into 6 well plates and covered with just enough CM to prevent sample dehydration. A few drops of fresh CM were added every 48 hours. Pre-adipocytes were noted to migrate out of the explants and attach on to the surface of the culture plate, however it would take several weeks to collect enough pre-adipocytes by this process for use in experiments, therefore the collagenase digest method was used instead.

#### **4.2.4 Collagenase Digest**

Primary pre-adipocytes were successfully isolated from paired subcutaneous and omental adipose tissue depots (n=8) by collagenase digest followed by centrifugation through phthalic acid dionyl ester. The adipose tissue samples retrieved from theatre were cut into 0.5-1 mm fragments and approximately 3 ml adipose tissue was placed into individual 20 ml universal containers. The tissue was combined with 7 mls Hank's balanced salt solution (HBSS), 2 mls 7.5% w/v bovine serum albumin (BSA, Sigma Aldrich) and 1 ml (30mg/ml) type II collagenase, and incubated for 1 hour in a 37°C water bath while shaking every 5 minutes. The contents were then transferred to a clean 15 ml falcon tube and 2 mls phthalic acid dionyl ester mixed isomer was added to each sample prior to centrifugation at 1500 rpm for 5 minutes at 4°C to allow separation into different cell and lipid layers as illustrated in Figure 4.3.

The supernatant was removed and the resultant cell pellet was resuspended in 10 mls CM in a 75 cm<sup>2</sup> Nunclon™ delta surface flask (Nunc, Roskilde, Denmark). Initially red blood cell removal was attempted with ammonia sulphate but this was not very effective therefore after 24 hours the cells were washed twice with 5 mls HBSS to remove any residual red cells, and this process was repeated after a further 24 hours if still required.

**Figure 4.3: Isolation Of Primary Pre-Adipocytes Using Collagenase Digest Followed By Centrifugation Through Phthalic Acid Dionyl Ester.**



#### **4.2.5 Routine Maintenance Of Human Primary Pre-Adipocytes**

All cell culture experiments were performed in sterile conditions at 37°C in an atmosphere containing humidified 5% CO<sub>2</sub> in air. Both subcutaneous and omental pre-adipocytes were grown in 75 cm<sup>2</sup> flasks. Culture medium was refreshed every 48 hours and upon reaching confluence, the cells underwent passage by trypsinisation as described in Chapter 3. It was noted that the primary pre-adipocytes invariably became senescent after the third passage, therefore where possible proliferation experiments were performed after the first, and differentiation experiments after the second passage.

#### **4.2.6 Proliferation Studies**

##### **4.2.6.1 Cell Culture Protocol**

Subcutaneous and omental pre-adipocytes were grown to confluence and trypsinised as described previously. The approximate number of cells per ml solution was calculated with

the aid of a haemocytometer (Camber counter, Weber Scientific International Ltd, Middlesex, UK). Cells were subsequently diluted and seeded at  $1 \times 10^3$  per well in 24 well plates (Nuncclon™ delta surface, Nunc, Roskilde, Denmark) and incubated at 37°C overnight to enable optimal attachment. Cells were then incubated in control CM alone, or supplemented with increasing concentrations of ACEA (1 nM to 10  $\mu$ M) or AM251 (10 nM to 500 nM). Each experiment was completed in quadruplicate and performed twice.

#### **4.2.6.2 Direct Cell Counting**

Proliferation rates in primary cells were considerably slower than in the cell lines, therefore the pre-adipocytes were collected for direct cell counting after 72 and 168 hours of treatment. Each well was washed with 0.5 mls of 1% w/v trypsin and then incubated with a further 0.5 mls trypsin until cells were free in suspension. The contents of individual wells were transferred to corresponding cell counting cuvettes containing 10 mls each of Coulter Isoton II Diluent (Beckman Coulter, GmbH, Germany). Cell densities were measured using a Coulter particle counter (Z2, Beckman Coulter GmbH, Germany) with particle size set between 3.8 nm and 9.0 nm. Each sample was counted twice and the average value used for statistical analysis.

#### **4.2.7 Adipogenesis Studies**

##### **4.2.7.1 Cell Culture Protocol**

Subcutaneous and omental pre-adipocytes were plated in 6 well plates and adipogenesis induced in confluent populations of pre-adipocytes by replacing CM with DM as described in Chapter 3. Cells were maintained in DM alone, or supplemented with 100nM ACEA or 100nM AM251, for 21 days with DM changes occurring every 72 hours. Morphological changes of differentiation were monitored by microscopic examination.

#### **4.2.7.2 Isolation Of Total RNA & Reverse Transcription To cDNA**

Samples for RNA extraction were collected on days 0, 7, 14 and 21. Total RNA was isolated using Invitrogen's TRIzol reagent as described in the previous chapter. The RNA concentration and quality was assessed by spectrophotometry (GeneQuant, GE Healthcare) and analysis on a 1.2% agarose gel. Samples were stored at -80°C until further use. Also, as per the cell line study methods, the RNA was treated with DNase, reverse transcribed to cDNA, and conventional PCR performed with primers for the human housekeeping gene PGK-1 to confirm the absence of contaminating genomic DNA.

#### **4.2.7.3 QPCR Measurement Of Markers Of Adipogenesis**

Real-time QPCR was performed to measure the expression of LPL, a terminal marker of adipogenesis and the housekeeper gene APRT. QPCR was performed using Stratagene's Brilliant® SYBR® Green Master Mix. The reaction components and thermal cycling protocol were identical to those detailed in chapter 3. Standard curves obtained from serial dilutions of PCR amplicons sub-cloned into pGEM-T vectors at  $10^6$  to  $10^2$  copies were included for each gene.

#### **4.2.7.4 ELISA Measurement Of Adiponectin**

Adiponectin concentrations were measured in conditioned medium collected on days 0, 7, 14 and 21 of the differentiation protocol using the Human Adiponectin DuoSet® ELISA development system (R&D Systems, Oxford, UK) according to the manufacturer's instructions. Costar ELI 96 well plates (R&D Systems, Oxford, UK) were coated with 100 µl / well capture antibody (55 µl / ml PBS) and stored overnight. Prior to use the next day, the plates were washed twice with wash buffer (0.05% Tween 20 in PBS, pH 7.4) following which the wells were blocked with diluent (1% w/v BSA in PBS) for 2 hours. After repeating the wash process, 100 µl of serially diluted adiponectin standards (25 to 4000 pg / ml) or 100 µl neat

conditioned medium was added to individual wells and incubated at room temperature for 2 hours. Once again the plates were washed and each well coated with 100 µl horseradish peroxidase conjugated Streptavidin (50 µl / ml), incubated at room temperature, washed again and coated with 100 µl substrate solution (tetramethylbenzidine peroxide). The reaction was terminated by the addition of 50 µl stop solution (10% sulphuric acid) and optical density was measured using an OpsysMR microplate reader (Dynex Technologies, Chantilly, USA) set to 450nm. The intra- and inter- assay coefficient of variation was less than 4%.

#### **4.2.8 Statistical Analysis**

Data were analysed using the SPSS (version 14.0) statistical software package.

The data generated by the proliferation and adipogenesis studies were not normally distributed (determined by generating Q-Q and P-P plots of data obtained) and therefore analysed according to median and interquartile ranges (IQR) using non-parametric statistical tests. The Friedman's test was performed on each experiment and the Wilcoxon Signed Ranks test was performed on individual treatments relative to control conditions. The QPCR data were analysed as absolute values per input microgram of mRNA and corrected relative to the appropriate housekeeper gene expression.



### 4.3 **RESULTS**

#### 4.3.1 **Study Participant Demographics**

Table 4.1 lists the anthropometric measurements of the patients who participated in this study. Paired subcutaneous and omental adipose tissue samples were collected from all 8 patients.

**Table 4.1: Anthropometric Data Of Study Participants**

Patient	Age (years)	Sex	Height (m)	Weight (kg)	BMI	Waist:Hip	Fat %
1	55	M	1.78	69.9	22.1	1.02	10
2	76	M	1.75	62.2	20.3	0.94	8.5
3	75	M	1.78	82	25.9	0.88	26
4	64	F	1.63	74	27.9	0.83	31
5	74	F	1.55	48	20.0	1.0	27
6	74	F	1.63	59.5	22.4	0.85	30
7	30	F	1.55	60	25	-	-
8	66	F	1.52	57	24.7	0.77	35


#### 4.3.2 **Primary Pre-Adipocyte Cell Culture**

Examples of the microscopic appearance of the primary pre-adipocytes, including the presence of atypical cells in the omental adipose tissue, are given in Figure 4.4. The primary pre-adipocytes were noted to be larger than the cell lines and exhibited much slower proliferation rates in comparison, with a population doubling time of almost 5 days, therefore

the number of cells available for use in experimentation was more limited than with the cell lines.


**Figure 4.4A : Subcutaneous Pre-Adipocytes**

(magnification 200x)



**Figure 4.4B: Omental Pre-Adipocytes**

(magnification 200x)



Atypical cells

Pre-adipocytes derived from all 8 individuals were used in the proliferation experiments but only the first 5 were used in the adipogenesis studies. This was due to difficulties encountered with the initial pre-adipocyte extraction method (explants) where sufficient numbers of cells could not be generated despite prolonged cell culture. Also it was noted in our early experiments that it was not possible to induce differentiation in primary pre-adipocytes beyond the third passage due to cell senescence. Lastly in one individual who underwent surgery for abdominal malignancy, a significant number of atypical cells were noted in the omental samples (Figure 4.4B) and thus could not be used for our studies.

### 4.3.3 CB<sub>1</sub> Agonist ACEA Stimulates Subcutaneous Pre-Adipocyte Proliferation


Exposure to the selective CB<sub>1</sub> agonist ACEA for 72 hours was associated with a significant, concentration-dependent increase in proliferation of the subcutaneous pre-adipocytes as illustrated in Table 4.2 and Figure 4.5.

**Table 4.2 Mean, Median & IQR For Subcutaneous Cells Treated With ACEA For 72 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	3766	3876	3332-4162	n/a
1 nM	3861	3904	3468-4232	0.029
10 nM	4050	4123	3602-4524	<0.001
100 nM	4230	4317	3741-4711	<0.001
1 µM	4375	4528	3734-4965	<0.001
10 µM	4324	4411	3706-4902	<0.001

**Figure 4.5: Effect Of ACEA On Subcutaneous Pre-Adipocyte Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Exposure to the CB<sub>1</sub> agonist ACEA for 168 hours was also associated with a significant, concentration-dependent increase in proliferation of the subcutaneous pre-adipocytes as illustrated in Table 4.3 and Figure 4.6.

**Table 4.3 Mean, Median & IQR For Subcutaneous Cells Treated With ACEA  
For 168 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	9416	9691	8329-10405	n/a
1 nM	9653	9760	8671-10582	<0.001
10 nM	10126	10308	9005-11312	<0.001
100 nM	10576	10793	9353-11779	<0.001
1 $\mu$ M	10938	11320	9337-12410	<0.001
10 $\mu$ M	10810	11028	92655-12255	<0.001

**Figure 4.6: Effect Of ACEA On Subcutaneous Pre-Adipocyte Proliferation At 168 Hours**

Cells were counted 168 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.



#### 4.3.4 CB<sub>1</sub> Agonist ACEA Stimulates Omental Pre-Adipocyte Proliferation


Exposure to the selective CB<sub>1</sub> agonist ACEA for 72 hours was associated with a significant, concentration-dependent increase in proliferation of the omental pre-adipocytes as illustrated in Table 4.4 and Figure 4.7.

**Table 4.4: Mean, Median & IQR For Omental Cells Treated With ACEA For 72 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	4531	4564	4193-4937	n/a
1 nM	4882	4830	4500-5294	<b>&lt;0.001</b>
10 nM	4780	4677	4306-5139	<b>&lt;0.001</b>
100 nM	5157	4979	4571-5648	<b>&lt;0.001</b>
1 $\mu$ M	5344	5312	4913-5780	<b>&lt;0.001</b>
10 $\mu$ M	4527	4495	4168-4901	0.753

**Figure 4.7: The Effect Of ACEA On Omental Pre-Adipocyte Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Exposure to the CB<sub>1</sub> agonist ACEA for 168 hours was associated with a significant, concentration-dependent increase in proliferation of the omental pre-adipocytes as illustrated in Table 4.5 and Figure 4.8.

**Table 4.5: Mean, Median & IQR For Omental Cells Treated With ACEA For 168 Hours**

ACEA concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	8239	8298	7624-8976	n/a
1 nM	8877	8782	8182-9627	<b>&lt;0.001</b>
10 nM	9559	9355	8612-10277	<b>&lt;0.001</b>
100 nM	9919	9575	8792-10862	<b>&lt;0.001</b>
1 $\mu$ M	9717	9658	8933-10508	<b>&lt;0.001</b>
10 $\mu$ M	9432	9354	8684-10210	<b>&lt;0.001</b>

**Figure 4.8: The Effect Of ACEA On Omental Pre-Adipocyte Proliferation At 168 Hours**

Cells were counted 168 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Freedman's test for overall experiment.



### 4.3.5 CB<sub>1</sub> Antagonist AM 251 Inhibits Subcutaneous Pre-Adipocyte Proliferation


Exposure to the CB<sub>1</sub> antagonist AM 251 for 72 hours was associated with a significant, concentration-dependent reduction in proliferation of the subcutaneous pre-adipocytes as illustrated in Table 4.6 and Figure 4.9.

**Table 4.6 Mean, Median & IQR For Subcutaneous Cells Treated With AM 251  
For 72 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	4226	4251	3809-4603	n/a
10 nM	4156	4195	3840-4489	<b>0.036</b>
50 nM	3855	3810	3542-4161	<b>&lt;0.001</b>
100 nM	3502	3451	3211-3776	<b>&lt;0.001</b>
250 nM	3322	3216	2954-3608	<b>&lt;0.001</b>
500 nM	3286	3137	2977-3515	<b>&lt;0.001</b>

**Figure 4.9: Effect Of AM251 On Subcutaneous Pre-Adipocyte Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Exposure to the CB<sub>1</sub> antagonist AM 251 for 168 hours was associated with a significant, concentration-dependent reduction in proliferation of the subcutaneous pre-adipocytes as illustrated in Table 4.7 and Figure 4.10.

**Table 4.7: Mean, Median & IQR For Subcutaneous Cells After AM 251 For 168 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	9829	9885	8857-10705	n/a
10 nM	9447	9534	8728-10202	<0.001
50 nM	9179	9072	8433-9908	<0.001
100 nM	8755	8629	8027-9440	<0.001
250 nM	8518	8245	7577-9251	<0.001
500 nM	8216	7843	7444-8790	<0.001

**Figure 4.10 Effect Of AM251 On Subcutaneous Pre-Adipocyte Proliferation At 168 Hours**

Cells were counted 168 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.



#### 4.3.6 CB<sub>1</sub> Antagonist AM 251 Inhibits Omental Pre-Adipocyte Proliferation


Exposure to the CB<sub>1</sub> antagonist AM 251 for 72 hours was associated with a significant, concentration-dependent reduction in proliferation of the omental pre-adipocytes as illustrated in Table 4.8 and Figure 4.11.

**Table 4.8: Mean, Median & IQR For Omental Cells Treated With AM 251 For 72 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	3889	3588	3178-4607	n/a
10 nM	3794	3509	3092-4445	<b>0.001</b>
50 nM	3459	3276	2811-4062	<b>&lt;0.001</b>
100 nM	3055	2926	2601-3450	<b>&lt;0.001</b>
250 nM	2773	2756	2334-3162	<b>&lt;0.001</b>
500 nM	2721	2798	2235-3140	<b>&lt;0.001</b>

**Figure 4.11: The Effect Of AM 251 On Omental Pre-adipocyte Proliferation At 72 Hours**

Cells were counted 72 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






Exposure to the CB<sub>1</sub> antagonist AM 251 for 168 hours was associated with a significant, concentration-dependent reduction in proliferation of the omental pre-adipocytes as illustrated in Table 4.9 and Figure 4.12.

**Table 4.9: Mean, Median & IQR For Omental Cells Treated With AM 251 For 168 Hours**

AM 251 concentration	Mean Cell number/ml	Median Cell number/ml	IQR Cell number/ml	p-value (vs control)
Control (0.1% ethanol)	9046	8344	7392-10714	n/a
10 nM	8624	7976	7028-10101	<0.001
50 nM	8236	7801	6693-9672	<0.001
100 nM	7638	7315	6502-8626	<0.001
250 nM	7110	7067	5984-8108	<0.001
500 nM	6802	6996	5588-7850	<0.001

**Figure 4.12: Effect Of AM 251 On Omental Pre-Adipocyte Proliferation At 168 Hours**

Cells were counted 168 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.






#### 4.3.7 CB<sub>1</sub> Antagonist AM 251 May Exert A Preferential Effect On Omental Pre-Adipocyte Proliferation

It was also noted that the inhibitory effect of CB<sub>1</sub> antagonism was greater in omental as compared to the subcutaneous cells obtained for individual patients at any given BMI in most but not all cases (Figure 4.13A). A trend was also observed for a greater reduction in omental preadipocyte number with increasing BMI but not in the subcutaneous populations. CB<sub>1</sub> agonist treatment was associated with an increased proliferation effect in the omental cells in subjects with a higher BMI (Figure 4.13B).


**Figure 4.13A: Effect Of 500 nM AM 251 On Primary Pre-adipocyte Proliferation**

Cells were counted 168 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for subcutaneous vs. omental for each individual patient.



**Figure 4.13B: Effect Of 10  $\mu$ M ACEA On Primary Preadipocyte Proliferation**

Cells were counted 168 hours after treatment after plating  $1 \times 10^3$  cells/well. Results represent the mean and SD from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by Wilcoxon Signed Ranks test for subcutaneous vs. omental for each individual patient.



#### 4.3.8 Summary Of The Effects Of Cannabinoid Receptor Modulation On Pre-Adipocyte Cell Line Proliferation

In the primary cell populations exposure to CB<sub>1</sub> agonist treatment resulted in a concentration-dependent increase in both subcutaneous and omental preadipocyte proliferation while CB<sub>1</sub> antagonism was associated with a reduction in cell numbers. The degree of inhibition by CB<sub>1</sub> antagonism was greater in omental pre-adipocytes compared to subcutaneous cells in all individuals.




#### 4.3.9

#### Adipogenesis In Primary Subcutaneous & Omental Cell Cultures

The effect of cannabinoid receptor modulation on adipogenesis was investigated by quantification of LPL expression by QPCR and measurement of adiponectin production. Morphological changes in the cells were observed microscopically and visible lipid droplet accumulation confirmed with oil red O staining. Differentiation in the primary cultures tended to occur in multiple foci as compared to the more generalised adipogenesis noted in the 3T3-L1 cell line. In the omental samples the foci were smaller and more multiple whereas the subcutaneous foci were larger in size and fewer in number (Figure 4.14).

**Figure 4.14A Subcutaneous Adipocytes**

(magnification 200x)




Subcutaneous pre-adipocytes

Lipid-rich mature adipocytes

**Figure 4.14B: Omental Adipocytes**

(magnification 200x)



Omental pre-adipocytes

#### 4.3.10 The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On LPL Expression In Subcutaneous Adipogenesis

Treatment with the CB<sub>1</sub> agonist ACEA had no significant effect on subcutaneous pre-adipocyte differentiation as measured by LPL expression whereas exposure to the CB<sub>1</sub> antagonist AM 251 resulted in an increase in LPL expression (Table 4.10 and Figure 4.15).

**Table 4.10: Effect Of ACEA & AM251 On LPL Expression In Subcutaneous Adipogenesis**


Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression and also expressed as fold-change relative to Day 0. Statistical significance for gene expression determined by Wilcoxon Signed Ranks test for individual treatments relative to control

Patient N		1	2	3	4	5	Mean	p-value
Day 0	LPL Copy №	223	255	331	255	270	267	n/a
	Normalised to APRT Copy №	999	1183	1248	1282	1312	1204	
Day 21 Control (0.1% ethanol)	LPL Copy №	2738	2913	2266	3255	2201	2675	n/a
	Normalised to APRT Copy №	19257	13313	10281	16997	10700	14110	
	FOLD change	19.3	11.3	8.2	13.3	8.15	11.7	
Day 21 100 nM ACEA	LPL Copy №	2356	3528	2877	3677	3387	3165	0.605
	Normalised to APRT Copy №	10685	18150	9006	20218	15752	14762	
	FOLD change	10.7	15.3	7.2	15.7	12.0	12.3	
Day 21 100 nM AM 251	LPL Copy №	5741	5818	5818	4947	4477	5360	<0.001
	Normalised to APRT Copy №	37791	35380	30145	32070	26230	32323	
	FOLD change	37.8	29.9	24.2	25.0	20.0	26.8	



#### Figure 4.15: Effect Of ACEA & AM251 On Subcutaneous Adipogenesis

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control.



#### 4.3.11 The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On UCP-1 Expression In Terminally Differentiated Subcutaneous Adipocytes

QPCR was performed on cDNA derived from RNA collected on day 0 and day 21 of the differentiation protocol and transcript expression for UCP-1 was normalised to housekeeper gene (APRT) expression. Transcript expression was at the limit of QPCR detection (Ct values > 35) and did not alter with adipogenesis in control conditions or when supplemented with ACEA or AM 251.



#### 4.3.12 The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On LPL Expression In Omental Adipogenesis

Treatment with the CB<sub>1</sub> agonist ACEA had no significant effect on omental pre-adipocyte differentiation as measured by LPL expression whereas exposure to the CB<sub>1</sub> antagonist AM 251 resulted in an increase in LPL expression (Table 4.11 and Figure 4.16).


**Table 4.11: Effect Of ACEA & AM251 On LPL Expression In Omental Adipogenesis**

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression and also expressed as fold-change relative to Day 0. Statistical significance for gene expression determined by Wilcoxon Signed Ranks test for individual treatments relative to control.

Patient №		1	2	3	4	5	Mean	p-value
Day 0	LPL Copy №	258	266	282	225	235	253	n/a
	Normalised to APRT Copy №	1368	957	1372	1412	1467	1315	
Day 21 Control (0.1% ethanol)	LPL Copy №	3671	2848	2664	438	237	2024	n/a
	Normalised to APRT Copy №	15209	15012	11943	2008	1099	9297	
	FOLD change	11.1	15.7	8.7	1.5	0.8	7.06	
Day 21 100 nM ACEA	LPL Copy №	2730	2410	3521	361	355	1875	0.906
	Normalised to APRT Copy №	10380	9467	13994	2469	1810	7624	
	FOLD change	7.6	9.9	10.2	1.7	1.2	5.8	
Day 21 100 nM AM 251	LPL Copy №	6149	6062	4678	363	347	3519	<0.001
	Normalised to APRT Copy №	40246	25499	19171	2323	1617	17771	
	FOLD change	29.4	26.6	14.0	1.6	1.1	13.5	

#### Figure 4.16: Effect Of ACEA & AM251 On Omental Adipogenesis

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control



#### 4.3.13 The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On UCP-1 Expression In Terminally Differentiated Omental Adipocytes

QPCR was performed on cDNA derived from RNA collected on day 0 and day 21 of the differentiation protocol and transcript expression for UCP-1 was normalised to housekeeper gene (APRT) expression. Transcript expression was at the limit of QPCR detection (Ct values > 35) and did not alter with adipogenesis in control conditions or when supplemented with ACEA or AM 251.



#### 4.3.14 The Effect Of CB<sub>1</sub> Agonist ACEA & CB<sub>1</sub> Antagonist AM 251 On Adiponectin Production During Subcutaneous & Omental Adipogenesis

Treatment with CB<sub>1</sub> antagonist was also associated with an increase in adiponectin concentration in both primary cell populations with a significantly greater effect in omental (Table 4.12 and Figure 4.17) as compared to subcutaneous adiponectin production (Table 4.13 and Figure 4.18).


**Table 4.12: Effect Of ACEA & AM251 On Omental Adiponectin Production**

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control

Patient №		1	2	3	4	5	p-value
Day 0	Adiponectin µg/ml	54	59	49	54	33.0	n/a
Day 21 Control (0.1% ethanol)	Adiponectin µg/ml	149.5	960.0	233.5	447.6	187.5	n/a
	FOLD change	2.8	16.2	4.8	8.3	5.7	
Day 21 100 nM ACEA	Adiponectin µg/ml	143.0	940.5	211.0	431.5	206.0	0.394
	FOLD change	2.6	15.9	4.3	7.9	6.2	
Day 21 100 nM AM 251	Adiponectin µg/ml	1128.5	1417.5	825.5	1024.0	946.5	0.026
	FOLD change	20.8	24.0	16.8	18.9	28.6	


**Figure 4.17: Effect Of ACEA & AM251 On Omental Adiponectin Production**

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control



**Figure 4.18: Effect Of ACEA & AM251 On Subcutaneous Adiponectin Production**

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control





**Table 4.13: Effect Of ACEA & AM251 On Subcutaneous Adiponectin Production**

Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to control

Patient №		1	2	3	4	5	p-value
Day 0	Adiponectin µg/ml	51	48.5	62.5	146.5	52.5	n/a
Day 21 Control (0.1% ethanol)	Adiponectin µg/ml	486.0	176.5	337.5	2196.5	272.0	n/a
	FOLD change	9.5	3.6	5.4	15.0	5.2	
Day 21 100 nM ACEA	Adiponectin µg/ml	481.0	158.5	311.0	1987.0	303.5	0.739
	FOLD change	9.4	3.3	4.9	13.6	5.8	
Day 21 100 nM AM 251	Adiponectin µg/ml	935.0	578.0	745.0	4258.0	597.0	0.009
	FOLD change	18.3	11.9	11.9	29.0	11.4	



Adipose tissue is now recognised as a dynamic endocrine organ producing biologically active adipocytokines involved in the regulation of energy metabolism and body weight homeostasis. These adipocytokines play a crucial role in development of obesity and the pathophysiology of obesity-related disease processes. Abdominal obesity is associated with an elevated risk of type II DM and CVD. The ECS has been implicated in obesity, promoting adverse metabolic processes resulting in weight gain, lipogenesis, insulin resistance and dyslipidaemia. Clinical studies have confirmed that intermediate-term CB<sub>1</sub> receptor blockade is associated with loss of body weight and waist circumference and an improvement in the metabolic profile including reductions in triglycerides, fasting insulin, HbA1c, blood pressure and an increase in HDL and adiponectin [77-80, 221].

The previous chapter demonstrated an increase in pre-adipocyte proliferation with CB<sub>1</sub> agonism in studies using the murine white pre-adipocyte cell line, 3T3-L1, whereas CB<sub>1</sub> antagonism had the opposite consequence. The anti-proliferative effect was associated with a block at the G1/S phase of the cell cycle. These findings are in keeping with those published elsewhere in the literature [207]. In this chapter these experiments have been repeated using human primary pre-adipocytes derived from both subcutaneous and omental adipose tissue depots. The same effects on proliferation were noted in both the subcutaneous and omental cell populations with a significantly greater effect of CB<sub>1</sub> antagonist-induced inhibition in the omental pre-adipocytes in all paired samples. As such this represents a novel observation since no other *in vitro* studies directly examining the effect of CB modulation in human primary subcutaneous and visceral pre-adipocytes are evident. These results may in part explain some of the anti-obesity effects observed with CB<sub>1</sub> antagonist treatment, including a reduction in waist circumference.

Sarzani et al have described an altered pattern of CB<sub>1</sub> receptor expression in adipose tissue in overweight individuals [222]. The investigators have demonstrated the highest mRNA expression of CB<sub>1</sub> to be in subcutaneous adipose tissue in normal weight subjects (BMI < 25 kg/m<sup>2</sup>) whereas CB<sub>1</sub> expression was increased in omental adipose tissue in individuals with a BMI ≥ 25 kg/m<sup>2</sup> suggesting CB<sub>1</sub>-mediated overactivity of the ECS in visceral adipose tissue in obesity [222]. This role is further supported by evidence from Matias et al that patients with obesity or hyperglycaemia caused by type 2 DM exhibit higher concentrations of endogenous endocannabinoids in visceral fat or serum, respectively, than their corresponding controls [76]. The differences in receptor expression may explain the possible differential effect of CB<sub>1</sub> receptor antagonism observed in the current experiments in cells derived from the subcutaneous and omental adipose tissue depots.

The anti-proliferative and cell cycle blocking effects of CB<sub>1</sub> antagonism are not limited to adipose tissue. Recent *in vitro* studies using SR 141716 have illustrated inhibition of human breast cancer cell proliferation in highly invasive metastatic MDA-MB-231 cells [223]. This effect was not accompanied by cell apoptosis or necrosis, and was characterised by arrest in the G1/S phase of the cell cycle [224]. Similarly CB<sub>1</sub> antagonism has been shown to inhibit proliferation of peripheral blood mononuclear cells, also associated with G1/S transition blockade [224]. Cell line studies of murine white pre-adipocytes indicate inhibition of MAP kinase activity by CB<sub>1</sub> blockade which may be one of the mechanisms involved in inhibition of cell proliferation [207, 208].

In addition to the anti-proliferative effects, in the preceding chapter we have also described an increase in mRNA expression of terminal markers of mature adipocytes following CB<sub>1</sub> antagonist treatment. These findings are also seen in the human primary cultures, where an increase in LPL expression was observed in both the subcutaneous and omental adipocytes. CB<sub>1</sub> agonist treatment did not appear to have an effect on primary adipogenesis. We also observed significantly greater levels of adiponectin produced by the cultured subcutaneous

and omental adipocytes after exposure to CB<sub>1</sub> antagonist treatment. These results are also in keeping with the cell line data in Chapter 3 as well as those published from other *in vitro* cell line studies in the literature [207, 225]. Alterations in the adipocytokine profile, as well as the anti-proliferative effects described previously, provide evidence for direct modulation of adipocyte function as part of the mechanism of action of the ECS on energy metabolism.

The data presented in this thesis do not demonstrate any increase in UCP-1 expression in the WAT cell line 3T3-L1 or in human primary cultures and thus do not support CB<sub>1</sub> blockade-mediated transdifferentiation towards a brown fat phenotype as part of the mechanism to explain the weight loss and improvement in metabolic parameters observed with CB<sub>1</sub> antagonism. This is in contrast to a recent study by Perwitz et al who demonstrated that CB<sub>1</sub> blockade with the antagonist SR 141716, or receptor knock down with small interfering RNA (siRNA), induces UCP-1 expression in murine white adipocytes in a time- and concentration-dependent manner at both the RNA and the protein level [209]. Whether these discrepancies are due to the differing cell types and CB<sub>1</sub> antagonist used for study, or secondary to the limitation of our QPCR technique for low copy number detection, still requires further clarification.

The first pharmacological CB<sub>1</sub> antagonist to be developed, SR 141716 or rimonabant, was associated with a significant adverse event profile and its clinical use has therefore been discontinued. Nevertheless, CB<sub>1</sub> receptor blockade still represents a new alternative for managing obesity and its associated risks. Further work is still required to fully elucidate the mechanism behind its observed clinical effects and also to explore the possibilities for body fat redistribution and white to brown fat transdifferentiation for greater metabolic benefit. Development of future agents will however require further clarification of both long-term effectiveness and an acceptable safety profile. Furthermore, any pharmacological intervention for the treatment of obesity can only be justified when accompanied by individuals' dietary and lifestyle modification to ensure benefits are sustained long-term.


## **CHAPTER 5: EFFECT OF METFORMIN ON VASCULAR FUNCTION, BODY COMPOSITION & METABOLIC PROFILE IN PCOS**

### **5.1 INTRODUCTION**

PCOS is the commonest endocrinopathy in women of reproductive age, affecting approximately 7% of the pre-menopausal population [226]. In addition to its effects on reproductive health it is now well recognized that PCOS is a metabolic disorder characterized by increased insulin resistance [88] which leads to an excess lifetime risk of type II diabetes [84, 85]. Patients with this condition display a cluster of metabolic disturbances, including obesity [227], dyslipidaemia [89], impaired fibrinolysis [228] and hypertension [87], which are often apparent at a young age, and it is therefore unsurprising that a number of studies have highlighted an increased prevalence of the metabolic syndrome amongst women with PCOS ranging from 15 to 50%.

**Figure 5.1: Age-Adjusted Prevalence Of Features Of The Metabolic Syndrome In Women With PCOS, Age-Matched Controls And Women From the NHANES Study.**

(Adapted from Dokras et al, 2005 [127])



For example, as illustrated in Figure 5.1, Dokras et al reported a 47.3% prevalence rate of the metabolic syndrome, according to the WHO criteria, in PCOS in contrast to 4.3% in an age-adjusted control population and 23.4% in comparison to the National Health and Nutrition Examination Survey (NHANES) study cohort [127].

Although epidemiological studies have thus far failed to demonstrate an increase in cardiovascular mortality in women with PCOS, these abnormalities are likely to contribute to an increased risk of cardiovascular disease, based on data from studies using surrogate markers such as carotid intima media thickness [134, 229]. Developing therapeutic strategies to minimise this vascular burden is therefore important.

Insulin resistance is intricately linked to large blood vessel compliance [230, 231] and endothelial function [232], and could contribute to the vascular dysfunction observed in patients with PCOS. For example, the inability of insulin to reduce aortic stiffness (as measured by augmentation index) in obese insulin-resistant subjects correlates closely with whole-body insulin resistance [233, 234], implying that defects in the metabolic action of insulin are accompanied by abnormal vascular function. Endothelial dysfunction, an early marker of vascular damage, has been demonstrated in women with PCOS [90, 91, 131, 135, 235] and is accompanied by reduced insulin-mediated vasodilatation [135]. Arterial stiffness, as assessed by pulse wave velocity (PWV), a strong independent predictor of cardiovascular mortality in subjects with type II diabetes [236] and other disease states [237, 238], is also increased in women with PCOS [135, 235], and correlates with insulin resistance [235, 239].

It is clear from these studies that insulin resistance *per se* may be an important vascular therapeutic target in women with PCOS and that medical therapies which improve insulin sensitivity might also improve vascular function. The oral biguanide metformin has been shown to improve insulin sensitivity in women with PCOS [139], and reduces circulating concentrations of endothelin-1 [140], a marker of endothelial dysfunction. More recently,



some studies have also shown that metformin can improve endothelial function in women with PCOS [240-243] while others reported either a neutral effect on vascular function [244, 245] or variable improvement or worsening dependent on smoking status [246]. However, interpretation of these studies is difficult due to their observational [240, 242-244] or open label [241, 245, 246] study designs. In light of this uncertainty and to minimise the potential for bias, the following studies sought to determine whether short-term metformin therapy could improve arterial stiffness and endothelial function in patients with PCOS using a randomized, double-blind, placebo-controlled crossover design.

## **5.1.2 Arterial Stiffness**

### **5.1.2.1 Mechanisms Of Arterial Stiffness**


The arterial wall is comprised of three layers – the outer adventitia consisting of connective tissue and the vessel's vascular supply, the smooth muscle and elastin-containing media which is the major determinant of elasticity, and the inner endothelium which regulates vascular tone, haemostasis and inflammatory processes. The Windkessel theory describes the circulation as a central elastic reservoir, comprised of compliant and expansile large arteries, into which the heart pumps, from which blood is transported to the tissues via relatively non-elastic peripheral vessels [247]. The elasticity of the proximal large arteries is largely the result of the high elastin to collagen ratio within the media layer of the vessel wall. Arterial stiffness can therefore arise as a consequence of structural changes within the vessel, for example secondary to age-related progressive elastin fibre degeneration, as well as disease states affecting vascular endothelial function such as hypertension and diabetes. A number of genetic factors have also been implicated including polymorphic variations in the fibrillin-1 [248] and endothelin receptor genes [249].

### 5.1.2.2 Arterial Pressure Waveform

The arterial pressure waveform is a composite representation of the pressure waves generated during ventricular systole (1<sup>st</sup> waveform peak) which then travels through the circulation until resistance is encountered at the peripheries when it is reflected back upon itself during diastole. The 2<sup>nd</sup> waveform peak represents a summation of the reflected waves as illustrated in Figure 5.2. Augmentation index (Alx), a composite measure of wave reflection and systemic arterial stiffness, is defined as the difference between the first and second systolic peaks of the central pressure waveform, expressed as a percentage of the central pulse pressure (Figure 5.2).

**Figure 5.2: Schematic Representation Of The Arterial Pressure Waveform**

(adapted from Oliver et al , 2003 [247])




With increasing arterial stiffness the speed with which the left ventricular ejection pressure wave travels through the arterial circulation increases, thus resulting in an earlier return of the reflected wave from the peripheries (Figure 5.3). If the reflected wave continues to return

less in diastole and more in systole itself, this can augment the late systolic pressure on the left ventricle (afterload) and reduce the coronary arterial perfusion pressure during diastole. This process leads to a greater risk of ischaemic heart disease (due to decreased coronary perfusion in diastole), cerebrovascular disease (due to increased central systolic pressure) and cardiac failure (due to increased left ventricular load).

**Figure 5.3: Schematic Representation Of Healthy & Stiffened Arterial Waveforms**

(adapted from Oliver et al, 2003 [247])



### 5.1.2.3 Arterial Stiffness & Cardiovascular Risk

Arterial stiffness can be assessed by measuring a number of factors including central blood pressure, Alx, and PWV. A number of studies have demonstrated an association between these indices of arterial stiffness and other cardiovascular risk factors. For example, Wilkinson and colleagues showed increased Alx and aortic PWV (aPWV) in subjects with hypercholesterolaemia [250] and type I diabetes [251]. Chronic smoking is associated with higher Alx and central systolic blood pressure (cSBP) when compared to matched non-smoking controls [252], while increased aPWV is also seen in individuals with essential

hypertension meeting the criteria for the metabolic syndrome [253]. A positive correlation has also been demonstrated between the inflammatory marker high-sensitivity C-reactive protein (hsCRP), and both aortic and brachial PWV [254], while declining endothelial function is also associated with elevated large artery stiffness and central systolic blood pressure (cSBP) [255]. There is also evidence for an independent association between manifestations of increased arterial stiffness derived from non-invasive pulse wave analysis (PWA), and the presence of CAD in individuals undergoing coronary angiography [256]. Arterial stiffness is independently predictive of cardiovascular mortality in a number of disease states, including renal failure, hypertension, and glucose intolerance/type II diabetes [236-238], and interventions to reduce stiffness indices are associated with improvements in survival. For example, survival of patients with end-stage renal disease is significantly better for patients whose aortic PWV declines in response to BP lowering intervention [257].

These studies illustrate the importance of arterial stiffness in predicting cardiovascular risk, thus making this a significant parameter with potential clinical application when evaluating patient risk, disease progression and response to intervention. The development of quick, reproducible, and non-invasive tools to measure arterial stiffness may also facilitate incorporation into diagnostic and therapeutic clinical trials.

### **5.1.3 Non-Invasive Assessment Of Arterial Stiffness**


There are numerous invasive and non-invasive methodologies that have been employed to measure arterial elasticity *in vivo*. While invasive techniques are more accurate, their widespread use is limited in research and clinical practice. The non-invasive measures can broadly be divided into three categories - analysis of arterial waveforms, measurement of pulse wave velocity, and relating change in arterial diameter to distending pressure.

### 5.1.3.1

### Analysis Of Arterial Waveforms

A number of technologies, including the SphygmoCor™ apparatus (AtCor Medical Ltd, Sydney, Australia) used in this study, utilise analyses of specific components of the arterial pressure waveform (Figure 5.2) to measure arterial stiffness. Peripheral arterial pressure waveforms from, for example, the radial, femoral, or carotid artery, can be acquired using applanation tonometry [258]. This involves placing a highly sensitive pressure transducer on the skin over the site of the peripheral pulse whilst compressing the artery against a firm structure such as bone. The sensor is then able to detect dynamic pressure and volume changes in the underlying vessel to generate the peripheral arterial waveform (Figure 5.4). This waveform is calibrated to conventionally measured peripheral blood pressure and the system software applies a validated mathematical transfer function to generate the central arterial waveform and measure the central blood pressure [259]. Pulse wave analysis (PWA) can then be performed to calculate  $AIx$  and  $T_R$  as described in the previous section.

**Figure 5.4: Schematic Representation Of Applanation Tonometry**





### **5.1.3.2 Measurement Of Pulse Wave Velocity**

PWV refers to the speed with which the arterial wave travels across a specified distance, and can be measured by a number of methods. Doppler ultrasound [260] or applanation tonometry [258], can be used to record the arterial waveform from a proximal site, e.g. the carotid, and a more distal site, e.g. the femoral artery. In order to travel between these two locations the arterial wave needs to traverse most of the abdominal aorta, an artery particularly prone to atherosclerotic change. The time-delay for the arrival of the foot of the arterial wave at these two sites can be calculated by either simultaneous measurements at both sites, or by gating to the peak of the R-wave of the ECG [247]. The distance between the two sites is measured externally and PWV calculated as distance/time in metres per second.

The manual measurement of distance between these two sites is an approximation of the true distance and depends upon the subject's body habitus and vessel tortuosity. A more accurate measurement can be obtained using magnetic resonance imaging (MRI) though this is significantly more expensive and not always readily available.

### **5.1.3.3 Relating Change In Arterial Diameter To Distending Pressure**

The change in diameter of an artery can be related to the distending pressure and measured using imaging modalities such as ultrasound or, less commonly, MRI. Diameter-pressure curves of the common carotid artery can be generated over the systolic-diastolic range by continuously recording both the pulsatile changes in internal diameter and, simultaneously on the contralateral artery, the pressure waveform using applanation tonometry [261]. This allows determination of the carotid pressures, though some investigators use brachial blood pressures instead. Distensibility can then be compared at the mean arterial pressure and at a fixed distending pressure e.g. 100 mm Hg, with decreasing distensibility indicating a higher degree of arterial stiffness.

#### 5.1.3.4

#### Comparison Of Non-Invasive Measures Of Arterial Stiffness

Table 5.1 summarises the relative strength and weaknesses of the major methods used to measure arterial stiffness.

**Table 5.1: Advantages & Disadvantages Of Non-Invasive Measures Of Arterial Stiffness**

(adapted from Oliver et al, 2003 [247])


	AIx (using PWA)	Arterial Ultrasound	PWV (PWA or ultrasound)	PWV (using MRI)
<b>Ease of use</b>	+++	+	++	+
<b>Affordability</b>	+++	++	+++	+
<b>Quality of validation</b>	++	++	++	+++
<b>Freedom from operator bias</b>	++	+	++	+++
<b>Evidence of prognostic value</b>	++	++	+++	+
<b>Endothelial function testing</b>	+++	+++	+	+

Of these techniques, measurement of AIx by PWA using applanation tonometry requires the least training, can be rapidly measured and thus easily incorporated into clinical trials. PWV and ultrasonography are more time-consuming and the latter in particular requires additional training and dedicated staff. MRI measures are also time-consuming and are further limited by affordability and availability. Both PWV and AIx can be measured with a high degree of reproducibility [258] and have been shown to carry significant prognostic value. For these reasons, as well as local availability, it was decided to measure PWV and AIx using PWA to assess arterial stiffness in the present clinical trial. Furthermore, this technique was also used for endothelial function testing and will be discussed in greater detail below.

#### **5.1.4 Vascular Endothelium & Endothelial Dysfunction**

The vascular endothelium lining the luminal surface of all blood vessel walls plays an integral role in the regulation of vascular tone, haemostasis and permeability, mediated by a number of endothelium-derived factors (Figure 5.5). Of the vasoactive factors that the endothelium can release, prostacyclin ( $\text{PGI}_2$ ), nitric oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF) are the most significant [262]. NO is synthesized from L-arginine by NO synthases (NOS) present in the endothelium (eNOS), or inflammatory cells (iNOS). NO is a lipophilic agent and is thus able to traverse cell membranes causing vasodilatation via activation of soluble guanylyl cyclase generating cyclic guanosine monophosphate within vascular smooth muscle cells [263]. NO production by eNOS can be stimulated directly by shear stress, as well as by muscarinic or bradykinin receptor-mediated calcium channel activation [264]. NO also inhibits the vasoconstrictive actions of angiotensin-II (AT II) and endothelin-1 (ET-1). AT-II binds to the G-protein-coupled angiotensin receptor on vascular smooth muscle cells which stimulates phospholipase C (PLC) mediated inositol triphosphate (IP3) production leading to an increase in intra-cellular calcium and consequent vasoconstriction [265]. ET-1, generated within the endothelial cells, acts upon the endothelin A receptor on smooth muscle cells, which in turn is also linked to PLC as well as voltage operated calcium channels leading to vasoconstriction [266]. When testing endothelial function, nitrate-containing pharmacological agents such as glyceryl trinitrate (GTN) can be used as direct, or endothelium-independent vasodilators due to direct delivery of NO to the vascular smooth muscle cells. Endothelium-dependent function can be examined using shear stress or drugs that depend upon NO generation via eNOS, for example, salbutamol [267].

**Figure 5.5: Modulators Of Vascular Tone [262-266]**



PGI<sub>2</sub> is synthesized from arachidonic acid by cyclooxygenase (COX) isozymes expressed in the vascular endothelium and is thought to contribute to the maintenance of vascular homeostasis. PGI<sub>2</sub> elicits smooth muscle relaxation by activating specific cell-surface receptors that are G-protein-coupled to adenylyl cyclase thereby elevating cyclic adenosine monophosphate (cAMP) levels and inducing smooth muscle relaxation [268]. PGI<sub>2</sub>-mediated vasodilation can also be stimulated by ET-1 via stimulation of the endothelin B receptor [266].

The identity of EDHF remains unclear, although several candidates have been proposed including K<sup>+</sup> ions, cAMP, cytochrome p450 2C products, H<sub>2</sub>O<sub>2</sub>, spread of electrotonic current and, most recently, C-type natriuretic peptide (CNP) [262, 269]. It is, however, accepted that

vasorelaxation resulting from EDHF follows opening of endothelial calcium-activated potassium channels, and that hyperpolarization of vascular smooth muscle associated with EDHF activity involves activation of the Na<sup>+</sup>/K<sup>+</sup>-ATPase and inward-rectifying potassium channels (K<sub>IR</sub>) [262].

### **5.1.5 Non-Invasive Assessment Of Endothelial Function**

Established methods for assessing vasomotor endothelial function centre on measuring the response to an endothelium-dependent, NO-mediated stimulus such as acetylcholine or reactive hyperaemia, and a direct (endothelium-independent) nitrovasodilator like sodium nitroprusside (SNP) or glyceryl trinitrate (GTN) [270]. However, these methods are not practical for inclusion in large-scale trials. PWA in combination with provocative administration of GTN (endothelium-independent) and salbutamol (endothelium-dependent), provides a simple, reproducible, and non-invasive means of *in vivo* assessment of endothelial function. Here, the magnitude of change in AIx in response to pharmacological stimulation represents the functional state of the endothelium.

Endothelial function can also be assessed by radiological measurements, usually by ultrasound, of vessel dilatation in response to pressure-controlled forearm blood flow (reactive hyperaemia test, or flow-mediated dilatation) [91]. This technique requires considerably more training than PWA, and comparative studies have demonstrated a significant correlation between both these methods [270].

### **5.1.6 Clinical Trial Design**

The clinical trial described in this chapter compares the effect of our investigational medicinal product (IMP), metformin, to that of placebo using a randomised, double-blind, crossover study design. The main advantage of the crossover study design is that each individual acts as



his or her own 'control,' thus reducing the influence of confounding variables. Removing patient variation in this way makes crossover trials potentially more efficient than similar sized, parallel group trials in which each subject is exposed to only one treatment – IMP or control [271]. In theory treatment effects can be estimated with greater precision given the same number of subjects. Another significant advantage is that a substantial within-subject correlation is expected, i.e. an individual's tendency to vasodilate in response to GTN should be consistent. The main drawback is the potential to carry-over a treatment effect from the 1<sup>st</sup> treatment phase to the 2<sup>nd</sup>. This can be overcome to a large extent by ensuring an adequate wash-out period and performing baseline measures prior to each treatment phase.

#### **5.1.7 Chapter Aims**

This chapter aims to describe the results obtained from a clinical trial analysing the effects of metformin on vascular function, body composition and metabolic profile in PCOS. The primary outcome measures for this study were defined as changes in markers of arterial stiffness ( $AIx$ ,  $T_R$ ,  $bPWV$ ,  $aPWV$ ), endothelial function and blood pressure (peripheral and central). The secondary outcome measures were to evaluate the effects of metformin therapy on anthropometric measurements of body composition (weight, BMI, fat percentage, waist and hip circumference), changes in serum androgens (testosterone, sex hormone binding globulin (SHBG), free androgen index (FAI)), insulin resistance (fasting insulin, glucose, HOMA-IR), lipid profile (TC, HDL, LDL, TG) biochemical markers of vascular risk (hsCRP, PAI-1), and adiponectin.

## **5.2 MATERIALS AND METHODS**

### **5.2.1 Trial Approval & Funding**

Prior to commencement of the clinical trial, the project was approved by the Research and Development Department at the University Hospital of Wales (Ref 05/CMC/3456E), the South Wales Research Ethics Committee (Ref 06/WSE04/33), and the United Kingdom Medicines and Healthcare Products Regulatory Authority (MHRA) (Ref 2005-005471-69). The study was sponsored by Cardiff University (Ref SPON CU 153) and placed on the International Standard Randomised Controlled Trial Number register and ascribed the registration ISRCTN 61785174 (<http://www.controlled-trials.com/isrctn/>).

The study was supported by the Lewis Thomas Gibbon Jenkins of Briton Ferry Fellowship Award from the Royal College of Physicians. The funding source had no input in the design, conduct, management, analysis or interpretation of the study.

### **5.2.2 Trial Participants – Inclusion & Exclusion Criteria**

Patients were recruited from the endocrine and dermatology clinics at the University Hospital of Wales (UHW). A diagnosis of PCOS was made according to the Rotterdam criteria [93]. Specifically, patients with androgen excess (clinical symptoms of hyperandrogenism and/or elevated testosterone) with ovulatory dysfunction (fewer than 6 menstrual cycles per year) were recruited, supported by ovarian ultrasound where available (polycystic ovaries present in 24/30 subjects on imaging). Congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumours, hyperprolactinemia and thyroid disease were excluded by biochemical testing.

Patients were aged between 18 and 35 years and were excluded from participation if they were pregnant or planning to become pregnant, breastfeeding, had a history of current or recent (within 6 months) use of oral contraceptives, antidiabetics or antiandrogens, or had any contraindications to metformin therapy including renal or hepatic impairment. Patients with a history of known hypertension, hyperlipidemia or diabetes were also excluded. As metformin is known to improve ovulation rates in women with PCOS, study participants were advised to use barrier methods of contraception if they were sexually active; pregnancy tests were performed at each visit with a plan for study withdrawal if pregnancy was confirmed.

### **5.2.3 Consent**


Initial contact was made by providing each subject with a patient invitation letter and information sheet explaining the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits involved and any discomfort it may entail (Appendix 3). This was followed by a telephone call a week later to determine interest in study participation and confirm eligibility. A personal visit at the Clinical Research Facility in UHW was then arranged where written informed consent was obtained (Appendix 4) prior to study commencement. Each subject was informed that participation in the study is voluntary and she may withdraw from the study at any time and that withdrawal of consent will not affect her subsequent medical treatment or relationship with the treating physician.

### **5.2.4 Treatments & Interventions**

Thirty participants were randomized to receive consecutive 12 week treatment periods of either metformin followed by placebo tablets of identical appearance or placebo followed by metformin administration. To minimise gastrointestinal side-effects metformin was given in a dose of 500mg once daily for 1 week, 500mg twice daily for 1 week then 500mg three times daily for the remaining 10 weeks (matched with equal tablet numbers in the placebo phase).

A washout interval of 8 weeks separated the two treatment phases. Metformin and placebo capsules were both supplied by Merck-Santé (Lyon, France) and packaged in a licensed pharmaceutical laboratory (St Mary's Pharmaceutical Unit, Cardiff, UK). The clinical trial study design is illustrated in Figure 5.6.

**Figure 5.6: Summary Of Clinical Trial Design**



### 5.2.5 Measurements

Participants were assessed in the Clinical Research Facility at the UHW at four points: baseline tests at visit 1 and at the end of the wash-out phase (visit 3) and after each treatment (metformin or placebo) phase (visits 2 and 4). On each occasion blood samples were collected after an overnight fast, followed by assessment of body composition, arterial stiffness and endothelial function. A full clinical history was obtained at the first visit and any changes recorded upon each subsequent visit. An example of the study visit case report form can be found in Appendix 5.

### 5.2.5.1 Measurement Of Arterial Stiffness & Endothelial Function

All measurements, were performed in a quiet, temperature-controlled room, and taken exclusively by the author of this thesis to avoid any inter-observer variability. Smokers were asked to refrain from smoking on the morning of their visit. Blood pressure was measured at the brachial artery of the dominant arm using a validated semi-automated oscillometric device (Omron 705IT, Omron Corporation, Tokyo, Japan) after 10 minutes rest in the seated position. Each blood pressure measurement used in this study was the mean of two recordings. Peripheral pressure waveforms were captured from the radial artery of the dominant hand at the wrist using a micromanometer (SPC-301; Millar Instruments, TX, USA) connected to the SphygmoCor™ apparatus (Model MM3, AtCor Medical Ltd, Sydney, Australia; software version 8.0). After 20 sequential waveforms had been acquired, with operator quality index of over 75%, the central (ascending aortic) pressure waveform was derived from an averaged peripheral waveform using a validated, generalized transfer function [259]. The AIx, and central aortic pressure were derived from analysis of the central waveform. The estimated aPWV was calculated as the time between the foot of the pressure wave and the first inflection point ( $T_R$ ). An example of a PWA measurement using this technique is given in Figure 5.7.


Pulse wave velocity (PWV) was measured by the Sphygmocor system by sequentially recording ECG-gated carotid and femoral waveforms (for aortic PWV; aPWV) and carotid and radial waveforms (for brachial PWV; bPWV) as described previously.

Endothelial function was assessed using a validated, non-invasive method whereby the change in AIx in response to the administration of nitroglycerin, (GTN, an endothelium-independent nitrovasodilator), and salbutamol (an endothelium-dependent  $\beta_2$ -adrenoceptor agonist) is determined by pulse wave analysis. Briefly, a 500  $\mu$ g tablet of GTN (Alpharma, Barnstable, UK) was placed under the tongue for 3 minutes and then removed;



haemodynamic recordings (pulse, blood pressure and AIx) were then made at 3, 5, 10, 15, 20 and 30 minutes after administration. At 30 minutes after GTN administration, 400 µg salbutamol (IVAX pharmaceuticals, London, UK) was given by inhalation through a spacer device and haemodynamic recordings were taken at 5, 10, 15 and 20 minutes after salbutamol administration. The response to GTN or salbutamol was defined as the maximum change in AIx after drug administration. Each of the above measurements was performed twice and averaged prior to data entry.

**Figure 5.7: Example Of SphygmoCor™ Generated PWA**



#### **5.2.5.2 Anthropometric Measurements**

Body height was measured to the nearest 0.5 cm using a stadiometer and body weight (in light clothing without shoes) to the nearest 0.5 kg on a balance beam scale. Waist circumference was measured at minimal respiration and reported to the nearest 0.5 cm by positioning a flexible anthropometric tape parallel to the floor and immediately above the iliac crest. Hip circumference was measured at the maximum circumference over the buttocks and recorded to the nearest 0.5 cm. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Percentage fat was measured by bioimpedance (Tanita Body Fat analyser TBF-305, Tanita Corporation, Japan).

#### **5.2.5.3 Metabolic Biochemistry Measurements**

Blood samples were collected on the morning of each visit following an overnight fast. Serum was prepared by centrifugation of blood at 4000 rpm for 8 minutes and stored at -20°C prior to analysis in a single laboratory at the UHW. The intra- and interassay coefficients of variation (all less than 9%), lower limits of assay detection and reference ranges used for biochemical testing, are listed in Table 5.2. Serum sex hormone binding globulin (SHBG) was measured using an Elecsys E170 automated immunoassay analyser (Roche SHBG assays, Roche Diagnostics, Lewes, UK), and testosterone, oestradiol, and progesterone using the Siemens Centaur automated immunoassay analyser (ADVIA Centaur Testosterone/Estradiol-6/Progesterone assays, Bayer, Newbury, UK). The free androgen index (FAI) was calculated using the equation:  $FAI = (testosterone / SHBG) \times 100$ . Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and triglycerides were assayed using an aeroset automated analyser (Abbott Diagnostics, Berkshire, UK); LDL cholesterol (LDL) was calculated using Friedewald's formula [272]. Insulin was measured using an immunometric assay specific for human insulin (Invitron, Monmouth, UK). Glucose was measured using the Aeroset chemistry system (Abbott Diagnostics, Berkshire, UK). High sensitivity C-reactive

protein (hsCRP) was assayed via nephelometry (BN™ II system, Dade Behring, Milton Keynes, UK) and PAI-1 was measured using a tissue plasminogen activator coated ELISA plate that assays only active PAI-1 (Zymutest, Hyphen Biomed, Nodia, Amsterdam). Insulin resistance was estimated using the homeostasis model assessment method (HOMA-IR) calculated by the formula: fasting serum insulin ( $\mu\text{U/ml}$ )  $\times$  fasting serum glucose ( $\text{mmol/l}$ )/22.5 [273]. Serum adiponectin was measured in duplicate by ELISA (R&D Systems, Oxford, UK) as described in Chapter 4.

**Table 5.2: Biochemical Assay Information**

Test	Coefficient of variation	Lower limit of detection	Reference range
Insulin	4.1-4.9%	1 mU/l	N/A
Glucose	1.5-2.2%	0.1 mmol/l	N/A
Triglycerides	0.8-1.1%	0.07 mmol/l	0.6-2.0 mmol/l
HDL	5.5-1.4%	0.13 mmol/l	0.7-1.7 mmol/l
Total cholesterol	0.8-1.6%	0.16 mmol/l	N/A
SHBG	1.1-4.0%	0.35 nmol/l	19.8-122 nmol/L (pre-menopausal)
Testosterone	2.7-7.6%	0.35 nmol/l	<2.5 nmol/l (females)
Oestradiol	7.9-8.3%	0.37 nmol/l	69.4-905.5 (follicular) 130.3-2094.8 (mid-cycle) 82.9-939.5 (luteal)
Progesterone	4.1-6.7%	0.67 nmol/l	0.48-4.45nmol/l (follicular) 10.62-81.28 nmol/l (luteal) 14.12-89.14 nmol/l (mid-luteal)
hsCRP	2.5-4%	0.1 mg/l	0-3.0 mg/l

### **5.2.6 Randomisation & Blinding**

The treatment assigned to each participant was determined according to a computer generated randomization list produced by an independent external pharmacist (St Mary's Pharmaceutical Unit, Cardiff, UK). The participant study drug boxes were labelled with unique patient identification numbers. When a participant was found eligible for the study, she was allocated a unique patient identification number in sequential, chronological order. The participant was then treated with the medication labelled with the same number. If a participant was withdrawn from the study, her medication was not reallocated. All participants and investigators remained blind to treatment allocation for the duration of the study.

### **5.2.7 Outcome Measures**

The primary outcome measures were defined as changes in arterial stiffness (Aix,  $T_R$ , bPWV and aPWV), endothelial function, and blood pressure (peripheral and central). Secondary outcome measures were defined as changes in serum androgens (testosterone, SHBG and FAI), body composition (weight, BMI, percentage fat, waist and hip circumference) and metabolic biochemistry (TC, HDL, LDL, Triglycerides, PAI-1, adiponectin, hsCRP, HOMA-IR).

### **5.2.8 Sample Size & Power Calculation**

Sample size advice was obtained from Professor R. Newcombe, Department of Primary Care and Public Health, School of Medicine, Cardiff University. Subsequently the aim was to recruit 32 subjects into the study in order to provide over 80% power to detect a shift of 0.5 times the standard deviation of within-group changes at the 5% alpha level using a paired t-test. Because the main rationale for using a crossover study was that a substantial within-subject

correlation was anticipated, it was therefore expected that the power should be well in excess of this figure.

### **5.2.9 Statistical Methods**

All statistical analyses were performed using SPSS version 14 for Windows (SPSS, Chicago, IL). All analyses were performed as per pre-established protocol and in line with previous guidance on analysis of crossover trials [274]. This assessment of treatment efficacy compares the within-subjects period I minus period II differences between the treatment sequence groups AP (active-placebo) and PA (placebo-active) by unpaired t-test. In the event of serious departure from Gaussian distributional form, scale transformation was used. Point and interval estimates of the treatment difference (estimated as above) are given as well as p-values. 5% and 1% levels of significance were set for the primary and secondary outcome measures, respectively.

### **5.2.10 Procedures & Instructions**

#### **5.2.10.1 Adverse Event Reporting**

An adverse event was any undesirable sign, symptom or medical condition occurring after the patient has given informed consent. A serious adverse event (SAE) was defined as an undesirable sign, symptom or medical condition which:

1. was fatal or life-threatening
2. required or prolongs hospitalisation
3. was significantly or permanently disabling or incapacitating
4. constituted a congenital anomaly or a birth defect



5. was medically significant, jeopardised the subject or required medical or surgical intervention to prevent one of the outcomes listed above.

Information about all non-serious and SAEs, irrespective of causality, whether volunteered by the subject, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, was collected and recorded. Adverse events were followed as appropriate. Where possible, each adverse event was described by:

1. Its duration
2. The severity grade (mild, moderate, severe)
3. Its relationship to study drug (suspected, not suspected)
4. The action(s) taken

Pregnancy was managed as a SAE and followed up to determine details of birth, outcome, including spontaneous or voluntary abortion, the presence or absence of any birth defects or congenital abnormalities, or any maternal/newborn hazards. Periodic safety reports were provided to all regulatory authorities. All SAEs were reported immediately to the trial sponsor (Cardiff University), regardless of the causal relationship and expectedness, as well as the MHRA as per European Union requirements and in accordance with Good Clinical Practice.

#### **5.2.10.2 Emergency Procedure For Unblinding**

The randomisation codes for each patient were held at the Pharmacy Department at UHW in individual sealed envelopes for emergency use only. Emergency unblinding was considered in the event of a SAE provided that knowledge of the subject's treatment allocation would be of benefit in her management.

### **5.2.10.3 End Of Study Unblinding**

After completion of the final subject's final visit, a complete electronic database was created which contained all the data collected on vascular, anthropometric and metabolic parameters. A copy of this database was supplied on a CD-ROM to a research governance officer from Cardiff University who undertook a final study closure inspection and confirmed source verification of the data. The Pharmacy department was then given permission to release the randomisation codes so data analysis could be performed.

### **5.2.11 Project Management & Administrative Procedures**

The author of this thesis was responsible for the day-to-day conduct of the study, and therefore co-ordinated recruitment, obtained consent, performed the blood sampling and measured PWV and Aix in all study participants. In the event of an emergency, the author was contactable 24 hours a day. Contact information was provided to all study participants and was printed on all study medication containers.

Formal meetings were undertaken on a weekly basis with Dr Aled Rees, the Principal Investigator, to discuss all aspects of the study and to plan the work for the forthcoming week. Informal discussions regarding any difficulties that arose with the project took place as required.

All data was entered into a secure electronic database kept locked within the department. Study data will be stored for 15 years after completion of the clinical trial. Dr Rees will act as custodian of this data and only the study investigators will have access to the data. In addition the trial master files and case report forms have been stored in hard copy form at the Cardiff University off-site archiving facility.

#### **5.2.11.1 Auditing Procedure**

As part of Good Clinical Practice the study protocol and all documentation were closely monitored. The study was conducted as outlined in the study protocol and in accordance with all applicable government regulation. All study documentation was made available for inspection at any time by appropriate regulatory authorities including internal audits by the Cardiff and Vale NHS Trust and Cardiff University Research and Development audit officers.

#### **5.2.11.2 Handling Of Study Medication**

All study medication was dispensed by the Pharmacy Directorate at UHW. Drug supplies were stored in an appropriate, secure area and all drug supplies were used only for this protocol and not for any other purpose.

#### **5.2.12 Intra-Observer Variability**

Formal training was undertaken for all aspects of pulse wave analysis at an 'Arterial Stiffness Theory & Practice' course at the Vascular Research Unit in Addenbrooke's Hospital, Cambridge, UK. Prior to commencement of the clinical trial, intra-observer variability was established by performing PWA on 20 healthy volunteers at two time points 30 minutes apart, to measure Aix. The mean overall intra-operator variability was less than 2% (Table 5.3).


**Table 5.3: Intra-Operator Variability**

Subject	Gender	Age (yrs)	Height (cm)	Weight (kg)	BP (mmHg)	AIx 1 (%)	AIx 2 (%)	Difference AIx 1 & 2
1	M	42	180	102	132/74	23	22.5	0.50
2	M	38	175	71	128/64	15	13.5	1.50
3	M	37	166	70	127/84	24	24	0.00
4	M	35	175	71	120/81	14.5	14	0.50
5	M	35	173	78	134/83	14.5	13.5	1.00
6	M	33	173	80	120/80	7	5	2.00
7	F	56	163	57	138/88	29	28	1.00
8	F	40	161	58	98/70	17	16	1.00
9	F	40	156	59	127/81	29	29	0.00
10	F	38	158	80	144/104	41	38	3.00
11	F	37	164	123	131/68	17.5	15	2.50
12	F	37	160	53	121/94	31	27	4.00
13	F	36	158	75	118/75	30	27	3.00
14	F	34	146	74	116/75	24	22	2.00
15	F	31	160	78	132/78	31	27.5	3.50
16	F	29	160	69	119/88	18	16	2.00
17	F	28	165	83	141/93	-4.5	-5	0.50
18	F	26	167	72	110/71	11	11	0.00
19	F	22	180	69	122/67	-6	-8	2.00
20	F	20	167	78	132/73	19	16	3.00
<b>Mean intra-operator variability (SD)</b>								<b>1.65(1.2)</b>

**5.3.1 Subject Recruitment And Trial Completion**

Figure 5.8 summarises the flow of participants through each phase of the study. 200 patients from the Endocrine and Dermatology clinics at the University Hospital of Wales, Cardiff, were screened for trial eligibility of which 80 fulfilled all the inclusion criteria. Of these a final 30 women consented to trial participation and were randomised accordingly.

**Figure 5.8: Flow Of Participants Through Each Phase Of The Clinical Trial**





25 subjects completed the full protocol. This gave a slightly reduced power of 70% to detect a shift of 0.5 times the SD of within-group changes. Five subjects were withdrawn during the course of the study: 1 participant because of pregnancy and 4 individuals because of protocol violation (non-attendance for study visits). The data analysed are therefore for the 25 subjects who completed the study. No significant carryover effect was noted in any of the measurements.

### 5.3.2 Baseline Demographic & Anthropometric Data

Table 5.4 summarises the baseline demographic and anthropometric characteristics of the study population. The mean age for the group was 30 years and 20% reported current smoking. The average BMI was 34.9 kg/m<sup>2</sup>, consistent with obesity, and associated with an increased mean waist circumference of 107.6 cm.

**Table 5.4: Baseline Demographic & Anthropometric Characteristics**

Values are based upon all 30 study participants & are expressed as mean (SD) or median (range).

Characteristic	Mean SD
Age (yr)	30 (18 - 35)
Smokers (n)	6 (20%)
Ferriman-Gallwey score	11 (2 - 23)
Weight (kg)	96.5 (23.4)
BMI (kg/m <sup>2</sup> )	34.9 (6.8)
Waist circumference (cm)	107.6 (21)
Hip circumference (cm)	119.5 (19.2)
Fat percentage	48 (21 - 57)

### 5.3.3 Baseline Vascular Parameters

Table 5.5 summarises the baseline vascular markers for the study population. Reference values for AIx using the SphygmoCor apparatus have been provided by the manufacturer (Atcor medical) derived from unpublished data by Cockcroft et al (Cardiff, UK) available at <http://www.atcormedical.com>. Based upon their data the mean AIx for a similar mean aged population is quoted to be 3.03% (95% CI -15.57 to 24.5) compared with a value of 18.5% in our PCOS study population, which may suggest increased baseline arterial stiffness. However, the demographic and anthropometric characteristics of this reference population are not stated in the manufacturer's literature. The baseline vascular parameters for PWV and blood pressure are comparable to those reported in similar studies in PCOS cohorts [245].

**Table 5.5: Baseline Vascular Parameters Of Study Participants**

Values are based upon all 30 study participants & are expressed as mean (SD).

Characteristic	Mean SD
T <sub>R</sub> (msec)	145.7 (11.4)
AIx (%)	18.5 (10.5)
bPWV (m/sec)	7.7 (1.1)
aPWV (m/sec)	7.0 (1.2)
Peripheral SBP (mm Hg)	127 (11)
Peripheral DBP (mm Hg)	85 (9)
Central SBP (mm Hg)	117 (11)
Central DBP (mm Hg)	85 (9)
Fall in AIx after GTN (%)	-16.8 (5)
Fall in AIx after salbutamol (%)	-14.6 (6.4)

### 5.3.4 Baseline Metabolic Biochemical Parameters

Table 5.6 summarises the baseline metabolic parameters for the study population.

**Table 5.6: Baseline Metabolic Biochemical Parameters Of Study Participants**

Values are based upon all 30 study participants & are expressed as mean (SD) or median (range).

Characteristic	Mean (SD) or Median (range)
Adiponectin (pg/ml)	474.3 (95.3 - 1915.3)
hsCRP (mg/liter)	3.4 (0.16 - 14.4)
Insulin (pmol/liter)	20.7 (5.1 - 42.2)
Glucose (mmol/liter)	5.1 (0.5)
HOMA-IR	2.5 (0.7 - 4.8)
TC (mmol/l)	4.8 (0.7)
HDL (mmol/l)	1.2 (0.3)
LDL (mmol/l)	3.0 (0.5)
Triglycerides (mmol/liter)	0.9 (0.4 - 5.2)
PAI-1 (ng/ml)	1.75 (0.5 - 23.9)
Testosterone (nmol/liter)	2.6 (0.8)
SHBG (nmol/liter)	33.2 (18.5 - 174.3)
FAI	7.6 (0.8 - 17.4)
Oestradiol (pmol/l)	156 (70-707)
Progesterone (nmol/l)	3.5 (2-31.5)

### 5.3.5 Prevalence Of Features Of The Metabolic Syndrome In Study Population

There was an increased prevalence of features of the metabolic syndrome based on the 2006 IDF definition amongst the study population (Table 5.7). The commonest abnormality was an increased waist circumference, a marker of visceral adiposity, in 93% of the subjects. 60% had evidence of hypertension, 53% low HDL, 20% hypertriglyceridaemia, and 13% impaired

fasting glucose. 47% fulfilled the criteria for the metabolic syndrome with  $\geq 3$  features present. These findings are in keeping with reports in the literature by Dokras et al [127] who reported a prevalence of 34% of the metabolic syndrome in PCOS, and 43% by Apridonidze and colleagues [129] as discussed previously.

**Table 5.7: Prevalence Of Features Of The Metabolic Syndrome In PCOS**  
**Based On the 2006 IDF Criteria**

Metabolic Syndrome Criteria	Prevalence N° (%)
Waist circumference ( $\geq 80$ cm)	28 (93 %)
Triglycerides ( $\geq 1.7$ mmol/l)	6 (20 %)
HDL cholesterol ( $< 1.29$ mmol/l)	16 (53 %)
BP (Systolic $\geq 135$ or diastolic $\geq 85$ mmHg)	18 (60 %)
Dysglycaemia (Fasting glucose $\geq 5.6$ mmol/l)	4 (13 %)
Central obesity + 2 other criteria	14 (47 %)

### 5.3.6 Treatment Compliance & Adverse Events

All adverse events were recorded in the trial case report forms and reported to the Cardiff and Vale NHS Trust Research and Development Department as well as Cardiff University (study sponsor). Annual safety reports were submitted to the South Wales Research and Ethics Committee as well as the Medicines and Healthcare Regulatory Authority.


Overall the study medication (active and placebo) was well tolerated. Five adverse events were reported during the course of the study, three of which were expected (gastrointestinal discomfort during the active treatment phase) but mild and self-limiting. One subject described a headache (while on metformin) and this was also mild in intensity and self-limiting. Another participant became pregnant (while on placebo) and was immediately

withdrawn from the study. The pregnancy was followed to term with no maternal or foetal complications.

### 5.3.7 Effect Of Metformin On Vascular Function


Metformin therapy significantly improved all markers of arterial stiffness in our study population (bPWV, aPWV, Alx; all  $p < 0.001$ ) with the exception of  $T_R$  which did not change (Figures 5.9 and 5.10).

**Figure 5.9: Effect Of Metformin Therapy On Augmentation Index In PCOS**






**Figure 5.10: Effect Of Metformin Therapy On Brachial & Aortic PWV In PCOS**




These improvements in measures of arterial stiffness following metformin therapy were accompanied by a lowering of peripheral and central aortic systolic (Figures 5.11 and 5.12) and diastolic blood pressure (all  $p < 0.001$ ).

**Figure 5.11: Effect Of Metformin Therapy On Peripheral Blood Pressure In PCOS**



**Figure 5.12: Effect Of Metformin Therapy On Central Systolic Blood Pressure In PCOS**



Metformin also improved endothelium-dependent and endothelium-independent vascular responses as evidenced by an increased reduction in Alx post-salbutamol ( $p=0.003$ ) and post-GTN ( $p<0.001$ ) respectively. A summary of the primary vascular outcome measures for the study is given in Table 5.8.

**Table 5.8: Effect Of Metformin vs. Placebo On Vascular Outcome In PCOS**

	Mean difference	95% CI for the difference	p-value
Alx (%)	-6.1	-8.46 to -3.74	<b>&lt;0.001</b>
bPWV(m/s)	-0.73	-1.09 to -0.38	<b>&lt;0.001</b>
aPWV (m/s)	-0.76	-1.12 to -0.4	<b>&lt;0.001</b>
Peripheral SBP (mmHg)	-7.65	-10.47 to -4.84	<b>&lt;0.001</b>
Peripheral DBP (mmHg)	-5.83	-8.4 to -3.22	<b>&lt;0.001</b>
Central SBP (mmHg)	-9.02	-12.05 to -6	<b>&lt;0.001</b>
Central DBP (mmHg)	-5.96	-8.74 to -3.17	<b>&lt;0.001</b>
Alx post-GTN (%)	-4.68	-6.93 to -2.43	<b>&lt;0.001</b>
Alx post-salbutamol (%)	-5.38	-8.68 to -2.07	<b>0.003</b>



### 5.3.8

### Effect Of Metformin On Anthropometric Measurements

Table 5.9 summarises the results of the anthropometric measures. Metformin significantly reduced body weight ( $p<0.001$ ), BMI ( $p<0.001$ ), waist circumference ( $p<0.001$ ), fat percentage ( $p<0.001$ ), with only a minimal change of doubtful significance noted in hip circumference. These results suggest the weight loss may have been related to a reduction in central, or visceral, adiposity.

**Table 5.9 : Effect Of Metformin vs. Placebo On Anthropometric Measurements In PCOS**


	Mean difference	95% CI for the difference	p-value
Weight (kg)	-2.05	-2.9 to -1.2	<b>&lt;0.001</b>
BMI (kg/m <sup>2</sup> )	-0.75	-1.06 to -0.43	<b>&lt;0.001</b>
Fat percentage (%)	-2.46	-3.26 to -1.65	<b>&lt;0.001</b>
Waist circumference (cm)	-4.88	-6.96 to -2.81	<b>&lt;0.001</b>
Hip circumference (cm)	-0.82	-1.62 to -0.02	<b>0.045</b>

### 5.3.9

### Effect Of Metformin On Metabolic Biochemical Parameters

Metformin significantly increased adiponectin concentrations ( $p=0.001$ ) as illustrated in Figure 5.13 and was also associated with a fall in plasma triglycerides. There were no changes observed with metformin therapy in hsCRP, insulin, glucose, HOMA-IR, total cholesterol, HDL, LDL, PAI-1, testosterone, SHBG, FAI, oestradiol or progesterone. Table 5.10 summarizes the results of the metabolic biochemistry.

**Figure 5.13: Effect Of Metformin Therapy On Adiponectin In PCOS**



**Table 5.10: Effect Of Metformin vs. Placebo On Metabolic Markers In PCOS**

	Mean difference	95% CI for the difference	p-value
Adiponectin (pg/ml)	+81.5	+18.7 to +144.3	<b>0.001</b>
hsCRP (mg/l)	-0.13	-0.34 to +0.86	0.216
Insulin (pmol/l)	-0.08	-4.75 to +4.58	0.971
Glucose (mmol/l)	-0.13	-0.46 to +0.21	0.43
HOMA-IR	-0.46	-2.21 to +1.3	0.583
TC (mmol/l)	-0.75	-2.42 to +0.92	0.35
HDL (mmol/l)	-0.69	-2.36 to +0.99	0.39
LDL (mmol/l)	-0.67	-2.35 to +1.02	0.41
Triglycerides (mmol/l)	-0.16	-0.26 to -0.56	<b>0.004</b>
PAI-1 (ng/ml)	+0.08	-1.69 to +1.84	0.3
Testosterone (nmol/l)	-0.81	-2.48 to +0.86	0.31
SHBG nmol/l	-3.31	-17.25 to +10.63	0.62
FAI	-1.26	-3.34 to +0.82	0.22
Oestradiol (pmol/l)	+15.34	-25.24 to +55.93	0.44
Progesterone (nmol/l)	+2.66	-2.85 to +8.18	0.33

A number of studies have recently examined the effects of metformin on vascular function [240-246], especially endothelial function, in young women with PCOS, although to the author's knowledge, this is the first study to prospectively test this in a randomized, double-blind, placebo-controlled design. It was deemed justifiable to include a short-term placebo arm because the study patients were not seeking fertility treatment, treatment for oligo-/amenorrhea, or systemic therapy for management of their hirsutism. A crossover design was chosen because a substantial within-subject correlation was anticipated, such that smaller sample sizes would be required to detect significant differences, and used a washout period of 8 wk to minimize the potential for a carryover effect. Although endothelial function has been found to vary according to phase of the menstrual cycle [275], we were unable to apply these temporal limitations to the vascular measurements because of the need for equal treatment duration in each phase of the crossover design. Nevertheless, it is not considered likely that any potential confounding influences of metformin on improved menstrual cyclicity [245] might account for the changes observed in vascular function because estradiol and progesterone levels did not differ after the metformin and placebo phases.

The data demonstrated that metformin significantly improved endothelial function in the PCOS cohort, an observation consistent with some [240-243], but not all [244-246], previous studies in young women with PCOS. The latter studies employed flow-mediated dilatation of the brachial artery as their method to assess endothelial function. An alternative technique based on a similar principle was used in the present study, whereby changes in Alx in response to endothelium-dependent (salbutamol) and endothelium-independent (GTN) pharmacological challenges are measured by pulse wave analysis [270]. Although this technique may offer reduced precision compared with flow-mediated dilatation in measuring endothelial function [276], it provides a more global assessment of endothelial function, including conduit and resistance vessel endothelial function, and correlates strongly with gold



standard measures [270]; hence, it was anticipated that the current findings would be comparable to other methodologies.

Endothelial dysfunction is an important process in the progression of atherosclerosis and independently predicts cardiovascular morbidity [277, 278]. An improvement in large artery stiffness was observed with metformin therapy as evidenced by a reduction in AIx and slowed brachial and aortic PWV. A slowing of aortic PWV in response to metformin is especially noteworthy given that this measure of arterial stiffness is independently predictive of cardiovascular mortality in a number of disease states, including renal failure, hypertension, and glucose intolerance/type II diabetes [236-238]. A 1 m/sec increase in aortic PWV was associated with a 39 and 8% increase in mortality in patients with renal failure [237] and type II diabetes [236] respectively; hence, the observed reduction of almost 0.8 m/sec is likely to be clinically important. In contrast, Meyer and colleagues [245] failed to detect a change in PWV with 6 months of metformin treatment in their population of women with PCOS but did note an increase in PWV with a high-dose oral contraceptive (35g ethinyl estradiol/2 mg cyproterone acetate), related principally to increased insulin resistance. These divergent effects on arterial stiffness of the two most commonly prescribed treatments for young women with PCOS thus has important practical implications when considering choice of therapy in the clinic. The study population in Meyer et al. had a similar mean age (31 years), BMI (36.3 kg/m<sup>2</sup>), systolic blood pressure (121mmHg), and aortic PWV (7.47 m/sec) to that described here; hence these discrepancies cannot be accounted for on the basis of differences in patient characteristics at baseline. Furthermore, although their sample size calculations were performed primarily for changes in insulin sensitivity, their study was also adequately powered to detect a 3–4% difference in PWV [245]. However, in contrast to the present findings, the participants in Meyer and colleagues' study did not lose weight, nor did their blood pressure change, which suggests that the vascular improvements observed in this thesis with metformin might be dependent at least in part on changes in these variables. In support of this, weight loss alone (8% over 1 yr) has been shown to reduce aPWV by 0.5

m/sec in subjects with type II diabetes [279], and a blood pressure reduction of 24/9 mm Hg with valsartan and hydrochlorothiazide is associated with a reduction in aortic PWV by 1.8 m/sec [280].

A fall in peripheral blood pressure with metformin therapy has been reported previously in women with PCOS [281, 282], although the reduction observed here in central aortic blood pressure is likely to have even greater clinical relevance because this has been shown to be a more powerful predictor of mortality than brachial blood pressure in patients with CVD [283]. The 2-kg reduction in weight and 0.75 kg/m<sup>2</sup> fall in BMI is consistent with the findings of a recent systematic review of insulin-sensitizing drugs on weight loss in women with PCOS in which a weighted mean difference of 0.68 in BMI was found compared with placebo [284]. The reduction in waist circumference suggests a predominant action on the visceral fat compartment, which others have confirmed using computerized tomography [285]. In keeping with this, in the present trial an increase in adiponectin was noted, which has previously been reported with metformin in overweight women with PCOS [286]. This rise may in itself have contributed to the improvements in vascular function because adiponectin enhances nitric oxide production by endothelial cells with attendant benefits on endothelial function [287].

It was a surprise that insulin resistance as measured by HOMA-IR did not improve with metformin, in contrast to a number of other studies that demonstrate improved insulin action with metformin in women with PCOS [139, 245]. These studies typically employed more sensitive measures of insulin resistance than HOMA-IR, and it is possible that an improvement in insulin resistance with metformin treatment might have been observed had a more robust measure been employed. Nevertheless, it is worth noting that the baseline values of HOMA-IR in this study were relatively low, suggesting only a modest degree of insulin resistance in the trial subjects despite their elevated BMI. Hence, the possibility that

metformin might be exerting its beneficial actions on the vasculature by a mechanism independent of improved insulin sensitivity cannot be entirely discounted.

Metformin was also noted to lower triglyceride levels but did not alter HDL, LDL, or TC. A proatherogenic dyslipidemia, characterized by raised triglyceride levels and reduced HDL concentrations accompanied by increased small, dense LDL particles, is common in women with PCOS [115]. This trial did not undertake any qualitative lipoprotein analysis; hence, an effect of metformin on LDL subclass cannot be excluded, but these findings of reduced triglycerides, although modest, are in agreement with some reports that have shown a reduction with metformin treatment, albeit with large variation among individuals [236, 288]. No changes in testosterone, FAI, or SHBG were observed with metformin therapy, suggesting that the beneficial effects of metformin on vascular function are independent of changes in androgen status. The impact of androgens on vascular function in women with PCOS is controversial, with some studies demonstrating an association of endothelial dysfunction with androgen level [90, 140] and others suggesting a favourable effect of androgens on vascular function [239, 289].

The improvements noted in vascular function raise the question as to how metformin might be exerting its benefits. The crossover design of the present study precluded the use of regression analysis to explore the major contributors to the improved vascular action. However, the magnitude of change (mean difference/SD of the active-placebo differences) for each variable significantly affected by metformin therapy was very similar, suggesting that these were all being influenced by the intervention to a similar degree and hence possibly by the same pathway. It may be speculated that this pathway might involve the key energy sensor AMP kinase (AMPK) [290]. In addition to metformin's ability to activate AMPK in the liver and in muscle, with consequent benefits on enhanced glucose uptake and reduced hepatic glucose output, metformin has also been shown to activate AMPK in the endothelium and in vascular smooth muscle, where it mediates vascular relaxation through the  $\alpha 1$  subunit

in an endothelium-independent manner [291, 292]. These findings may thus explain our observations whereby metformin enhanced endothelium-independent (NTG) as well as endothelium-dependent (salbutamol) vascular responses.

In conclusion, the data presented in this chapter support an important action of metformin in improving vascular function in young overweight women with PCOS, but further studies are needed to confirm these findings and to delineate the potential mechanisms in operation. In particular, this study was limited by the lack of a weight-loss control group; hence, further trials that include this as a control arm are required to fully assess whether metformin therapy has additional benefits on vascular function beyond weight loss alone. Furthermore, overweight, anovulatory women with PCOS may be particularly at risk of insulin resistance and vascular dysfunction. Therefore, trials in normal weight and eumenorrheic subpopulations are also required before these findings can be generalized to all women with PCOS. Additional studies should also explore the potential for additive or synergistic interactions with other agents known to improve vascular function, such as statins, or exercise regimens, which also have the potential to activate AMPK.

## **CHAPTER 6:      GENERAL DISCUSSION**

### **6.1              Background**

Global cardiometabolic risk represents the overall likelihood of developing type II diabetes, cardiovascular disease, or both, due to a cluster of modifiable adverse factors [21]. These include classic risk factors such as smoking, high LDL cholesterol levels, hypertension and elevated blood glucose, in addition to others closely associated with abdominal obesity, such as insulin resistance, low HDL cholesterol, high triglycerides and elevated inflammatory markers [21]. The rationale for the concept of the metabolic syndrome arises from the observation that a clustering of these adverse metabolic and vascular risk factors represents a high-risk group requiring careful attention and treatment following an integrated approach.

Treatment approaches to date have largely been directed at individual traits such as hypertension and dyslipidaemia. However, the pathogenesis of the components of the metabolic syndrome is largely linked to underlying obesity, especially an accumulation of central or visceral adiposity, and insulin resistance. Therefore therapies targeting these factors should help minimise the increasing health burden arising from CVD and type II diabetes attributable to obesity.

### **6.2              Thesis Aims**

The aims of this thesis were to examine the effects of existing (metformin) and novel (CB<sub>1</sub> antagonist) pharmacological agents that target components of the metabolic syndrome using appropriate models of the syndrome *in vivo* (PCOS) and *in vitro* (adipogenesis) by:

1. Evaluating the actions of cannabinoid receptors on proliferation, differentiation and adipokine production in models of *in vitro* adipogenesis.



2. Determining the *in vivo* effects of metformin therapy on arterial stiffness, endothelial function, adipokine profile and insulin sensitivity in young women with PCOS.

It was hypothesised that these agents may exert their benefits not only by improving insulin sensitivity and obesity, but also through indirect mechanisms involving a switch in the adipokine profile.

### **6.3 Current Pharmacological Therapies For The Management Of Obesity**

Obesity trends amongst adults in the UK continue to increase. The National Heart Forum report published in February 2010 predicts that by 2020 the proportion of adults who will be overweight aged 20-65 is 40% for men and 32% for women [293]. The team also predict a 23% rise in the prevalence of obesity-related stroke, a 34% rise in obesity-related hypertension, a 44% rise in obesity-related coronary heart disease and a 98% rise in obesity-related diabetes [293].

Effective weight management requires lifestyle modification to encourage healthy eating habits and increased levels of physical activity to ensure that energy expenditure is at least equal to, if not greater than energy intake. A number of studies including the Diabetes Prevention Programme (DPP) and the Finnish Diabetes Prevention Trial (FDPT) have provided convincing evidence for the benefits of lifestyle interventions facilitating weight loss in the prevention of diabetes [294, 295]. However, such approaches are not always sufficient to achieve and maintain weight loss outside of clinical trial settings. Given the health risks associated with increased adiposity, there is a demand for safe and effective anti-obesity agents to act as an adjunct to lifestyle modification in both promoting and maintaining weight loss, to help improve co-morbidity.

The early drugs used for weight loss were centrally-acting appetite suppressants including amphetamines but these are no longer an option due to their high addiction potential. 5-hydroxytryptamine (5-HT) uptake inhibitors such as fenfluramine have been used in the past as well but have been removed from the market due to an association with pulmonary hypertension and valvular heart disease [296].

Until recently there have only been two drugs available as pharmacological adjuncts for weight loss with license for use in the developed world. Orlistat can cause modest weight loss and acts by inhibiting the absorption of ingested fat within the gastrointestinal tract, though its use can be limited by the side effects of faecal incontinence and interference with the absorption of fat soluble vitamins [297]. Sibutramine, a centrally acting drug that stimulates the sensation of satiety and increases energy expenditure, was the alternative agent. However, in January 2010, the MHRA announced the suspension of the marketing authorisation for sibutramine following a review by the European Medicines Agency (EMA). It was determined that sibutramine's cardiovascular risks outweigh its benefits, with emerging evidence to suggest an increased risk of non-fatal heart attacks and strokes with this medicine [298].

A third agent, the first-in-class CB<sub>1</sub> receptor blocker drug, rimonabant was available from 2006 to 2008, and represented a novel approach targeting both central and peripheral sites in the regulation of weight and energy homeostasis. However, due to safety concerns (detailed below) the drug is no longer available but the endocannabinoid system still remains a promising therapeutic target for further research and development, and will be discussed in greater detail in the following section.

## **6.4 The ECS As A Therapeutic Target In The Management Of Obesity & The Metabolic Syndrome**

### **6.4.1 The Role Of CB<sub>1</sub> Receptors In The Regulation Of Metabolism**

In one of the earliest animal studies examining the effect of CB<sub>1</sub> receptor blockade on appetite suppression by Colombo and colleagues, chronic administration of rimonabant resulted in a transient reduction in food intake as well as a longer lasting reduction in body weight, suggesting a beneficial metabolic effect of this treatment independent of energy intake [299]. This has been supported by further observations in CB<sub>1</sub> receptor-deficient mice who exhibit hypophagia and leanness compared to their wild-type littermates, and also maintained a lean phenotype in comparison to the wild-type mice despite identical paired feeding, indicating possible altered energy expenditure and metabolism [59]. Diet induced obesity in mice is accompanied by dyslipidaemia, insulin resistance and fatty liver, and can thus be considered a murine model of the metabolic syndrome [21]. Once daily treatment with rimonabant at 10 mg/kg for forty days, has been shown to result in a 50% reduction in adipose tissue mass in mice with diet-induced obesity [300]. Furthermore, CB<sub>1</sub> receptor knockout mice are resistant to diet induced obesity and maintain a more favourable metabolic profile when compared to the wild-type mice who do become obese on an identical high calorie diet [58].

The human clinical trials of rimonabant in obesity (RIO) have been divided into four main groups: RIO-North America [79], RIO-Europe [221], RIO-Lipids [78] and RIO-Diabetes [80]. In these studies up to two years treatment with rimonabant resulted in significant weight loss that was also associated with improvements in the metabolic profile including lower plasma TG, increase in HDL, reductions in the elevations of plasma insulin and leptin, and an increase in adiponectin concentration [78-80, 221]. An interesting observation is that the majority of the weight loss occurred during the first year of treatment whereas improvements in lipid and glycaemic profiles continued even in the second year, and thus may not be attributable to

weight loss alone [221, 301]. These findings support an additional role of the ECS in peripheral sites, including adipose tissue, to produce beneficial metabolic effects beyond weight loss in obese patients.

#### **6.4.2            *In Vitro* Studies Supporting A Role Of Peripheral CB<sub>1</sub> Receptors**

The relevance of the ECS to adipocyte physiology is supported by studies, including the experiments described in this thesis, demonstrating CB<sub>1</sub> receptor expression in pre-adipocytes which changes dynamically through adipogenesis, becoming more prominent in mature adipocytes and is closely associated with PPAR $\gamma$  receptor profiles during adipocyte differentiation [76, 207]. In keeping with these findings, Bouboula et al demonstrated PPAR $\gamma$  transcriptional activation in the presence of endogenous endocannabinoids in murine 3T3-L1 though this remains to be confirmed in human *in vitro* models [302]. Perhaps more interesting is the observation that CB<sub>1</sub> receptors are differentially expressed in WAT derived from different depots [222]. The current studies confirmed a more significant effect of CB<sub>1</sub> receptor antagonism in cells originating in omental adipose tissue, thus modifying an important adverse cardiovascular risk marker. Similarly, higher levels of the endocannabinoid 2-AG have been detected in the intra-abdominal visceral, but not subcutaneous fat of obese subjects [303], and an increase in circulating 2-AG has been shown to positively correlate with important cardiometabolic risk factors, such as BMI, waist circumference, fasting plasma triglyceride and insulin levels, low HDL cholesterol, and adiponectin levels [304].

CB<sub>1</sub> activation in adipose tissue is not limited to promoting cell proliferation but also acts to increase energy storage. Endocannabinoids stimulate lipogenesis by inducing triglyceride accumulation through the inhibition of adenylate cyclase and the consequent reduction of lipolysis, and via activation of lipoprotein lipase to provide exogenous fatty acids for the adipocytes [59, 300]. In addition, endocannabinoids increase the expression and activity of

enzymes involved in fatty acid and triglyceride biosynthesis thus promoting *de novo* lipogenesis [59]. CB<sub>1</sub> activation in adipocytes also modulates insulin signalling and glucose uptake in order to increase energy storage and modify insulin sensitivity [303]. Therefore it would be interesting to expand the *in vitro* studies detailed in the previous chapters to examine the effects of CB<sub>1</sub> receptor blockade upon energy storage within adipose tissue and to determine if a differential effect exists between WAT derived from different fat depots.

Adipose tissue is now recognised as an endocrine organ capable of secreting a number of adipokines which influence adipocyte physiology. The present studies have illustrated an increase in adiponectin production arising from CB<sub>1</sub> antagonism treatment in *in vitro* models of adipogenesis using human primary cultures, which may in part explain the changes in insulin sensitivity observed with rimonabant therapy. Further studies looking at the effects upon other adipokines including visfatin, leptin and IL-6, for example, may improve our understanding of the mechanisms by which CB<sub>1</sub> antagonists exert their metabolic effects.

Recent studies have found that the administration of CB<sub>1</sub> antagonists in diet-induced obese Wistar rats induces an increase in energy expenditure, thus identifying another possible peripheral mechanism contributing to a reduction in adipose mass [305]. This is thought to be mediated by CB<sub>1</sub> antagonist-mediated generation of futile, or substrate, cycles, where two metabolic pathways (in this instance glycogen synthesis and glycolysis) run simultaneously in opposite directions resulting in the dissipation of energy in the form of heat [300]. Although in the studies presented in this thesis CB<sub>1</sub> modulation did not alter UCP-1 expression, a marker of BAT, Perwitz et al have highlighted a rimonabant-induced transdifferentiation in white adipocytes towards a mitochondria-rich brown fat phenotype [209]. CB<sub>1</sub> receptor antagonist treatment may therefore also lead to an eventual increase in energy expenditure via mitochondrial thermogenesis by increasing brown-type adipocytes. Though the presence of BAT has recently been described in adult humans [181, 182], the functional significance is not yet well established and still demands further study.



CB<sub>1</sub> receptor blockade has also been shown to increase mitochondrial biogenesis in cultured white adipocytes by inducing the expression of eNOS [306] and is accompanied by the prevention of high-fat diet-induced fat accumulation, without concomitant changes in food intake [306]. A possible mediator of these functions may be the AMPK system. Endocannabinoids decrease AMPK activity in adipose tissue, contributing to a rise in adiposity and lipogenesis and resulting in decrease in energy expenditure, and induction of AMPK activity has been found to increase mitochondrial content in adipocytes. [306]. Thus, the anti-obesity effects associated with CB<sub>1</sub> blockade may also result from enhanced  $\beta$ -oxidation of free fatty acids elicited by AMPK activation and by eNOS-dependent mitochondrial biogenesis.

The aforementioned studies and the experiments described in this thesis support a significant role for the ECS in the periphery in targeting obesity and thus the metabolic syndrome. This is of importance when considering the future of CB<sub>1</sub> antagonist therapy given the adverse events associated with the first generation drug in this class, rimonabant which have largely been attributable to central CB<sub>1</sub> blockade.

### **6.4.3 Adverse Events Associated With Rimonabant**

The reduction in weight and changes in metabolic parameters observed with rimonabant therapy have unfortunately been accompanied by a significant side effect profile. Pooled data obtained from analyses of the RIO studies following 1 year of treatment with rimonabant highlights adverse effects which can be broadly categorised into three main groups: psychiatric symptoms (1.9% vs. 0.8% in treatment group vs. placebo), gastrointestinal disturbances predominantly in the form of nausea (1.4% vs. 0.1%), and neurological alterations including headaches and vertigo [301]. Altogether, 13.8% of patients receiving 20 mg rimonabant daily discontinued treatment in comparison to 7% of those receiving placebo [301].

In October 2008, the EMA recommended suspending its marketing authorisation for Sanofi-Aventis's first-in-class CB<sub>1</sub> receptor blocker rimonabant, due to an increased risk of psychiatric side-effects including severe depression, anxiety and stress disorders which outweighed the potential benefits [307]. This led to the decision by Sanofi-Aventis in November 2008 to withdraw rimonabant from the market world-wide and discontinue clinical trials of rimonabant for all clinical indications [308]. This move was followed closely by termination of development programmes and clinical trials of other CB<sub>1</sub> receptor blocking compounds by competing pharmaceutical companies including Pfizer (otenabant) and Merck (taranabant) [309].

Previous studies have shown that up to 48% of obese individuals exhibit features of depression and that obese women in particular are 20% more likely to have experienced suicidal ideation and 23% more likely to have actually attempted suicide in comparison to their non-obese counterparts [310]. Whilst in clinical trial settings subjects are rigorously screened for such conditions, it is not clear how robustly this is undertaken in general clinical practice, and may have also contributed to the increase in mood-related adverse effects. Since overweight individuals represent one of the target populations for this class of drugs, any future drug development will need to address the potential for psychiatric disturbance.

However, abandoning the ECS as a potential therapeutic target in weight management may be a little premature, and recently some efforts have been made to circumvent the psychiatric side-effects currently limiting the use of this class of drugs. This has largely focused on targeting the ECS in peripheral tissues which may still preserve some of the metabolic benefits described in the previous section.

#### 6.4.4 Future Drug Development Targeting The ECS

The initial approach towards modulating the ECS to affect weight has predominantly focused on targeting central CB<sub>1</sub> receptors with the aim of appetite suppression [299, 311], though later studies, including the experiments described in this thesis, have supported the additional role of peripheral mechanisms contributing to the reduction in adiposity [207, 225]. Initially drug development included optimising the compound for high brain penetration and antagonism of central CB<sub>1</sub> receptors, thus also contributing to the CNS-mediated psychiatric side-effects. New strategies now include developing agents that preferentially target peripheral CB<sub>1</sub> receptors located within, for example, adipose tissue, liver, muscle and the gastrointestinal tract, with the aim of maintaining the peripherally-mediated beneficial effects whilst minimising the central adverse consequences.

Pavon et al have developed a novel CB<sub>1</sub> receptor antagonist, LH-21, a triazol derivative with poor penetration into the central nervous system [312]. When given acutely it decreases food intake and enhances the anorectic actions of oleoylethanolamide, a feeding suppressant lipid that acts on peripheral sensory terminals, in a similar way to rimonabant [312]. However, unlike rimonabant, chronic administration of LH-21 (3 mg/kg) reduces feeding but does not improve hypertriglyceridaemia or hypercholesterolaemia; nor does it reduce liver fat deposits in Zucker rats suggesting that antagonism of central CB<sub>1</sub> receptors may be necessary for the metabolic benefits of CB<sub>1</sub> blockade, but not for the appetite reduction [312].

Another scientific group working at Jenrin Discovery have developed two CB<sub>1</sub> receptor antagonists, JD 2114 and JD 5006 whose structures are yet to be disclosed, that have been chemically modified to possess little potential to cross the blood-brain barrier [313]. Both these substances have been shown to have high affinity for CB<sub>1</sub> receptors (< 30 nM) with greater selectivity versus CB<sub>2</sub> receptors [313]. Animal studies have been conducted with these compounds using once daily oral administration at doses of 10 mg/kg in diabetic and

dyslipidaemic obese mice, and compared to control populations treated with rimonabant. Significant weight loss was observed with all these substances as well as a reduction in fasting blood glucose, insulin and triglycerides within seven days of treatment thus demonstrating beneficial effects of CB<sub>1</sub> receptor antagonism by targeting peripheral receptors, though further work is still required to establish efficacy and safety in humans [313].

An alternative avenue that is being pursued by some research groups focuses on targeting a binding site on the CB<sub>1</sub> receptor by developing ligands that act as allosteric inhibitors of agonist signalling efficacy. One of the first *in vivo* reports using this class of agents describes the use of PSNCBAM-1, a novel allosteric antagonist at the CB<sub>1</sub> receptor, which in an acute rat feeding model decreased food intake and body weight [314]. Another technique in development is to bypass the CB receptors and modulate the endocannabinoid system by different means. One such approach involves targeting the enzyme fatty acid amide hydrolase, thus affecting the breakdown of endogenous endocannabinoids [315]. Whether these approaches will result in weight reduction and improvements in metabolic profiles in humans, whilst maintaining a satisfactory risk-benefit ratio, remains to be determined.

## **6.5 Metformin In PCOS – An *In Vivo* Model Of The Metabolic Syndrome**

PCOS is the commonest endocrinopathy affecting women of reproductive age and a significant proportion of the affected women fulfil the criteria for the metabolic syndrome, a finding confirmed in the clinical trial reported in this thesis [316]. PCOS therefore represents a useful model to evaluate treatment effects upon cardiometabolic risk. In the presented clinical trial, metformin reduced arterial stiffness and improved endothelial function in young women with PCOS [317]. The improvements noted in vascular function do however raise the question as to how metformin might be exerting its beneficial effects.

Metformin is an oral biguanide and the most commonly prescribed insulin sensitiser used for the treatment of type II diabetes. Its principal metabolic action is thought to be mediated via suppression of hepatic gluconeogenesis and lipogenesis while improving peripheral glucose uptake and glycolysis [138]. Increasing recognition of its pleiotropic actions on a variety of tissues including the liver, adipose tissue, skeletal muscle and endothelium, have led to recent interest in expanding the therapeutic potential of this old drug originally used only for the management of established diabetes [138].

#### **6.5.1 Action Of Metformin In Adipose Tissue**

Although adipose tissue is not thought to be the principal site of action of metformin, there is evidence for modest effects on this tissue. There is conflicting evidence regarding the effect of metformin therapy on insulin-mediated glucose transport in adipose tissue [318, 319], but there are data supporting its effects on adipose tissue lipolysis. In primary rat adipocytes stimulated with TNF $\alpha$  and/or high glucose concentrations, metformin treatment inhibits agonist-induced lipolysis [320]. The resulting reduction in available systemic FFAs could also contribute to the insulin sensitising effects of metformin.

In experiments using murine 3T3-L1 cells, metformin has been associated with counteracting adipose tissue expansion via a direct inhibition of adipogenesis through AMPK-dependent stimulation of FA oxidation and inhibition of lipogenesis [321]. This observation may in part explain the weight loss noted in the clinical trial presented in this thesis via a mechanism independent of metformin's actions upon insulin sensitivity.

Metformin may also affect adipose tissue endocrine function by modulating adipokine synthesis and secretion [138]. Leptin deficiency is associated with hyperphagia, a reduction in energy deficiency and morbid obesity [322], and a positive correlation between insulin resistance and hyperleptinaemia has been noted in women with PCOS [323]. In a brown



adipocyte model, metformin treatment resulted in a dose-dependent inhibition of leptin secretion through the stimulation of MAPK [324]. Adiponectin is an insulin-sensitising adipokine secreted exclusively from adipocytes, whilst resistin has been implicated in the pathogenesis of obesity and type II diabetes [325]. Lewandowski and colleagues have demonstrated a reciprocal correlation between adiponectin and resistin independent of insulin resistance in PCOS, though the role of the resistin in PCOS and cardiometabolic risk in this group is not yet fully understood [326, 327].

### **6.5.2 Action Of Metformin In The Vascular Endothelium**

The endothelium is a major target of insulin and endothelial function is considered a marker of insulin sensitivity in the vasculature, thus insulin plays an important role in linking metabolic and cardiovascular pathophysiology [138]. Treatment with insulin sensitising agents such as metformin have been associated with improvements in endothelial function [240]. However, metformin may also exert direct and beneficial effects on the endothelium independent of glucose lowering and insulin sensitisation as suggested by the improvements in vascular function noted in this thesis without a significant change in insulin sensitivity. In addition to metformin's ability to activate AMPK in the liver and in muscle, with consequent benefits on enhanced glucose uptake and reduced hepatic glucose output, metformin has also been shown to activate AMPK in the endothelium and in vascular smooth muscle, where it mediates vascular relaxation through the  $\alpha 1$  subunit in an endothelium-independent manner [291, 292]. Additionally, AMPK may stimulate FA oxidation thereby reducing FFAs, and inhibit glyceride synthesis and thus alleviate endothelial lipotoxicity, a known factor contributing to increased superoxide production and impaired NO activity [328]. Further work is however still required to ascertain these underlying mechanisms.

### **6.5.3 Direct Effect Of Adiponectin On Endothelial Function**

Levels of adiponectin inversely correlates with weight, and a reduction in serum adiponectin is closely related to peripheral arterial endothelial dysfunction [329], and is considered to be an independent predictor of cardiovascular disease [330]. Hypoadiponectinaemia observed with weight gain is thus hypothesised to be a potential underlying regulator for the impaired vascular function associated with obesity. A recent study by Deng et al provided evidence that the diminished ability of endothelium-dependent vasodilation in high-fat diet induced obese rats-derived aortic segments can be partially restored by incubation with adiponectin [331]. This process not only improved endothelium-dependent relaxation but also increased total NO production as well as enhanced eNOS activity thus supporting a role for a direct endothelial effect of adiponectin [331].

A significant rise in serum adiponectin concentration associated with metformin therapy was observed in the trial presented in the previous chapter, and appeared independent of the insulin sensitising effects of metformin. This change in the adipokine profile in the PCOS subjects could therefore underlie some of the effects noted with metformin therapy. Similarly, adiponectin has also been shown to activate AMPK and thereby stimulate FA oxidation and glucose uptake thus improving endothelial function as described above [332].

### **6.5.4 Future Studies**

This discussion has concentrated on the potential effects of pharmacotherapy with metformin to improve cardiometabolic risk. What is not clear however is whether metformin produces these additional effects beyond weight loss alone. Future studies are required to compare the effects of metformin therapy with and without lifestyle modification with a control arm of subjects managed with lifestyle change alone using a randomised, double-blind, placebo-

controlled parallel group design trial. This would help clarify the effects of weight loss alone and direct effects of metformin in improving cardiometabolic risk.

## **6.6 Conclusion**

Owing to the long-term health risks associated with increased adiposity and the limited efficacy of existing anti-obesity agents, there is an urgent need for further development of alternative therapeutic options to serve as an adjunct to diet and exercise to promote weight loss, and thus reduce the risk of developing obesity-related illnesses. This thesis has described benefits with both novel (CB<sub>1</sub> antagonism) and existing (metformin) treatment approaches targeting models of the metabolic syndrome, though further work is still required to elucidate the mechanism underlying the observed effects. Although the first CB<sub>1</sub> receptor antagonist rimonabant carried an unacceptable psychiatric risk profile, this should not deter future research in this field since the benefits observed with this drug and preliminary data emerging from the newer generation of agents in this class indicate that there is still potential to more selectively target the ECS in the management of obesity, and thus the metabolic syndrome. Both the *in vitro* and *in vivo* studies have demonstrated an increase in adiponectin, either by direct effect on adipose tissue (CB<sub>1</sub> antagonist studies) or associated with accompanying weight loss (metformin effect in PCOS). Treatments targeting a switch in the adipokine profile as the therapeutic goal may therefore represent a new approach to addressing global cardiometabolic risk associated with the metabolic syndrome. Furthermore, the AMPK pathway is also emerging as a key player in regulating energy balance, and both CB<sub>1</sub> antagonists and metformin, as well as adipokines such as adiponectin exert metabolic effects at least in part through this system, providing yet another potential future target for treatment of the metabolic syndrome.

## **Appendix 1**

### **PATIENT INFORMATION SHEET**

Version 2 May 2006

#### **1. Title of study**

Physiological and pharmacological modulation of adipose/connective tissue remodelling.

#### **2. Introduction**

You are being invited to take part in a research study. Before you decide whether you wish to become involved it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with others if you wish.

Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

#### **3. What is the purpose of this study?**

A number of hormones can change the amount of fat that is stored in the body. Our research group is interested in studying the effects of some of these hormones, including thyroid hormones, growth hormone and a hormone called DHEA which is made in the adrenal gland, on the function of fat cells in the laboratory. Not all fat reacts in the same way. In some parts of the body hormones may cause fat to build up while in others it may break down.

In order for us to fully understand how these hormones affect fat cells, we are asking people to donate a small sample of their fat to us for our research studies. This sample will be obtained during your planned operation. We will measure how the cells grow and work in response to treatment with hormones.

We are also interested in studying whether changes in genes controlling growth hormone levels and function can have an effect on fat cells. In order for us to test this we will also ask you to donate a blood sample for us to analyse your growth hormone genes.

#### **4. Why have I been chosen?**

You have been chosen for this study as your surgeon has identified you as someone who will be undergoing an operation soon. A total of 100 patients will be studied.

#### **5. Do I have to take part?**

No. It is up to you to decide whether or not to take part. If you do, you will be given this information sheet to keep and be asked to sign a consent form. You are still free to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision not to take part, will not affect the standard of care you receive. If you withdraw your permission after we have obtained your samples, any stored blood or tissue samples that can still be identified as yours will be destroyed if you wish.

#### **6. What will happen to me if I take part?**

A sample, about the size of one sugar cube, will be taken from the fat under your skin during your planned surgery. If you are having abdominal surgery we would also plan to remove a further sample of fat of the same size from the fat tissue that sits around your bowel (called

omental or visceral fat). This procedure will not affect your operation scar. The fat samples would be used in laboratory experiments for further study. During these we would break up the fat and separate it into different cell types. We will measure how the cells grow and work in response to treatment with hormones.

The tests to examine your growth hormone genes (called GH1 and GHR) would involve us taking an extra sample of blood (equivalent to roughly two tablespoons). We would plan to take this sample while you are under anaesthetic during your operation so that you do not feel any discomfort.

#### 7. What do I have to do?

There are no lifestyle or dietary restrictions and you can continue your daily activities normally. There will be no changes to the way in which you need to prepare for your operation and your surgical team will fully instruct you on this as normal. With your permission we will check with you and in your records on your previous medical health in case you have a medical condition or are taking any medication which may affect our ability to analyse your fat cells.

#### 8. What are the possible disadvantages of taking part?

Occasionally patients may experience discomfort (temporary pain, swelling, bruising and rarely infection) caused by the collection of blood. Removing a small sample of fat from under the skin or from around the bowel is unlikely to cause any additional complications to those which could be expected from your type of operation.

The genetic blood sampling will test for variation in your growth hormone genes. These changes occur extremely commonly in the general population and can be seen as a variation of normal. The samples will be fully anonymised and the results of these genetic tests will have no implications for you in terms of inherited risk, reproductive decisions or insurance status.

#### 9. What are the possible benefits of taking part?

The study may provide us with important information in identifying how hormones affect fat cell function. While there are unlikely to be any direct benefits to you, we hope that the results of these studies may help in the future treatment of patients with weight-related conditions such as obesity and diabetes.

#### 10. What if there is a problem?

If you have a concern about any aspect of this study, you should ask to speak with the researchers who will do their best to answer your questions (Dr Aled Rees 02920 745002). If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints Procedure. Details can be obtained from the hospital.

You are unlikely to be harmed as a result of taking part in this research project, but if you are you should be aware that there are no special compensation arrangements. If you are harmed due to someone's negligence, then you may have grounds for a legal action but you may have to pay your legal costs. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you have been approached or treated during the course of this study, the normal National Health Service complaints mechanisms should be available to you.



**11. Will my taking part in this study be kept confidential?**

All information which is collected about you during the course of the research will be kept strictly confidential. Any information about you which leaves the hospital will have your name and address removed so that you cannot be recognised from it.

With your permission your GP will be informed of your participation in this study.

If you join the study, some parts of your medical records and the data collected for the study may be looked at by the research team, by representatives of regulatory authorities and by authorised people from the Cardiff and Vale NHS Trust to check that the study is being carried out correctly. All will have a duty of confidentiality to you as a research participant and nothing that could reveal your identity will be disclosed outside the research site. Our procedures for handling, processing, storage and destruction of data are compliant with the Data Protection Act 1998.

**12. What will happen to any samples I give?**

After the sample of fat has been obtained at surgery the research doctors will immediately freeze this sample and store it for later analysis, or break it up and grow the fat cells in the laboratory. The blood samples will be used to test your growth hormone genes. Both the fat and blood samples will be stored securely in the Section of Endocrinology at the University Hospital of Wales (Room 168, 2<sup>nd</sup> Floor). The research investigators, Dr Aled Rees and Dr Marian Ludgate, will act as the day-to-day custodians for these samples. Only Dr Rees and Dr Ludgate, and immediate members of their research team will have access to the use of these samples. In addition, all the samples will be coded and anonymised such that your personal details will not be identifiable. We propose to store the fat and genetic samples for up to 15 years. After this time the samples will be destroyed by incineration.

It is possible that we may wish to use your fat sample for future studies looking at how other hormone systems could affect fat cell function. If this is the case then a further application will be made to the Research Ethics Committee for consideration. Similarly, we may wish to conduct genetic studies on genes other than the growth hormone system in the future. If this is the case then this will also be submitted to an Ethics Committee for consideration. The results of these tests done for research purposes are unlikely to have any direct clinical implications for you. It is possible that these studies may be carried out by researchers other than Dr Rees or Dr Ludgate, including researchers working for commercial companies.

There is little prospect that the current studies will have any commercial significance but if future information from our research using your tissue samples shows any likelihood of commercial benefit, such as the development of a new treatment or medical test, then you would not benefit financially.

**13. What will happen to the results of the research study?**

The results of the research study will be prepared for publication in appropriate medical journals together with presentation at medical conferences. Patients participating in the study will be able to obtain a copy of the results after they have been published in the relevant journal(s). Patients will not be identified in any report/publication.

**14. Who is organising and funding the research?**

The study is being organised by Dr Aled Rees and Dr Marian Ludgate in the Section of Endocrinology. Funding for the study is provided from the Section of Endocrinology and the doctors conducting the research are not being paid for including and looking after patients in the study, nor will they be able to sell for profit any samples that are collected.

**15. Who has reviewed the study?**

The study has been reviewed by the Cardiff and Vale NHS Trust Research and Development Office and by the South East Wales Local Research Ethics Committee.

**16. Contact for further information**

Should you have any further questions or queries regarding this research study, then please do not hesitate to contact me on 029 20745002. I can also be contacted via email (reesda@cf.ac.uk).

Thank you for considering taking part and taking time to read this sheet.

Aled Rees

Principal Investigator/Senior Lecturer in Endocrinology

You will be given a copy of this Patient Information Sheet and a signed consent form to keep

## **Appendix 2**

### **CONSENT FORM**

Version 2, May 2006.

**Thank you for reading the information about our research project. If you would like to take part, please read and sign this form.**

Patient Identification Number for this study:

**Title of project:** Physiological and pharmacological modulation of adipose/connective tissue remodelling

**Name of researchers:** Dr Aled Rees and Dr Marian Ludgate

**Contact details for research team:** Centre for Endocrine and Diabetes Sciences, University Hospital of Wales, Heath Park, Cardiff CF14 4XN. Telephone: 02920 742182.

**Please initial boxes**

1. I have read the attached information sheet on this project, dated May 2006 (version 2), and have been given a copy to keep. I have been able to ask questions about the project and I understand why the research is being done and any risks involved.

☐

2. I agree to give a sample of fat for research in this project. I understand how the sample will be collected, that giving a sample for this research is voluntary and that I am free to withdraw my approval for use of the sample at any time without giving a reason and without my medical treatment or legal rights being affected.

☐

3. I give permission for someone from the research team to look at my medical records to get information on my previous medical health. I understand that the information will be kept confidential.

☐

4. I understand that I will not benefit financially if this research leads to the development of a new treatment or medical test.

☐

5. I know how to contact the research team if I need to, and how to get information about the results of the research.

☐

6. I consent to my GP being informed of my participation in the study.

☐

**7. Consent for storage and use in possible future research projects**

I agree that the sample I have given and the information gathered about me can be stored by Dr Aled Rees/Dr Marian Ludgate at the Centre for Endocrine and Diabetes Sciences, School of Medicine, Cardiff University for possible use in future projects, as described in the attached information sheet. I understand that some of these projects may be carried out by researchers other than Dr Aled Rees/Dr Marian Ludgate who ran the first project, including researchers working for commercial companies.

☐**8. Consent for genetic research**

**A.** I give permission for growth hormone 1 (GH1) and growth hormone receptor (GHR) genotyping to be carried out on the samples I give, as part of this project

☐

**B.** I understand that the project/future research using the samples I give may include genetic research aimed at understanding the genetic influences on fat cell regulation but that the results of these investigations are unlikely to have any implications for me personally.

☐

\_\_\_\_\_  
Name of patient  
(BLOCK CAPITALS)

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Name of person taking consent  
(if different from researcher)

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Name of Researcher

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

☐☐

Would you like to be sent information about the progress of the project?

Yes

No

**Thank you for agreeing to participate in this research**

1 copy for patient; 1 for researcher; 1 to be kept with hospital notes

## **Appendix 3**

### **EFFECTS OF METFORMIN ON VASCULAR FUNCTION IN POLYCYSTIC OVARY SYNDROME**

#### **PATIENT INFORMATION SHEET (Version 3 May 2006)**

##### *1. Title of study*

A randomised, double-blind, placebo-controlled crossover trial of the effects of metformin therapy on vascular and metabolic risk in young women with polycystic ovary syndrome.

##### *2. Introduction*

You are being invited to take part in a clinical research study. Before you decide whether you wish to become involved it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with others if you wish. Please do not hesitate to ask us if there is anything that is not clear or if you would like more information. Take time to consider whether or not you would wish to take part.

Thank you for reading this.

##### *3. What is the purpose of this study?*

Polycystic ovary syndrome (PCOS) is the commonest hormone condition in women of reproductive age, affecting up to 10% of the premenopausal population. In addition to its well-recognised effects on weight gain, excessive hair growth and infertility, it is becoming increasingly apparent that PCOS is associated with long-term health risks including diabetes and arterial (blood vessel) disease, both of which are related to impaired action of insulin throughout the body, also known as insulin resistance. Metformin, a drug which acts by improving the action of insulin in the body, is helpful in regularising the menstrual cycle in such patients and restoring fertility.

There have not been many studies on the effects of metformin on the function of blood vessels in PCOS, but this may be an important area to study as research in the middle-aged and elderly without PCOS, has shown that insulin resistance is associated with an increased risk of blood vessel dysfunction, and thus heart disease. Other studies have shown that treating insulin resistance with metformin improves the function of their blood vessels, and therefore reduces this risk.

It is unclear at present whether metformin is able to reduce the risk of diabetes and blood vessel disease in PCOS. We aim to address this question by studying the effects of short-term metformin therapy on blood vessel function and insulin sensitivity in a group of women with PCOS.



This study will involve four visits to the Endocrinology department at the Heath hospital and will last for a total of 32 weeks.

#### *4. Why have I been chosen?*

You have been chosen for this study as your endocrinologist has identified you as having PCOS, and you have not been on any treatment for this in the recent past. A total of 36 patients will be studied.

#### *5. Do I have to take part?*

It is up to you to decide whether or not to take part. If you decide to take part you will be given this information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision not to take part, will not affect the standard of care you receive.

#### *6. What will happen to me if I take part?*

The study will last for a total of 32 weeks and you will be asked to attend the Clinical Investigation Unit at the Henry Wellcome Biomedical Sciences building on 4 separate occasions. Each of these visits will last approximately 3 hours.


In order to know whether metformin changes blood vessel function we need to make comparisons. Metformin will be compared in this study with a placebo tablet. A placebo is a dummy treatment such as a pill which looks like the real thing but is not. It contains no active ingredient.

People will be put into two groups and then compared. The groups are selected by a computer which has no information about the individual i.e. by chance (or randomised). Half the patients will be put into group A and will receive metformin treatment for 12 weeks. The other half will be put into group B and will receive placebo treatment. These groups will be compared.

Neither you nor your doctor will know in which treatment group you are (although your doctor is able to find out if he/she needs to do so). This is to make sure that the results cannot be influenced in any way.

At the end of 12 weeks of treatment you will have a break of 8 weeks before taking the other treatment for a further 12 weeks (placebo treatment if you received metformin for the first part of the study and metformin if you received placebo initially). The break of 8 weeks between treatments will ensure that the first drug is cleared from your body before you start the new treatment.

A summary of what will happen and when the study visits will take place is shown in the following flow chart.



On each visit the measurements performed are designed to measure the stiffness of your blood vessels. The techniques that we use are completely painless and 'non-invasive'. The main equipment we use is called a 'Sphygmocor' machine. This consists of a small pencil-like probe placed over the wrist, which measures the waveform of the pulse. During the measurements you will also be asked to take a puff of a salbutamol inhaler (like that used in asthma) and a GTN tablet under your tongue (like that used in angina). Both these drugs act to change the shape of the pulse waveform that we measure. Both drugs are safe and are unlikely to produce any side effects although you may experience a headache and flushing after the GTN.

During each visit we will also take blood samples (approximately three tablespoons) to check your hormones, cholesterol, insulin, clotting factors and CRP (a non-specific marker of inflammation in the body). As well as this we take measurements such as your height, weight, and blood pressure.

We will also require you to have a pregnancy test at each study visit before carrying out the above measurements.

If you wish then we will be able to reimburse any travelling expenses / car parking fees incurred while attending for a study visit.

## 7. What do I have to do?

It is important that you take your regular medication in the normal way without altering the dose or timing of these during the course of the study. You should inform us of any dose adjustments. You will be asked to take the study medication regularly for the duration of the

study. The tablets will be taken once a day for the first week, twice a day for the second week and then three times a day for the next ten weeks during each cycle of treatment.

There are no lifestyle or dietary restrictions and you can continue your daily activities normally. We request that you report any illnesses to us as they may influence the timing of the test visits.

You should inform us immediately if you become pregnant.

For each of the study visits, we ask that you attend the Clinical Investigation Unit at 8 o'clock in the morning having fasted from midnight the previous night. You can drink water freely.

#### *8. What is the drug that is being tested?*

Metformin is a drug that is usually used to treat diabetes, but many patients with PCOS are now taking this treatment on a regular basis. It acts by improving the action of insulin in the body and in PCOS, is helpful in restoring menstruation and fertility. The drug comes in tablet form and we will provide you with a card to carry explaining the details of this trial. You should carry this with you at all times.

#### *9. What are the side effects of Metformin?*

Metformin is a widely used drug and most patients tolerate it well, though some will experience gastrointestinal side effects such as nausea, vomiting, diarrhoea and abdominal pain. This is usually transient and we aim to minimise this by building up the dose gradually over the first three weeks of treatment. The side effects can also be reduced by taking the medication with, or immediately after food. You will be told if any new side effect is found as a result of this study or any other studies using metformin.

If you become in any way concerned you should contact Dr Neera Agarwal on telephone number 02920 748251.

#### *10. What are the possible disadvantages and risks of taking part?*

Metformin can rarely cause a low level of acidity in the blood, but this tends only to be in people whose liver, kidneys, or heart do not work properly. Other than possible discomfort (temporary pain, swelling, bruising and rarely infection) caused by the collection of blood, no other side effects are anticipated from the study procedures.

The risks to an unborn human foetus or a breastfed child from metformin are not fully known. Women who are pregnant or breastfeeding a child may therefore not participate in this trial, neither should women who plan to become pregnant during the study. All women will be asked to have a pregnancy test at each study visit. Women who could become pregnant must use an effective contraceptive during the course of this study. We would request that barrier methods are used, as the oral contraceptive pill and implantable contraceptives may influence some of the measurements we are taking. Any woman who finds that she has become pregnant while taking part in the study should immediately tell her research doctor.

*11. What are the potential benefits of taking part?*

Some patients experience restored menstruation and fertility, and we hope to demonstrate improved blood vessel function. However, this cannot be guaranteed. The information we get from this study may help us to treat future patients with PCOS better.

*12. What if new information becomes available?*

Sometimes during the course of a research project, new information becomes available about the drug that is being studied. If this happens, your research doctor will tell you about it and discuss with you whether you want to continue in the study. If you decide to withdraw, your research doctor will make arrangements for your care to continue. If you decide to continue in the study you will be asked to sign an updated consent form.

Also, on receiving new information your research doctor might consider it to be in your best interests to withdraw you from the study. He/she will explain the reasons and arrange for your care to continue.

*13. What happens when the research study stops?*

If you feel you would wish to continue metformin therapy at the end of the study you will be able to discuss this with your Endocrinologist.

*14. What if something goes wrong?*

This study is being indemnified by Cardiff University. If you are harmed by taking part in this research project, there are no special compensation arrangements. If you are harmed due to someone's negligence, then you may have grounds for a legal action but you may have to pay for it. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you have been approached or treated during the course of this study, the normal National Health Service complaints mechanisms should be available to you.

*15. Will my taking part in this study be kept confidential?*

All information which is collected about you during the course of the research will be kept strictly confidential. Any information about you which leaves the hospital will have your name and address removed so that you cannot be recognised from it. With your permission your GP will be informed of your participation in this study. With your permission we may also look at sections of your medical notes which are relevant to the research study.

*16. What will happen to the results of the research study?*

The results of the research study will be prepared for publication in appropriate medical journals together with presentation at medical conferences. Patients participating in the study will be able to obtain a copy of the results after they have been published in the relevant journal(s). Patients will not be identified in any report/publication. Patients will be able to discover which arm of the study they were in if they so wish, but only after the study has been completed in its entirety.

*17. Who is organising and funding the research?*

The study is being organised by Dr Aled Rees in the Section of Endocrinology (the Principal Investigator) and Dr Neera Agarwal (Research Registrar). Funding for the study is provided from the Royal College of Physicians UK, and the Section of Endocrinology in the Heath hospital. The doctors conducting the research are not being paid for including and looking after patients in the study.

*18. Who has reviewed the study?*

The study has been reviewed by the Cardiff and Vale NHS Trust Research and Development Office and by the South Wales Research Ethics Committee.

*19. Contact for further information*

Should you have any further queries regarding this research study, then please do not hesitate to contact me on 02920 748251 or 07816 888636, or Dr Aled Rees on 02920 742309. You can also contact me via e-mail on [neeraagarwal@yahoo.co.uk](mailto:neeraagarwal@yahoo.co.uk)

Thank you for considering taking part in this study.

Dr Neera Agarwal  
Clinical Research Fellow in Endocrinology

You will be given a copy of this Patient Information Sheet and a signed consent form to keep.



## **Appendix 4**

### **EFFECTS OF METFORMIN ON VASCULAR FUNCTION IN POLYCYSTIC OVARIAN SYNDROME - CONSENT FORM (Version 3 May 2006)**

Patient Identification Number for this trial:

**Title of Study:** A randomised, double-blind, placebo-controlled crossover trial of the effects of metformin therapy on vascular and metabolic risk in young women with polycystic ovary syndrome.

**Name of Researchers:** Dr Aled Rees, Dr Neera Agarwal

Please initial box

1. I confirm that I have read and understood the information sheet dated May 2006 (version 3) for the above study and have had the opportunity to ask questions. ☐
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected. ☐
3. I understand that sections of my medical notes may be looked at by responsible individuals from regulatory authorities where it is relevant to my taking part in research. I give permission for these individuals to have access to my records. ☐
4. I consent to my GP being informed of my participation in the Study. ☐
5. I consent to a pregnancy test at each study visit. ☐
6. I agree to take part in the above study. ☐

\_\_\_\_\_  
Name of patient

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Researcher

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Name of person taking consent  
(if different from researcher)

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

1 copy for patient; 1 for researcher; 1 to be kept with hospital notes

## **Appendix 5**

### ***EFFECTS OF METFORMIN ON VASCULAR FUNCTION IN POLYCYSTIC OVARY SYNDROME – CASE REPORT FORM***

#### **PATIENT DETAILS**

Initials .....

Date of Birth .....

Trial Enrolment Number .....

Date of Visit .....

#### **INCLUSION CRITERIA**

☐ Diagnosis of PCOS (require 2 out of 3)

- Androgen excess (clinical or biochemical)
- Ovulatory dysfunction
- Cysts on ovarian ultrasound

☐ Age 18-30

#### **EXCLUSION CRITERIA**

☐ Pregnancy

☐ Breastfeeding

☐ Current/previous use (within last 6 months) of:

- Oral contraceptive pill
- Anti-diabetic drugs
- Anti-hypertensive drugs

☐ Renal impairment

☐ Hepatic impairment

☐ Diabetes

☐ Hypertension

☐ Discuss information sheet & complete consent form.

☐ Discuss contraception.

#### **PREGNANCY TEST**

☐ Negative

☐ Positive

**MEDICAL HISTORY**

.....

.....

..... Birth weight.....

**SMOKING STATUS**

Current smoker      ☐ No      ☐ Yes Details .....

Ex-smoker      ☐ No      ☐ Yes Details .....

**FAMILY HISTORY**

.....

.....

**DRUG THERAPY**      Previous OCP use .....

Drug	.....	.....	.....	.....	.....
Dose	.....	.....	.....	.....	.....
Duration	.....	.....	.....	.....	.....

**Allergies** .....

## **MENSTRUAL HISTORY**

Age at menarche .....

☐ Eumenorrhoeic    Cycle length.....    Day No.....

☐ Oligomenorrhoeic    LMP.....

☐ Amenorrhoeic    LMP.....

## **CLINICAL EXAMINATION**

**BMI**                      Height (cm).....    Weight(kg).....    BMI .....

**Body Composition**    Fat mass(kg) .....    Fat % .....

**Waist:Hip**              Waist(cm) .....    Hip(cm).....    Ratio .....

**Acanthosis Nigricans**    ☐ Yes    ☐ No    Site .....

**Ferriman-Gallwey score** .....

## **ADDITIONAL INFORMATION**

.....

.....

.....

.....

**AUGMENTATION INDEX & PULSE WAVE VELOCITY****Distance:**

SSN to carotid pulse.....mm

SSN to radial pulse.....mm

SSN to femoral pulse.....mm

**Blood Pressure:**

A. ....mmHg

B. ....mmHg

Average .....mmHg

**AUGMENTATION INDEX**

	A	B	Average
Augmentation index (%)			
Central aortic pressure (mmHg)			
Tr (ms)			

**PULSE WAVE VELOCITY**

	A	B	Average
Carotid-radial (m/s)			
Carotid-femoral (m/s)			

**ASSESSMENT OF ENDOTHELIAL FUNCTION - BASELINE MEASUREMENTS**

Time		A	B	Average
5 mins	BP			
	HR			
7 mins	Alx			
15 mins	BP			
	HR			
17 mins	Alx			



**ENDOTHELIAL FUNCTION - GTN**

Time		A	B	Average
0 min	<b>Sublingual GTN</b>			
1 min	BP			
	HR			
3 min	<b>Remove GTN</b>			
	Alx			
5 mins	Alx			
7 mins	BP			
	HR			
10 mins	Alx			
12 mins	BP			
	HR			
15 mins	Alx			
17 mins	BP			
	HR			
20 mins	Alx			
25 mins	BP			
	HR			
28 mins	Alx			

**ENDOTHELIAL FUNCTION - SALBUTAMOL**

Time		A	B	Average
0 min	<b>2 puffs salbutamol via spacer (x2)</b>			
2 mins	BP			
	HR			
5 mins	AIx			
7 mins	BP			
	HR			
10 mins	AIx			
12 mins	BP			
	HR			
15 mins	AIx			
17 mins	BP			
	HR			
20 mins	AIx			

**LABORATORY RESULTS**

<b>Investigation</b>	<b>Result</b>
Testosterone	
SHBG	
HsCRP	
PAI-1	
Total cholesterol	
LDL	
HDL	
TG	
Glucose	
Insulin	
Adiponectin	

## REFERENCES

1. Kylin E: **Studien uber das hypertonie-hyperglykamie-hyperurikamiesyndrom.** *Zentralblatt Fuer Innere Med* 1923(44):105-127.
2. Vague J: **Sexual differentiation. A determinant factor of the forms of obesity.** 1947. *Obes Res* 1996, 4(2):201-203.
3. Reaven GM: **Banting lecture 1988. Role of insulin resistance in human disease.** *Diabetes* 1988, 37(12):1595-1607.
4. Eckel RH, Grundy SM, Zimmet PZ: **The metabolic syndrome.** *Lancet* 2005, 365(9468):1415-1428.
5. Alberti KG, Zimmet P, Shaw J: **Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.** *Diabet Med* 2006, 23(5):469-480.
6. **Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation.** In.: World Health Organization; 1999.
7. Balkau B, Charles MA: **Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).** *Diabet Med* 1999, 16(5):442-443.
8. **Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).** *JAMA* 2001, 285(19):2486-2497.
9. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM *et al*: **American College of Endocrinology position statement on the insulin resistance syndrome.** *Endocr Pract* 2003, 9(3):237-252.

10. Lee IM, Manson JE, Hennekens CH, Paffenbarger RS, Jr.: **Body weight and mortality. A 27-year follow-up of middle-aged men.** *JAMA* 1993, **270**(23):2823-2828.
11. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G: **The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913.** *Diabetes* 1985, **34**(10):1055-1058.
12. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE: **Abdominal adiposity and coronary heart disease in women.** *JAMA* 1998, **280**(21):1843-1848.
13. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: **Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.** *Am J Cardiol* 1994, **73**(7):460-468.
14. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: **Adiponectin and metabolic syndrome.** *Arterioscler Thromb Vasc Biol* 2004, **24**(1):29-33.
15. Jazet IM, Pijl H, Meinders AE: **Adipose tissue as an endocrine organ: impact on insulin resistance.** *Neth J Med* 2003, **61**(6):194-212.
16. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: **Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.** *Diabetes* 1998, **47**(10):1643-1649.
17. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM: **Insulin and risk of cardiovascular disease: a meta-analysis.** *Circulation* 1998, **97**(10):996-1001.
18. Boden G, Shulman GI: **Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction.** *Eur J Clin Invest* 2002, **32 Suppl 3**:14-23.
19. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: **Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats:**



- impairment in adipocyte-beta-cell relationships.** *Proc Natl Acad Sci U S A* 1994, **91**(23):10878-10882.
20. Despres JP: **Is visceral obesity the cause of the metabolic syndrome?** *Ann Med* 2006, **38**(1):52-63.
  21. Despres JP, Lemieux I: **Abdominal obesity and metabolic syndrome.** *Nature* 2006, **444**(7121):881-887.
  22. Williams G, Pickup JC: **Handbook of Diabetes: Normal physiology of insulin secretion and action:** Blackwell publishing; 2004.
  23. Savage DB, Petersen KF, Shulman GI: **Mechanisms of insulin resistance in humans and possible links with inflammation.** *Hypertension* 2005, **45**(5):828-833.
  24. Carr MC, Brunzell JD: **Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.** *J Clin Endocrinol Metab* 2004, **89**(6):2601-2607.
  25. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G: **Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.** *J Clin Invest* 1995, **95**(1):158-166.
  26. Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L, Sirtori CR, Franceschini G: **Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma.** *Arterioscler Thromb Vasc Biol* 1995, **15**(11):1819-1828.
  27. **American Heart Disease and American Stroke Association - Heart Disease and Stroke Statistics 2008 Update.** In.: 18-20.
  28. Bakris GL: **Current perspectives on hypertension and metabolic syndrome.** *J Manag Care Pharm* 2007, **13**(5 Suppl):S3-5.
  29. Barbato A, Cappuccio FP, Folkerd EJ, Strazzullo P, Sampson B, Cook DG, Alberti KG: **Metabolic syndrome and renal sodium handling in three ethnic groups living in England.** *Diabetologia* 2004, **47**(1):40-46.

30. Tooke JE, Hannemann MM: **Adverse endothelial function and the insulin resistance syndrome.** *J Intern Med* 2000, **247**(4):425-431.
31. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: **Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.** *J Clin Invest* 1991, **87**(6):2246-2252.
32. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P: **Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects.** *Diabetes* 2003, **52**(12):2882-2887.
33. Nawrocki AR, Scherer PE: **The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation.** *Curr Opin Pharmacol* 2004, **4**(3):281-289.
34. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: **Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.** *J Clin Invest* 2001, **108**(12):1875-1881.
35. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA *et al*: **Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.** *J Clin Invest* 2003, **112**(12):1821-1830.
36. Hotamisligil GS, Shargill NS, Spiegelman BM: **Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.** *Science* 1993, **259**(5091):87-91.
37. Cameron AJ, Shaw JE, Zimmet PZ: **The metabolic syndrome: prevalence in worldwide populations.** *Endocrinol Metab Clin North Am* 2004, **33**(2):351-375, table of contents.
38. Ford ES, Giles WH, Dietz WH: **Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.** *JAMA* 2002, **287**(3):356-359.
39. Ford ES, Giles WH, Mokdad AH: **Increasing prevalence of the metabolic syndrome among u.s. Adults.** *Diabetes Care* 2004, **27**(10):2444-2449.

40. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB: **Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.** *Circulation* 2005, **112**(20):3066-3072.
41. Alberti KG, Zimmet PZ: **Should we dump the metabolic syndrome? No.** *BMJ* 2008, **336**(7645):641.
42. Gale EA: **Should we dump the metabolic syndrome? Yes.** *BMJ* 2008, **336**(7645):640.
43. Hanson RL, Imperatore G, Bennett PH, Knowler WC: **Components of the "metabolic syndrome" and incidence of type 2 diabetes.** *Diabetes* 2002, **51**(10):3120-3127.
44. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: **Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.** *Arch Intern Med* 2004, **164**(10):1066-1076.
45. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS: **Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.** *Circulation* 2004, **109**(1):42-46.
46. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M *et al*: **The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.** *Ann Intern Med* 2005, **143**(10):722-728.
47. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: **The metabolic syndrome and chronic kidney disease in U.S. adults.** *Ann Intern Med* 2004, **140**(3):167-174.
48. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, Casimirri F, Morselli-Labate AM: **The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.** *Clin Endocrinol (Oxf)* 1999, **50**(4):517-527.

49. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP: **Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.** *J Clin Endocrinol Metab* 2000, **85**(3):1151-1158.
50. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM: **Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?** *Diabetes Care* 2004, **27**(11):2676-2681.
51. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: **Cardiovascular morbidity and mortality associated with the metabolic syndrome.** *Diabetes Care* 2001, **24**(4):683-689.
52. Kaplan NM: **The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.** *Arch Intern Med* 1989, **149**(7):1514-1520.
53. Haffner S, Cassells HB: **Metabolic syndrome - a new risk factor of coronary heart disease?** *Diabetes Obes Metab* 2003, **5**(6):359-370.
54. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA: **Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.** *Circulation* 2004, **109**(4):551-556.
55. Jung RT: **Obesity as a disease.** *Br Med Bull* 1997, **53**(2):307-321.
56. Peters H, Nahas GG: **A brief history of four millennia (BC 2000 - AD 1974).** In: *Marihuana and Medicine*. Totowa: Humana Press; 1999.
57. Gaoni Y, Mechoulam R: **The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish.** *J Am Chem Soc* 1971, **93**(1):217-224.
58. Di Marzo V, Matias I: **Endocannabinoid control of food intake and energy balance.** *Nat Neurosci* 2005, **8**(5):585-589.

59. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S *et al*: **The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.** *J Clin Invest* 2003, **112**(3):423-431.
60. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: **The emerging role of the endocannabinoid system in endocrine regulation and energy balance.** *Endocr Rev* 2006, **27**(1):73-100.
61. Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, Caput D, Ferrara P: **Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.** *J Biol Chem* 1996, **271**(12):6941-6946.
62. Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG: **The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.** *J Clin Pharmacol* 2007, **47**(5):642-652.
63. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M: **The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum.** *J Neurosci* 2006, **26**(11):2991-3001.
64. Giuffrida A, Beltramo M, Piomelli D: **Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.** *J Pharmacol Exp Ther* 2001, **298**(1):7-14.
65. **Role of the endocannabinoid system in contributing to obesity**  
[<http://www.medscape.com/viewprogram/8345.pnt>]
66. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D: **Formation and inactivation of endogenous cannabinoid anandamide in central neurons.** *Nature* 1994, **372**(6507):686-691.
67. Di Marzo V, Bifulco M, De Petrocellis L: **The endocannabinoid system and its therapeutic exploitation.** *Nat Rev Drug Discov* 2004, **3**(9):771-784.



68. Pertwee RG: **The pharmacology of cannabinoid receptors and their ligands: an overview.** *Int J Obes (Lond)* 2006, **30 Suppl 1**:S13-18.
69. Piomelli D: **The molecular logic of endocannabinoid signalling.** *Nat Rev Neurosci* 2003, **4**(11):873-884.
70. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V: **Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response.** *Neuroscience* 1999, **92**(1):377-387.
71. Hao S, Avraham Y, Mechoulam R, Berry EM: **Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice.** *Eur J Pharmacol* 2000, **392**(3):147-156.
72. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P: **CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.** *Int J Obes Relat Metab Disord* 2004, **28**(4):640-648.
73. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM *et al*: **Activation of the peripheral endocannabinoid system in human obesity.** *Diabetes* 2005, **54**(10):2838-2843.
74. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V: **Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa.** *Neuropsychopharmacology* 2005, **30**(6):1216-1221.
75. Sipe JC, Waalen J, Gerber A, Beutler E: **Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).** *Int J Obes (Lond)* 2005, **29**(7):755-759.
76. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R *et al*: **Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.** *J Clin Endocrinol Metab* 2006, **91**(8):3171-3180.

77. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: **Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.** *Lancet* 2005, **365**(9468):1389-1397.
78. Despres JP, Golay A, Sjostrom L: **Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.** *N Engl J Med* 2005, **353**(20):2121-2134.
79. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: **Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.** *JAMA* 2006, **295**(7):761-775.
80. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF: **Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.** *Lancet* 2006, **368**(9548):1660-1672.
81. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A: **SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naïve Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naïve type 2 diabetes.** *Diabetes Care* 2008, **31**(11):2169-2176.
82. Pagotto U, Pasquali R: **Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.** *Lancet* 2005, **365**(9468):1363-1364.
83. Franks S: **Polycystic ovary syndrome.** *N Engl J Med* 1995, **333**(13):853-861.
84. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J: **Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.** *Diabetes Care* 1999, **22**(1):141-146.
85. Legro RS, Kusanman AR, Dodson WC, Dunaif A: **Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.** *J Clin Endocrinol Metab* 1999, **84**(1):165-169.

86. Legro RS, Kusanman AR, Dunaif A: **Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.** *Am J Med* 2001, **111**(8):607-613.
87. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS: **Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.** *Clin Endocrinol (Oxf)* 1996, **45**(5):623-629.
88. Dunaif A: **Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.** *Endocr Rev* 1997, **18**(6):774-800.
89. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L: **Coronary heart disease risk factors in women with polycystic ovary syndrome.** *Arterioscler Thromb Vasc Biol* 1995, **15**(7):821-826.
90. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD: **Polycystic ovary syndrome is associated with endothelial dysfunction.** *Circulation* 2001, **103**(10):1410-1415.
91. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C: **Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.** *J Clin Endocrinol Metab* 2004, **89**(11):5592-5596.
92. Dunaif A, Thomas A: **Current concepts in the polycystic ovary syndrome.** *Annu Rev Med* 2001, **52**:401-419.
93. **Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).** *Hum Reprod* 2004, **19**(1):41-47.
94. Pastor CL, Griffin-Korf ML, Aloji JA, Evans WS, Marshall JC: **Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.** *J Clin Endocrinol Metab* 1998, **83**(2):582-590.
95. Rosenfield RL: **Ovarian and adrenal function in polycystic ovary syndrome.** *Endocrinol Metab Clin North Am* 1999, **28**(2):265-293.

96. Diamanti-Kandarakis E: **Insulin resistance in PCOS.** *Endocrine* 2006, **30**(1):13-17.
97. Leventhal ML: **The Stein-Leventhal syndrome.** *Am J Obstet Gynecol* 1958, **76**(4):825-838.
98. Burghen GA, Givens JR, Kitabchi AE: **Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.** *J Clin Endocrinol Metab* 1980, **50**(1):113-116.
99. Chang RJ, Nakamura RM, Judd HL, Kaplan SA: **Insulin resistance in nonobese patients with polycystic ovarian disease.** *J Clin Endocrinol Metab* 1983, **57**(2):356-359.
100. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: **Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.** *Diabetes* 1989, **38**(9):1165-1174.
101. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L: **Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings.** *J Clin Endocrinol Metab* 1991, **73**(3):590-595.
102. Cohen JC, Hickman R: **Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids.** *J Clin Endocrinol Metab* 1987, **64**(5):960-963.
103. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, Fanta M, Vondra K, Skrha J: **Insulin sensitivity in women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2004, **89**(6):2942-2945.
104. Katsuki A, Sumida Y, Murashima S, Fujii M, Ito K, Tsuchihashi K, Murata K, Yano Y, Shima T: **Acute and chronic regulation of serum sex hormone-binding globulin levels by plasma insulin concentrations in male noninsulin-dependent diabetes mellitus patients.** *J Clin Endocrinol Metab* 1996, **81**(7):2515-2519.
105. Sattar N, Fleming R: **Polycystic Ovary Syndrome.** In: *The Metabolic Syndrome*. Edited by Byrne C, Wild S. Chichester: John Wiley & Sons, Ltd; 2005: 305-332.

106. Escobar-Morreale HF, Botella-Carretero JJ, Villuendas G, Sancho J, San Millan JL: **Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity.** *J Clin Endocrinol Metab* 2004, **89**(2):806-811.
107. Yildirim B, Sabir N, Kaleli B: **Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome.** *Fertil Steril* 2003, **79**(6):1358-1364.
108. Holte J, Bergh T, Berne C, Berglund L, Lithell H: **Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance.** *J Clin Endocrinol Metab* 1994, **78**(5):1052-1058.
109. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: **Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study.** *Diabetes* 2004, **53**(7):1782-1789.
110. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA: **Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.** *J Clin Epidemiol* 1998, **51**(5):415-422.
111. Wild RA: **Polycystic ovary syndrome: a risk for coronary artery disease?** *Am J Obstet Gynecol* 2002, **186**(1):35-43.
112. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA: **Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.** *J Clin Endocrinol Metab* 2010, **95**(5):2038-2049.



113. Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN: **Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.** *J Clin Endocrinol Metab* 1997, **82**:3389-3394.
114. Essa PA, Nestler JE, Carmina E: **Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.** *J Endocrinol Invest* 2008, **31**:35-41.
115. Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E: **Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2007, **92**(1):186-189.
116. Mason H, Colao A, Blume-Peytavi U, Rice S, Qureshi A, Pellatt L, Orio F, Atkin SL: **Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review.** *Clin Endo* 2008, **69**:831-844.
117. Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R, Krakoff LR: **Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.** *J Clin Endocrinol Metab* 1992, **75**(2):508-513.
118. Fridstrom M, Nisell H, Sjoblom P, Hillensjo T: **Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia?** *Hypertens Pregnancy* 1999, **18**(1):73-80.
119. Wild S, Pierpoint T, Jacobs H, McKeigue P: **Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study.** *Hum Fertil (Camb)* 2000, **3**(2):101-105.
120. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW: **Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.** *Jama* 2000, **283**(2):221-228.
121. Mennen LI, Balkau B, Charles MA, D'Hour A, le Mauff JM: **Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking.** D.E.S.I.R. Study Group. Data

**from an Epidemiological Study on Insulin Resistance Syndrome. *Thromb Haemost* 1999, 82(3):1106-1111.**

122. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: **C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004, 350(14):1387-1397.**
123. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N: **Low grade chronic inflammation in women with polycystic ovarian syndrome. *J Clin Endocrinol Metab* 2001, 86(6):2453-2455.**
124. Peral B, San Millan JL, Castello R, Moghetti P, Escobar-Morreale HF: **Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. *J Clin Endocrinol Metab* 2002, 87(8):3977-3983.**
125. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL: **Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. *Obes Res* 2003, 11(8):987-996.**
126. Orio F, Jr., Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R: **Adiponectin levels in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003, 88(6):2619-2623.**
127. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH: **Screening women with polycystic ovary syndrome for metabolic syndrome. *Obstet Gynecol* 2005, 106(1):131-137.**
128. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS: **Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004, 89(11):5454-5461.**

129. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: **Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2005, **90**(4):1929-1935.
130. Widlansky ME, Gokce N, Keaney JF, Jr., Vita JA: **The clinical implications of endothelial dysfunction.** *J Am Coll Cardiol* 2003, **42**(7):1149-1160.
131. Orio F, Jr., Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A: **Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2004, **89**(9):4588-4593.
132. Birdsall MA, Farquhar CM, White HD: **Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.** *Ann Intern Med* 1997, **126**(1):32-35.
133. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, 2nd, Fitzpatrick LA: **Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2003, **88**(6):2562-2568.
134. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH: **Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.** *Arterioscler Thromb Vasc Biol* 2000, **20**(11):2414-2421.
135. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM: **Altered vascular function in young women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2002, **87**(2):742-746.
136. Wild S, Pierpoint T, McKeigue P, Jacobs H: **Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.** *Clin Endocrinol (Oxf)* 2000, **52**(5):595-600.
137. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE: **Menstrual cycle irregularity and risk for future cardiovascular disease.** *J Clin Endocrinol Metab* 2002, **87**(5):2013-2017.

138. Diamanti-Kandarakis E, Christakou CD, Kandarakis E, Economou FN: **Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.** *Eur J Endocrinol* 2010, **162**(2):193-212.
139. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolini E, Muggeo M: **Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.** *J Clin Endocrinol Metab* 2000, **85**(1):139-146.
140. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I: **Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.** *J Clin Endocrinol Metab* 2001, **86**(10):4666-4673.
141. Nolan T, Hands RE, Bustin SA: **Quantification of mRNA using real-time RT-PCR.** *Nat Protoc* 2006, **1**(3):1559-1582.
142. Dallman MJ, Montgomery RA, Larsen CP, Wanders A, Wells AF: **Cytokine gene expression: analysis using northern blotting, polymerase chain reaction and in situ hybridization.** *Immunol Rev* 1991, **119**:163-179.
143. Trayhurn P: **Northern blotting.** *Proc Nutr Soc* 1996, **55**(1B):583-589.
144. Romkes M, Buch S: **Molecular Toxicology Protocols.** In: *Strategies for Measurement of Biotransformation Enzyme Gene Expression*. Edited by P Keohavong SG, vol. 291: Humana Press; 2005.
145. Ausubel FM: **Current protocols in molecular biology.** In., Supplement 79 edn. New York: J. Wiley; 2007.
146. Schena M, Shalon D, Davis RW, Brown PO: **Quantitative monitoring of gene expression patterns with a complementary DNA microarray.** *Science* 1995, **270**(5235):467-470.
147. **Protocols and Applications Guide**, 3rd edn: Promega; 2006.
148. Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C: **Role of adipose tissue as an inflammatory organ in human diseases.** *Endocr Rev* 2006, **27**(5):449-467.

149. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM: **Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve.** *Science* 1987, **237**(4813):402-405.
150. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: **A novel serum protein similar to C1q, produced exclusively in adipocytes.** *J Biol Chem* 1995, **270**(45):26746-26749.
151. Hu E, Liang P, Spiegelman BM: **AdipoQ is a novel adipose-specific gene dysregulated in obesity.** *J Biol Chem* 1996, **271**(18):10697-10703.
152. Hotamisligil GS, Spiegelman BM: **Tumor necrosis factor alpha: a key component of the obesity-diabetes link.** *Diabetes* 1994, **43**(11):1271-1278.
153. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: **Positional cloning of the mouse obese gene and its human homologue.** *Nature* 1994, **372**(6505):425-432.
154. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: **The hormone resistin links obesity to diabetes.** *Nature* 2001, **409**(6818):307-312.
155. Arner P: **Visfatin--a true or false trail to type 2 diabetes mellitus.** *J Clin Endocrinol Metab* 2006, **91**(1):28-30.
156. Scherer PE: **Adipose tissue: from lipid storage compartment to endocrine organ.** *Diabetes* 2006, **55**(6):1537-1545.
157. Ailhaud G, Grimaldi P, Negrel R: **Cellular and molecular aspects of adipose tissue development.** *Annu Rev Nutr* 1992, **12**:207-233.
158. Rosen ED, Spiegelman BM: **Molecular regulation of adipogenesis.** *Annu Rev Cell Dev Biol* 2000, **16**:145-171.
159. Trujillo ME, Scherer PE: **Adipose tissue-derived factors: impact on health and disease.** *Endocr Rev* 2006, **27**(7):762-778.
160. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM: **Transcriptional regulation of adipogenesis.** *Genes Dev* 2000, **14**(11):1293-1307.

161. Rosen ED, MacDougald OA: **Adipocyte differentiation from the inside out.** *Nat Rev Mol Cell Biol* 2006, **7**(12):885-896.
162. Entenmann G, Hauner H: **Relationship between replication and differentiation in cultured human adipocyte precursor cells.** *Am J Physiol* 1996, **270**(4 Pt 1):C1011-1016.
163. Smas CM, Sul HS: **Molecular mechanisms of adipocyte differentiation and inhibitory action of pref-1.** *Crit Rev Eukaryot Gene Expr* 1997, **7**(4):281-298.
164. Wu Z, Bucher NL, Farmer SR: **Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids.** *Mol Cell Biol* 1996, **16**(8):4128-4136.
165. Tamori Y, Masugi J, Nishino N, Kasuga M: **Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes.** *Diabetes* 2002, **51**(7):2045-2055.
166. Fajas L, Fruchart JC, Auwerx J: **PPARGgamma3 mRNA: a distinct PPARGgamma mRNA subtype transcribed from an independent promoter.** *FEBS Lett* 1998, **438**(1-2):55-60.
167. Mukherjee R, Jow L, Croston GE, Paterniti JR, Jr.: **Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARGgamma2 versus PPARGgamma1 and activation with retinoid X receptor agonists and antagonists.** *J Biol Chem* 1997, **272**(12):8071-8076.
168. Tontonoz P, Hu E, Spiegelman BM: **Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.** *Cell* 1994, **79**(7):1147-1156.
169. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E *et al*: **Selective disruption of PPARGgamma 2 impairs the development of adipose tissue and insulin sensitivity.** *Proc Natl Acad Sci U S A* 2004, **101**(29):10703-10708.



170. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD *et al*: **Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.** *Diabetes* 2003, **52**(4):910-917.
171. Ludtke A, Buettner J, Wu W, Muchir A, Schroeter A, Zinn-Justin S, Spuler S, Schmidt HH, Worman HJ: **Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.** *J Clin Endocrinol Metab* 2007, **92**(6):2248-2255.
172. Monajemi H, Zhang L, Li G, Jenning EH, Cao H, Maas M, Brouwer CB, Kalkhoven E, Stroes E, Hegele RA *et al*: **Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.** *J Clin Endocrinol Metab* 2007, **92**(5):1606-1612.
173. Imai T, Takakuwa R, Marchand S, Dentz E, Bornert JM, Messaddeq N, Wendling O, Mark M, Desvergne B, Wahli W *et al*: **Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse.** *Proc Natl Acad Sci U S A* 2004, **101**(13):4543-4547.
174. Mori T, Sakaue H, Iguchi H, Gomi H, Okada Y, Takashima Y, Nakamura K, Nakamura T, Yamauchi T, Kubota N *et al*: **Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis.** *J Biol Chem* 2005, **280**(13):12867-12875.
175. Gray S, Feinberg MW, Hull S, Kuo CT, Watanabe M, Sen-Banerjee S, DePina A, Haspel R, Jain MK: **The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4.** *J Biol Chem* 2002, **277**(37):34322-34328.
176. Banerjee SS, Feinberg MW, Watanabe M, Gray S, Haspel RL, Denking DJ, Kawahara R, Hauner H, Jain MK: **The Kruppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis.** *J Biol Chem* 2003, **278**(4):2581-2584.

177. Chen Z, Torrens JI, Anand A, Spiegelman BM, Friedman JM: **Krox20 stimulates adipogenesis via C/EBPbeta-dependent and -independent mechanisms.** *Cell Metab* 2005, **1**(2):93-106.
178. Kim J, M W, Spiegelman BM: **ADD1/SREBP1 activates PPAR $\gamma$  through the production of endogenous ligand** *Proc Natl Acad Sci USA* 1998(95):4333-4337.
179. Tong Q: **Function of GATA transcription factors in preadipocyte-adipocyte transition** *Science* 2000(290):134-138.
180. Cannon B, Nedergaard J: **Brown adipose tissue: function and physiological significance.** *Physiol Rev* 2004, **84**(1):277-359.
181. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A *et al*: **Identification and importance of brown adipose tissue in adult humans.** *N Engl J Med* 2009, **360**(15):1509-1517.
182. Nedergaard J, Bengtsson T, Cannon B: **Unexpected evidence for active brown adipose tissue in adult humans.** *Am J Physiol Endocrinol Metab* 2007, **293**(2):E444-452.
183. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, Iwanaga T, Miyagawa M, Kameya T, Nakada K *et al*: **High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity.** *Diabetes* 2009, **58**(7):1526-1531.
184. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ: **Cold-activated brown adipose tissue in healthy men.** *N Engl J Med* 2009, **360**(15):1500-1508.
185. Garruti G, Ricquier D: **Analysis of uncoupling protein and its mRNA in adipose tissue deposits of adult humans.** *Int J Obes Relat Metab Disord* 1992, **16**(5):383-390.
186. Green H, Meuth M: **An established pre-adipose cell line and its differentiation in culture.** *Cell* 1974, **3**(2):127-133.

187. Negrel R, Grimaldi P, Ailhaud G: **Establishment of preadipocyte clonal line from epididymal fat pad of ob/ob mouse that responds to insulin and to lipolytic hormones.** *Proc Natl Acad Sci U S A* 1978, **75**(12):6054-6058.
188. Zilberfarb V, Pietri-Rouxel F, Jockers R, Krief S, Delouis C, Issad T, Strosberg AD: **Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis.** *J Cell Sci* 1997, **110** ( Pt 7):801-807.
189. Todaro GJ, Green H: **Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines.** *J Cell Biol* 1963, **17**:299-313.
190. Girard J, Perdereau D, Foufelle F, Prip-Buus C, Ferre P: **Regulation of lipogenic enzyme gene expression by nutrients and hormones.** *FASEB J* 1994, **8**(1):36-42.
191. Reed BC, Lane MD: **Expression of insulin receptors during preadipocyte differentiation.** *Adv Enzyme Regul* 1980, **18**:97-117.
192. Schmidt W, Poll-Jordan G, Löffler G: **Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP.** *J Biol Chem* 1990, **265**(26):15489-15495.
193. Smas CM, Chen L, Zhao L, Latasa MJ, Sul HS: **Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation.** *J Biol Chem* 1999, **274**(18):12632-12641.
194. Gregoire F, Genart C, Hauser N, Remacle C: **Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors.** *Exp Cell Res* 1991, **196**(2):270-278.
195. Kletzien RF, Clarke SD, Ulrich RG: **Enhancement of adipocyte differentiation by an insulin-sensitizing agent.** *Mol Pharmacol* 1992, **41**(2):393-398.
196. Yarwood SJ, Anderson NG, Kilgour E: **Cyclic AMP modulates adipogenesis in 3T3-F442A cells.** *Biochem Soc Trans* 1995, **23**(2):175S.
197. Catalioto RM, Gaillard D, Ailhaud G, Negrel R: **Terminal differentiation of mouse preadipocyte cells: the mitogenic-adipogenic role of growth hormone is**

- mediated by the protein kinase C signalling pathway. *Growth Factors* 1992, **6**(3):255-264.
198. Gharbi-Chihi J, Grimaldi P, Torresani J, Ailhaud G: **Triiodothyronine and adipose conversion of OB17 preadipocytes : binding to high affinity sites and effects on fatty acid synthetizing and esterifying enzymes.** *J Recept Res* 1981, **2**(2):153-173.
199. Safonova I, Darimont C, Amri EZ, Grimaldi P, Ailhaud G, Reichert U, Shroot B: **Retinoids are positive effectors of adipose cell differentiation.** *Mol Cell Endocrinol* 1994, **104**(2):201-211.
200. Negrel R, Gaillard D, Ailhaud G: **Prostacyclin as a potent effector of adipose-cell differentiation.** *Biochem J* 1989, **257**(2):399-405.
201. Mattern CF, Brackett FS, Olson BJ: **Determination of number and size of particles by electrical gating: blood cells.** *J Appl Physiol* 1957, **10**(1):56-70.
202. Lamb JR, Goehle S, Ludlow C, Simon JA: **Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.** *Biotechniques* 2001, **30**(5):1118-1120, 1122, 1124.
203. Smith JA, Martin L: **Do cells cycle?** *Proc Natl Acad Sci U S A* 1973, **70**(4):1263-1267.
204. Elledge SJ: **Cell cycle checkpoints: preventing an identity crisis.** *Science* 1996, **274**(5293):1664-1672.
205. Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W: **Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O.** *Histochemistry* 1992, **97**(6):493-497.
206. [<http://www.tocris.com/>]
207. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M: **The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.** *Mol Pharmacol* 2006, **69**(2):471-478.
208. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J *et al*: **A selective inverse agonist for central**

- cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.** *J Biol Chem* 1997, **272**(35):22330-22339.
209. Perwitz N, Wenzel J, Wagner I, Buning J, Drenckhan M, Zarse K, Ristow M, Lilienthal W, Lehnert H, Klein J: **Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.** *Diabetes Obes Metab* 2010, **12**(2):158-166.
210. Darimont C, Zbinden I, Avanti O, Leone-Vautravers P, Giusti V, Burckhardt P, Pfeifer AM, Mace K: **Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization.** *Cell Death Differ* 2003, **10**(9):1025-1031.
211. Perrini S, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Natalicchio A, Orlando MR, Garruti G, De Fazio M *et al*: **Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells.** *Diabetologia* 2008, **51**(1):155-164.
212. Williams JR: **The Declaration of Helsinki and public health.** *Bull World Health Organ* 2008, **86**(8):650-652.
213. Thorne A, Lonnqvist F, Aelman J, Hellers G, Arner P: **A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding.** *Int J Obes Relat Metab Disord* 2002, **26**(2):193-199.
214. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS: **Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.** *N Engl J Med* 2004, **350**(25):2549-2557.
215. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H: **Depot-specific differences in adipose tissue gene expression in lean and obese subjects.** *Diabetes* 1998, **47**(1):98-103.

216. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, Byrne CD, O'Rahilly S: **Depot-related gene expression in human subcutaneous and omental adipocytes.** *Diabetes* 1998, **47**(9):1384-1391.
217. Morimoto C, Tsujita T, Okuda H: **Norepinephrine-induced lipolysis in rat fat cells from visceral and subcutaneous sites: role of hormone-sensitive lipase and lipid droplets.** *J Lipid Res* 1997, **38**(1):132-138.
218. Santaniemi M, Kesaniemi YA, Ukkola O: **Low plasma adiponectin concentration is an indicator of the metabolic syndrome.** *Eur J Endocrinol* 2006, **155**(5):745-750.
219. **ELISA development guide.** In.: R&D Systems.
220. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, Haffaf Y, Cesari M, Festy F: **Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.** *Histochem Cell Biol* 2006, **126**(2):177-187.
221. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O: **Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.** *Eur Heart J* 2008, **29**(14):1761-1771.
222. Sarzani R, Bordicchia M, Marcucci P, Bedetta S, Santini S, Giovagnoli A, Scappini L, Minardi D, Muzzonigro G, Dessi-Fulgheri P *et al*: **Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients.** *Metabolism* 2009, **58**(3):361-367.
223. Sarnataro D, Pisanti S, Santoro A, Gazerro P, Malfitano AM, Laezza C, Bifulco M: **The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.** *Mol Pharmacol* 2006, **70**(4):1298-1306.
224. Malfitano AM, Laezza C, Pisanti S, Gazerro P, Bifulco M: **Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.** *Br J Pharmacol* 2008, **153**(5):1003-1010.
225. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P: **The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA**



**expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.**

*Mol Pharmacol* 2003, **63**(4):908-914.

226. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: **The prevalence and features of the polycystic ovary syndrome in an unselected population.** *J Clin Endocrinol Metab* 2004, **89**(6):2745-2749.
227. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI: **Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2008, **93**(3):999-1004.
228. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M: **Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.** *J Clin Endocrinol Metab* 2002, **87**(8):3871-3875.
229. Lakhani K, Hardiman P, Seifalian AM: **Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries.** *Atherosclerosis* 2004, **175**(2):353-359.
230. Emoto M, Nishizawa Y, Kawagishi T, Maekawa K, Hiura Y, Kanda H, Izumotani K, Shoji T, Ishimura E, Inaba M *et al*: **Stiffness indexes beta of the common carotid and femoral arteries are associated with insulin resistance in NIDDM.** *Diabetes Care* 1998, **21**(7):1178-1182.
231. Giltay EJ, Lambert J, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD: **Arterial compliance and distensibility are modulated by body composition in both men and women but by insulin sensitivity only in women.** *Diabetologia* 1999, **42**(2):214-221.
232. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM: **Insulin action is associated with endothelial function in hypertension and type 2 diabetes.** *Hypertension* 2000, **35**(1 Pt 2):507-511.
233. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H: **Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity.** *Diabetes* 1999, **48**(4):821-827.

234. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Jarvinen H: **Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels.** *Hypertension* 1999, **33**(5):1118-1122.
235. Meyer C, McGrath BP, Teede HJ: **Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.** *J Clin Endocrinol Metab* 2005, **90**(10):5711-5716.
236. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG: **Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?** *Circulation* 2002, **106**(16):2085-2090.
237. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: **Impact of aortic stiffness on survival in end-stage renal disease.** *Circulation* 1999, **99**(18):2434-2439.
238. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A: **Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.** *Hypertension* 2001, **37**(5):1236-1241.
239. Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ: **Vascular dysfunction and metabolic parameters in polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2005, **90**(8):4630-4635.
240. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M: **Metformin administration improves endothelial function in women with polycystic ovary syndrome.** *Eur J Endocrinol* 2005, **152**(5):749-756.
241. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, Pfeifer M: **Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.** *Eur J Endocrinol* 2008, **159**(4):399-406.
242. Orio F, Jr., Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G *et al*: **Improvement in endothelial structure and**

- function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. *J Clin Endocrinol Metab* 2005, **90**(11):6072-6076.
243. Romualdi D, Costantini B, Selvaggi L, Giuliani M, Cristello F, Macri F, Bompiani A, Lanzone A, Guido M: **Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective.** *Hum Reprod* 2008, **23**(9):2127-2133.
  244. Lowenstein L, Damti A, Pillar G, Shott S, Blumenfeld Z: **Evaluation of endothelial function in women with polycystic ovary syndrome.** *Eur J Obstet Gynecol Reprod Biol* 2007, **134**(2):208-212.
  245. Meyer C, McGrath BP, Teede HJ: **Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome.** *Diabetes Care* 2007, **30**(3):471-478.
  246. Luque-Ramirez M, Mendieta-Azcona C, del Rey Sanchez JM, Maties M, Escobar-Morreale HF: **Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.** *Eur J Endocrinol* 2009, **160**(3):469-480.
  247. Oliver JJ, Webb DJ: **Noninvasive assessment of arterial stiffness and risk of atherosclerotic events.** *Arterioscler Thromb Vasc Biol* 2003, **23**(4):554-566.
  248. Medley TL, Cole TJ, Gatzka CD, Wang WY, Dart AM, Kingwell BA: **Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease.** *Circulation* 2002, **105**(7):810-815.
  249. Lajemi M, Gautier S, Poirier O, Baguet JP, Mimran A, Gosse P, Hanon O, Labat C, Cambien F, Benetos A: **Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives.** *Am J Hypertens* 2001, **14**(8 Pt 1):755-760.

250. Wilkinson IB, Prasad K, Hall IR, Thomas A, MacCallum H, Webb DJ, Frenneaux MP, Cockcroft JR: **Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia.** *J Am Coll Cardiol* 2002, **39**(6):1005-1011.
251. Wilkinson IB, MacCallum H, Rooijmans DF, Murray GD, Cockcroft JR, McKnight JA, Webb DJ: **Increased augmentation index and systolic stress in type 1 diabetes mellitus.** *Qjm* 2000, **93**(7):441-448.
252. Mahmud A, Feely J: **Effect of smoking on arterial stiffness and pulse pressure amplification.** *Hypertension* 2003, **41**(1):183-187.
253. Schillaci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G, Franklin SS, Mannarino E: **Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension.** *Hypertension* 2005, **45**(6):1078-1082.
254. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB: **C-reactive protein is associated with arterial stiffness in apparently healthy individuals.** *Arterioscler Thromb Vasc Biol* 2004, **24**(5):969-974.
255. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, Cockcroft JR, Wilkinson IB: **Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans.** *Hypertension* 2006, **48**(4):602-608.
256. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B: **Arterial stiffness, wave reflections, and the risk of coronary artery disease.** *Circulation* 2004, **109**(2):184-189.
257. London GM, Marchais SJ, Guerin AP, Pannier B: **Arterial stiffness: pathophysiology and clinical impact.** *Clin Exp Hypertens* 2004, **26**(7-8):689-699.
258. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ: **Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis.** *J Hypertens* 1998, **16**(12 Pt 2):2079-2084.
259. Chen CH, Nevo E, Fetis B, Pak PH, Yin FC, Maughan WL, Kass DA: **Estimation of central aortic pressure waveform by mathematical transformation of radial**

- tonometry pressure. Validation of generalized transfer function. *Circulation* 1997, **95**(7):1827-1836.
260. Sutton-Tyrrell K, Mackey RH, Holubkov R, Vaitkevicius PV, Spurgeon HA, Lakatta EG: **Measurement variation of aortic pulse wave velocity in the elderly.** *Am J Hypertens* 2001, **14**(5 Pt 1):463-468.
  261. Laurent S, Caviezel B, Beck L, Girerd X, Billaud E, Boutouyrie P, Hoeks A, Safar M: **Carotid artery distensibility and distending pressure in hypertensive humans.** *Hypertension* 1994, **23**(6 Pt 2):878-883.
  262. Villar IC, Francis S, Webb A, Hobbs AJ, Ahluwalia A: **Novel aspects of endothelium-dependent regulation of vascular tone.** *Kidney Int* 2006, **70**(5):840-853.
  263. Moncada S, Palmer RM, Higgs EA: **Nitric oxide: physiology, pathophysiology, and pharmacology.** *Pharmacol Rev* 1991, **43**(2):109-142.
  264. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A: **The kallikrein-kinin system: current and future pharmacological targets.** *J Pharmacol Sci* 2005, **99**(1):6-38.
  265. Goodfriend TL, Elliott ME, Catt KJ: **Angiotensin receptors and their antagonists.** *N Engl J Med* 1996, **334**(25):1649-1654.
  266. Masaki T, Kimura S, Yanagisawa M, Goto K: **Molecular and cellular mechanism of endothelin regulation. Implications for vascular function.** *Circulation* 1991, **84**(4):1457-1468.
  267. Figueroa XF, Poblete I, Fernandez R, Pedemonte C: **NO production and eNOS phosphorylation induced by epinephrine through the activation of beta-adrenoceptors.** *Am J Physiol Heart Circ Physiol* 2009, **291**(1):H134-143.
  268. Mitchell JA, Warner TD: **COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.** *Nat Rev Drug Discov* 2006, **5**(1):75-86.
  269. Ahluwalia A, Hobbs AJ: **Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor.** *Trends Pharmacol Sci* 2005, **26**(3):162-167.

270. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, van der Arend BJ, Shu YE, MacKay LS, Webb DJ, Cockcroft JR: **Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function.** *Arterioscler Thromb Vasc Biol* 2002, **22**(1):147-152.
271. Sibbald B, Roberts C: **Understanding controlled trials. Crossover trials.** *BMJ* 1998, **316**(7146):1719.
272. Friedewald WT, Levy RI, Fredrickson DS: **Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.** *Clin Chem* 1972, **18**(6):499-502.
273. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: **Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.** *Diabetologia* 1985, **28**(7):412-419.
274. Hills M, Armitage P: **The two-period cross-over clinical trial.** *Br J Clin Pharmacol* 1979, **8**(1):7-20.
275. Williams MR, Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K, Komesaroff PA: **Variations in endothelial function and arterial compliance during the menstrual cycle.** *J Clin Endocrinol Metab* 2001, **86**(11):5389-5395.
276. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ, Millasseau SC, Deanfield JE, Halcox JP: **Non-invasive assessment of endothelial function: which technique?** *J Am Coll Cardiol* 2006, **48**(9):1846-1850.
277. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P *et al*: **Prognostic significance of endothelial dysfunction in hypertensive patients.** *Circulation* 2001, **104**(2):191-196.
278. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A: **Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.** *Circulation* 2000, **101**(9):948-954.



279. Barinas-Mitchell E, Kuller LH, Sutton-Tyrrell K, Hegazi R, Harper P, Mancino J, Kelley DE: **Effect of weight loss and nutritional intervention on arterial stiffness in type 2 diabetes.** *Diabetes Care* 2006, **29**(10):2218-2222.
280. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G: **Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.** *Hypertension* 2008, **51**(6):1617-1623.
281. Lord JM, Flight IH, Norman RJ: **Metformin in polycystic ovary syndrome: systematic review and meta-analysis.** *Bmj* 2003, **327**(7421):951-953.
282. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF: **Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome.** *Fertil Steril* 2009, **91**(6):2527-2536.
283. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, London GM: **Central pulse pressure and mortality in end-stage renal disease.** *Hypertension* 2002, **39**(3):735-738.
284. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ: **Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.** *Hum Reprod Update* 2009, **15**(1):57-68.
285. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R: **Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.** *J Clin Endocrinol Metab* 2006, **91**(10):3970-3980.
286. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R: **Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2008, **93**(7):2670-2678.

287. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: **Adiponectin stimulates production of nitric oxide in vascular endothelial cells.** *J Biol Chem* 2003, **278**(45):45021-45026.
288. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N: **Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.** *J Clin Endocrinol Metab* 2002, **87**(2):569-574.
289. Dagre A, Lekakis J, Mihas C, Protogerou A, Thalassinou L, Tryfonopoulos D, Douridas G, Papamichael C, Alevizaki M: **Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome.** *Eur J Endocrinol* 2006, **154**(6):883-890.
290. Lim CT, Kola B, Korbonits M: **AMPK as a mediator of hormonal signalling.** *J Mol Endocrinol* 2009, **44**(2):87-97.
291. Davis BJ, Xie Z, Viollet B, Zou MH: **Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase.** *Diabetes* 2006, **55**(2):496-505.
292. Goirand F, Solar M, Athea Y, Viollet B, Mateo P, Fortin D, Leclerc J, Hoerter J, Ventura-Clapier R, Garnier A: **Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice.** *J Physiol* 2007, **581**(Pt 3):1163-1171.
293. McPherson K, Brown M, Marsh T, Byatt T: **A prediction of Obesity Trends for Adults and their associated diseases. Analysis from the Health Survey for England 1993-2007..** *National Heart Forum UK* 2010.
294. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: **Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.** *N Engl J Med* 2002, **346**(6):393-403.
295. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M *et al*: **Prevention of**

**type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001, 344(18):1343-1350.**

296. Dahl CF, Allen MR, Urie PM, Hopkins PN: **Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. *BMC Med* 2008, 6:34.**
297. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimbürger DC, Lucas CP, Robbins DC, Chung J *et al*: **Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. *JAMA* 1999, 281(3):235-242.**
298. **The European Medicines Agency recommends suspension of marketing authorisations for sibutramine.** In.: European Medicines Agency press office; 2010.
299. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL: **Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. *Life Sci* 1998, 63(8):PL113-117.**
300. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S *et al*: **The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. *Faseb J* 2005, 19(11):1567-1569.**
301. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A: **Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. *Diabetes Care* 2008, 31 Suppl 2:S229-240.**
302. Bouaboula M, Hilairat S, Marchand J, Fajas L, Le Fur G, Casellas P: **Anandamide induced PPARGgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. *Eur J Pharmacol* 2005, 517(3):174-181.**
303. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G *et al*: **The endogenous cannabinoid system stimulates**

- glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms.** *J Clin Endocrinol Metab* 2007, **92**(12):4810-4819.
304. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, Di Marzo V: **Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.** *Int J Obes (Lond)* 2007, **31**(4):692-699.
  305. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W: **Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.** *Endocrinology* 2008, **149**(5):2557-2566.
  306. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R, Carruba MO, Marsicano G, Lutz B *et al*: **Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.** *Diabetes* 2008, **57**(8):2028-2036.
  307. **The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia.** In: European Medicines Agency press office; 2008.
  308. Sanofi-Aventis: **Sanofi-Aventis to discontinue all clinical trials with rimonabant.** Paris 2008.
  309. Lee HK, Choi EB, Pak CS: **The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.** *Curr Top Med Chem* 2009, **9**(6):482-503.
  310. Wadden TA, Sarwer DB, Womble LG, Foster GD, McGuckin BG, Schimmel A: **Psychosocial aspects of obesity and obesity surgery.** *Surg Clin North Am* 2001, **81**(5):1001-1024.
  311. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA: **Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.** *Psychopharmacology (Berl)* 2003, **167**(1):103-111.

312. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, Macias M, Goya P, de Fonseca FR: **Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.** *J Neuroendocrinol* 2008, **20 Suppl 1**:116-123.
313. McElroy J, Sieracki K, Chorvat R: **Non Brain-Penetrant CB1 receptor antagonists as a novel treatment of obesity and related metabolic disorders.** *Obesity* 2008, **16 (Suppl.1)**:Abst 3-OR.
314. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, Wong Kai In P: **PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.** *Br J Pharmacol* 2007, **152(5)**:805-814.
315. Scherma M, Panlilio LV, Fadda P, Fattore L, Gamaledin I, Le Foll B, Justinova Z, Mikics E, Haller J, Medalie J *et al*: **Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats.** *J Pharmacol Exp Ther* 2008, **327(2)**:482-490.
316. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L: **Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.** *Metabolism* 2003, **52(7)**:908-915.
317. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA: **Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.** *J Clin Endocrinol Metab* 2010, **95(2)**:722-730.
318. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S *et al*: **Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.** *Diabetes* 2002, **51(1)**:30-36.

319. Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, Tolvanen T, Knuuti J, Ronnema T, Huupponen R *et al*: **Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans.** *J Clin Endocrinol Metab* 2002, **87**(8):3902-3910.
320. Ren T, He J, Jiang H, Zu L, Pu S, Guo X, Xu G: **Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol.** *J Mol Endocrinol* 2006, **37**(1):175-183.
321. Alexandre KB, Smit AM, Gray IP, Crowther NJ: **Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1.** *Diabetes Obes Metab* 2008, **10**(8):688-690.
322. Friedman JM, Halaas JL: **Leptin and the regulation of body weight in mammals.** *Nature* 1998, **395**(6704):763-770.
323. Calvar CE, Intebi AD, Bengolea SV, Hermes R, Spinedi E: **[Leptin in patients with polycystic ovary syndrome. Direct correlation with insulin resistance].** *Medicina (B Aires)* 2003, **63**(6):704-710.
324. Klein J, Westphal S, Kraus D, Meier B, Perwitz N, Ott V, Fasshauer M, Klein HH: **Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes.** *J Endocrinol* 2004, **183**(2):299-307.
325. Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL, Ho LT: **Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance.** *Hum Reprod* 2004, **19**(1):48-53.
326. Lewandowski KC, Szosland K, O'Callaghan C, Tan BK, Randeve HS, Lewinski A: **Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices.** *Mol Genet Metab* 2005, **85**(1):61-69.
327. Cho LW, Randeve HS, Atkin SL: **Cardiometabolic aspects of polycystic ovarian syndrome.** *Vasc Health Risk Manag* 2007, **3**(1):55-63.



328. McCarty MF: **AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.** *Med Hypotheses* 2005, **64**(6):1211-1215.
329. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, Ueda S, Shimomura I, Funahashi T, Matsuzawa Y: **Hypoadiponectinemia is closely linked to endothelial dysfunction in man.** *J Clin Endocrinol Metab* 2003, **88**(7):3236-3240.
330. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H: **Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany.** *J Am Coll Cardiol* 2006, **48**(7):1369-1377.
331. Deng G, Long Y, Yu YR, Li MR: **Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway.** *Int J Obes (Lond)* 2010, **34**(1):165-171.
332. Kadowaki T, Yamauchi T: **Adiponectin and adiponectin receptors.** *Endocr Rev* 2005, **26**(3):439-451.